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Chapter 1
InTRoduCTIon
Heart failure (HF) is a common and complex clinical syndrome.1 HF is associated with very 
poor outcome (1-year mortality of 20%), which becomes even worse when co-morbidities are 
present.2-4 HF may arise from various aetiology and has variable clinical manifestations, notably 
including dysfunction of other organs than the heart, such as skeletal muscle, kidney and the 
bone marrow. In addition to increased mortality, high rates of hospital admission, extensive 
diagnostic testing and the chronic use of multiple pharmacological agents account for an 
immense healthcare expenditure.5 As a result, about 1% of the entire health care budget is 
spent on HF. Over the past decades, treatment options for HF have improved importantly with 
the addition of beta-blockers, angiotensin converting enzyme (ACE)-inhibitors, aldosterone 
antagonists, angiotensin receptor blockers (ARBs), and device therapy such as biventricular 
pacing with cardiac resynchronization therapy and internal defibrillators.6-16 However, despite 
all these treatment options, morbidity and mortality rates are still increasing globally. New 
therapeutic possibilities either focusing on the prevention of HF or on the improvement of 
signs and symptoms of already existing HF are therefore pivotal.
Before overt HF ensues, the heart, specifically the left ventricle (LV) undergoes changes in 
response to damaging stimuli, which is referred to as LV remodelling. Common aetiologic 
factors for HF are hypertension, ischemic heart disease with or without myocardial infarction 
(MI), valvular disease and myocarditis. All of these factors initiate the remodelling process. 
The initial response of the heart to stress is cardiomyocyte hypertrophy, while in later stages 
fibroblast and macrophage activation leads to apposition of extracellular matrix, and often 
remodelling becomes progressive and finally results in LV dilatation and congestive HF.
So  although  deemed  initially  useful,  remodelling  over  time  often  becomes  maladaptive. 
Maladaptive remodelling is characterised by excessive myocyte hypertrophy and apoptosis, 
interstitial and perivascular fibrosis (including replacement fibrosis) and a decrease in number of 
capillaries. The growth (in number and size) of capillaries, which theoretically would be needed 
to supply the hypertrophic LV with oxygen and nutrients, is insufficient in LV hypertrophy, thus 
creating an imbalance between the number of capillaries and cardiomyocytes. This imbalance 
is thought to further contribute to the remodelling process as it causes chronic hypoxia and 
less flow reserve, with further tissue damage as a result.17,18 Without treatment, this downward 
spiral continues, resulting in HF, and finally in death. Current treatment targets in HF target the 
cardiomyocyte hypertrophy or are anti-fibrotic. However, the microvasculature is difficult to 
target and no specific treatments are available. 
One of the common co-morbidities in HF is anaemia, which is associated with a poor outcome.2,4 
Its prevalence varies with the severity of HF and with the definition of anaemia that is used.19 
The causes of anaemia in HF are only partially understood, although several mechanisms have 
been implicated,20 including treatment with ACE-inhibitors,21 a blunted erythropoietin (EPO) 
production due to renal dysfunction,22 congestion,23 and iron deficiency.24 However, these 
causes only partially explain the severity of anaemia and proved to be difficult targets for 
treatment.
        11
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ExPERImEnTAl fIndIngs AfTER EPo AdmInIsTRATIon
EPO  is  a  haematopoietic  hormone  and  increases  red  blood  cell  maturation  and  growth. 
Remarkably, EPO has extensive non-haematopoietic properties, which suggest that EPO has 
functions other than haematopoiesis alone. A functional EPO receptor (EPOR), which was 
previously thought only to be present in haematopoietic progenitor cells, is also expressed in 
non-haematopoietic systems, such as the cardiovascular system (cardiomyocytes, endothelial 
cells) and the central nervous system.25 These discoveries fuelled intense research on the 
non-haematopoietic effects of EPO. EPO modulates a broad array of cellular processes that 
include progenitor stem cell release, cellular integrity and apoptosis, and angiogenesis. EPO 
has emerged as a potential anti-apoptotic agent and a vascular growth factor with promising 
protective potential in the setting of acute and chronic myocardial ischemia. In numerous 
experimental studies it has been established that EPO exerts cytoprotective and angiogenic 
effects.26-35 The anti-apoptotic effect of EPO is the predominant acute protecting mechanism 
of EPO during ischemia, while induction of neovascularisation is the predominant long-term 
effect of EPO.
EPO administration in ischemia-reperfusion (I/R) injury models reduces cardiomyocyte loss 
by  50%,  decreases  infarct  size,  enhances  LV  function  and  reduces  apoptosis,  even  when 
EPO  is  administered  after the  onset  of  reperfusion  or  in  low  non-haematocrit  increasing 
dosages.27,33,34,36-42 In models of permanent MI, EPO induces neovascularisation, but only in the 
presence of ischemia.42-44 Because of these non-haematopoietic effects, EPO may potentially 
represent a powerful pharmacologic addendum in the fight against cardiovascular diseases.
REsulTs fRom ClInICAl TRIAls wITH EPo
The very first feasibility and safety study in patients with acute MI was performed by Lipsic et al.45 
No adverse events were recorded during 30-days follow-up. Left ventricular ejection fraction 
(LVEF) measured with planar radionuclide ventriculography after four months, was similar in 
both groups. Although haematocrit levels were not significantly different in both groups, EPO 
treatment significantly increased the amount of endothelial progenitor cells (EPCs) (CD34+/
CD45-). Further small studies showed variable results that ranged from no effect on enzymatic 
infarct size and LV function to increase in angiogenesis signalling proteins in peripheral blood 
mononuclear cells (table 1).46-49 One of these studies, the REVIVAL-3, raised safety concerns.46 
The REVIVAL-3 evaluated the effect of a short-term infusion of high dose EPO in patients with 
ST-segment elevation MI treated with primary percutaneous coronary intervention (PCI). The 
primary endpoint was LVEF assessed by MRI at 6 months, which was similar in both groups. 
The secondary endpoint of this study, consisting of combined clinical events (death, recurrent 
MI, infarct-related artery revascularization, or stroke) occurred in 13% of EPO-treated patients 
as compared with 6% in the placebo group. Although this difference did not reach statistical 
significance, the tendency towards an increase in serious adverse events raised concerns about 
the safety profile of EPO in patients with MI.
Several small trials addressed the use of EPO in chronic HF. Again, these small scale studies                 12
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Study Study Design Number
Patients
Patient 
Characteristics
Results
Lipsic et al 45 Investigator-initiated, 
feasibility and safety 
study
22 First STEMI 
treated with 
primary PCI
Safe and well tolerated
Stimulates EPC 
mobilisation
Liem et al 47 Randomised, placebo-
controlled study
51 NSTEMI No effect on enzymatic 
infarct size
Ott et al 46 Randomised, double-
blind, placebo-controlled 
study
138 First STEMI 
treated with 
primary PCI
No difference in left 
ventricular function or 
infarct size
Binbrek et al 48 Randomised, open label, 
blinded endpoint study
236 STEMI 
treated with 
tenecteplase
Safe, but no enhanced 
preservation of 
jeopardised ischemic 
myocardium
Tang et al 49 Randomised, double-
blind, placebo-controlled 
study
44 Acute MI treated 
with aspirin and 
clopidogrel after 
successful PCI
No alteration of markers 
of platelet and endothelial 
cell activation associated 
with thrombosis
Increase in expression of 
angiogenesis signalling 
proteins in PBMCs (EPOR, 
VEGFR-1, p-PI3K)
Voors et al 60 Randomised, placebo-
controlled, open label, 
blinded endpoint study
529 First STEMI 
treated with 
primary PCI
No difference in LVEF after 
6 weeks
Less MACE in EPO group
REVIVAL-3 46 Randomised, double-
blinded, placebo-
controlled study
138 First STEMI 
treated with 
primary PCI
Results are awaited
REVEAL 59 Randomised, double-
blinded, placebo-
controlled study
210 First STEMI 
treated with 
primary PCI
Results are awaited
Table 1. Clinical studies: The effects of EPO in acute myocardial infarction
STEMI  =  ST-elevation  myocardial  infarction,  NSTEMI  =  non-ST-elevation  myocardial  infarction,  EPC  =  endothelial 
progenitor cell, EPO = erythropoietin, EPOR = erythropoietin receptor, MI = myocardial infarction, PBMC = peripheral 
blood mononuclear cell, PCI = percutaneous coronary intervention, p-PI3K = phosphorylated phosphatidylinositol 
3-kinase, VEGFR-1 = vascular endothelial growth factor receptor 1, LVEF = left ventricular ejection fraction, MACE = 
major adverse cardiac events, LV = left ventricle.
showed  variable  results.  Some  studies  showed  improvement  in  cardiac  function,  less 
hospitalisation and enhancement of exercise capacity, where other studies showed no effects 
on six minutes walk test, New York Heart Association (NYHA)-class and LVEF (table 2).50-55 
Large prospective, randomised, clinical trials are necessary to provide definitive answers if 
EPO could be beneficial as an pharmacologic addendum against cardiovascular disease.56 To 
evaluate the use of EPO in myocardial ischemia, our group therefore designed a multicenter, 
prospective, randomised, openlabel trial with blinded evaluation of the primary endpoint 
(HEBE III).57 The primary objective was to study the effect on LVEF of a single bolus of EPO, 
administered directly after a primary PCI for a first MI. Eligible patients were randomly assigned 
to either receive standard medical care or a single bolus with 60,000 IU of EPO on top of        13
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Study Study Design Number
Patients
Patient 
Characteristics
Results
Silverberg et al 52 Randomised 
controlled study
32 CHF with anaemia Improvement in cardiac function
Less hospitalisation and less 
renal impairment
Mancini et al 51 Randomized, 
single-blind, 
placebo-
controlled study
26 Enhancement of exercise 
capacity 
van Veldhuisen 
et al 50
Randomised, 
double-blind, 
placebo-
controlled study
152 CHF with anaemia Increase in Hb
Improvement in Kansas City 
Cardiomyopathy Questionnaire 
score
No effect on 6 min. walk 
distance, Patient’s Global 
Assessment score, NYHA class, 
LVEF, and HF Questionnaire score
Ponikowski et
al 53
Randomised, 
double-blind, 
placebo-
controlled study
51 CHF with anaemia Increased in Hb
Improvement in Patient’s Global 
Assessment score
No effect in Kansas City 
Cardiomyopathy and Minnesota 
Living with Heart Failure 
Questionnaire scores
Palazzuoli et al 54 Randomised, 
double-blind, 
placebo-
controlled study
40 CHF with anaemia Improvement in NYHA-class, 
exercise endurance, oxygen use 
during exercise, renal function 
and BNP
Reduced hospitalisation
Palazzuoli et al 55 Randomised, 
double-blind, 
placebo-
controlled study
51 CHF with anaemia Improvement in LV systolic 
function, LV remodelling,
BNP levels, and PAP
RED-HF 58 Randomised, 
double-blind, 
placebo-
controlled study
2600 CHF and anaemia Results are awaited
standard medical care within three hours of the PCI procedure. Primary endpoint of the study 
was LVEF assessed by planar radionuclide ventriculography after six weeks.
The results of the RED-HF trial (a large, randomised, clinical trial evaluating morbidity and 
mortality with the use of EPO in chronic HF) are expected at the end of 2011 and should give 
the definitive answer to the use of EPO in chronic HF.58
Table 2. Clinical studies: The effects of EPO in chronic heart failure
(C)HF = (chronic) heart failure, NYHA = New York Heart Association, BNP = B-natriuretic peptide, LVEF = left ventricular 
ejection fraction, LV = left ventricle, PAP = pulmonary artery pressure, Hb = haemoglobin.                14
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RECEnT TRIAls
Both the REVEAL and the HEBE III study were designed to evaluate the effect of EPO in first 
ST-segment elevation MI.57,59 As the results of the REVEAL are still awaited, very recently the 
results of the HEBE III were published.60 A single dose of EPO did not improve global LVEF 
after six weeks. However, more major adverse cardiovascular events occurred in the control 
group than in the EPO group, suggesting a potentially relevant cardioprotective effect and a 
favourable clinical safety profile of EPO.
Recent large trials with EPO in other diseases, i.e. in patients with chronic kidney disease 
(CHOIR, TREATE), haemodialysis (CREATE), and stroke (German Multicenter EPO Stroke Trial) 
indicated that high dose of EPO is associated with excess stroke and mortality, possibly due to 
the hyperviscosity and hypercoaguability associated with high haematocrit.61-64 We therefore 
have postulated that EPO should be administered in low dosages,42 so that the undesired 
side effects due to increasing haematocrit are avoided, yet the desirable anti-ischemic and 
cytoprotective effects are preserved. Alternative EPO-like compounds, which have no effects 
on erythropoiesis, have been advocated in this respect.65-68
Figure 1. Figure shows the mechanisms of the various factors described in this thesis and its interplay with ischemia 
and left ventricular hypertrophy. HIF = hypoxia inducible factor, EPO = erythropoietin, EPOR = EPO receptor, HO-1 
heme oxygenase-1, CO = carbon monoxide, VEGF = vascular endothelial growth factor, EPC = endothelial progenitor 
cell. For colour figure, see supplement 1.       15
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AIm of THIs THEsIs
The aim of this thesis was to evaluate in HF the non-haematopoietic effects of EPO and 
associated factors with similar protective mechanisms, such as estradiol and heme arginate. 
In the first part of this thesis, we evaluated the extra-erythropoietic mechanisms of EPO and 
its role in the EPO-EPOR system. In chapter 2, we review the function of EPO and its receptor 
in the cardiovascular system and the use of EPO in both acute MI as in chronic HF. In chapter 
3 we evaluate the mechanisms of EPO-induced vascular endothelial growth factor (VEGF) 
production in the heart and establish that VEGF is crucial for EPO-induced improvement of 
cardiac performance. In chapter 4, the role of the EPOR in physiologic (cardiac) hypertrophy is 
investigated. We show that EPO-EPOR signalling is crucial for physiologic hypertrophy. Chapter 
5 describes the existence of I/R injury in ventricular tissue during coronary artery bypass graft 
surgery with the use of cardiopulmonary bypass. It shows that ventricular tissue maybe more 
sensitive to detect changes than atrial tissue. Furthermore, this chapter also includes the 
design and rationale to further study these mechanisms.
The second part of this thesis evaluates interventions (with estradiol and heme arginate) in 
downstream pathways of EPO and focuses on feasible targets. These factors were chosen as 
they share working mechanisms with EPO, namely anti-apoptotic and angiogenic properties. 
In chapter 6, we investigate whether estradiol administration could induce EPC-mediated 
neovascularisation in a model of hind-limb ischemia. In chapter 7 we focus on the use of heme 
arginate as a reactive oxygen species scavenger in cardiac I/R injury. Chapter 8 evaluates the 
existence of HF-associated anaemia in an experimental HF model and if EPO administration 
could be an efficacious treatment option.                16
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Chapter 2
ABsTRACT
Erythropoietin (EPO) is a haematopoietic hormone with extensive non-haematopoietic effects. 
The discovery of an EPO receptor (EPOR) outside the haematopoietic system has fuelled the 
research into the beneficial effects of EPO for various conditions, predominantly in cardiovascular 
disease. Experimental evidence has revealed the cytoprotective and angiogenic properties of 
EPO and it seems that the EPO-EPOR system provides a powerful backbone against acute and 
chronic myocardial ischemia, each gaining from the different properties of EPO. Clinical trials in 
which EPO was titrated to achieve certain haematocrit levels have generated equivocal results. 
It has been suggested that a (too) high haematocrit is undesirable in cardiovascular disease. 
We  have  shown  that  intermittent  (low-dose)  EPO  administration,  that  does  not  increase 
haematocrit substantially, suffices to activate the beneficial downstream pathways of EPO. 
We postulate that intermittent administration or a lower than conventional dose of EPO, not 
only aimed at increasing haemoglobin at high levels, will provide powerful cellular protection 
and will improve cardiac outcome, without the side-effects of EPO associated with increased 
haematocrit.       25
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InTRoduCTIon
Erythropoietin (EPO) is a haematopoietic hormone with extensive non-haematopoietic effects. 
The recombinant human form of EPO has been used for several decades now in the treatment of 
anaemia, mostly in chronic kidney disease. The use of EPO has markedly increased, as it is now 
widely applied e.g. in cancer patients receiving chemotherapy, HIV positive patients treated 
with zidovudine, and treatment of myelodysplastic syndromes. Furthermore, EPO treatment 
as prophylaxis to reduce blood transfusions during mayor surgery is nowadays also common 
practice. Recently, several large scale trials suggested an adverse effect of EPO in patients with 
chronic kidney disease.1,2 This has prompted a fierce discussion on the use of EPO in chronic 
kidney disease and other (off-label) indications. Much debate is on the optimal dosage of EPO, 
since both very low and very high haematocrit are associated with excess mortality.3-5 
We  postulate  that  EPO  exerts  its  effects  mainly  via  activation  of  anti-apoptotic  and  pro-
angiogenic pathways, while the erythropoietic effects are rather secondary. To achieve this 
pro-angiogenic, anti-apoptotic, and haematocrit-neutral status, intermittent, not continuous, 
administration  of  EPO  is  warranted.  By  doing  this,  we  may  circumvent  the  problems  of 
complicated EPO titration and (too) high haematocrit and associated side-effects.
EPo And ITs RECEPToR
Already a century ago, in 1906, Carnot and DeFlandre suggested the existence of a circulating 
erythropoietic factor.6 Fifty years later EPO was discovered and the kidneys were established 
as the predominant site of production.7 The glycoprotein EPO has is a predominant role in 
red blood cell production. The EPO gene is located on chromosome seven, encoding for a 
polypeptide chain containing 193 amino acids. EPO is produced in the foetal liver and in the 
adult kidney in response to hypoxia, mainly under control of hypoxia inducible factor (HIF)-1.8 
Tissue oxygen demand and oxygen transport capacity regulate EPO production and secretion.9,10 
A principal effect of EPO is the prevention of physiological apoptosis, which normally adds to 
erythroid progenitor cell turnover.11
A  functional  EPO  receptor  (EPOR),  which  was  previously  thought  only  to  be  present  in 
haematopoietic progenitor cells, is also expressed in non-haematopoietic systems, such as 
the cardiovascular system, the central nervous system, and others.12 This discovery started 
extensive research to the non-haematopoietic effects of EPO. EPO modulates a broad array 
of cellular processes that include progenitor stem cell development, cellular integrity, and 
angiogenesis. As we stand, EPO is emerging as a cell death blocker and a vascular growth factor 
with promising protective potential in the setting of acute and chronic myocardial ischemia 
and may potentially represent a powerful pharmacological addendum in the fight against 
cardiovascular diseases.                 26
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EPo RECEPToR In THE CARdIoVAsCulAR sysTEm
In 1992 the first clues of existence of an EPOR outside the haematopoietic progenitor cells 
were published when Tan et al. demonstrated the existence of EPO messenger RNA in the 
brain.13 Nowadays,  the  expression  of  EPO  and  its  receptor  has  been  shown  in  numerous 
tissues,  including  the  reproductive  organs,  liver,  kidney,  endothelial  and  vascular  smooth 
muscle cells, brain and the heart.10,14-22 The EPOR is expressed in even more tissues, such as in 
gastric mucosal cells, pancreatic islets and even in the prostate epithelial cells.23-26 The EPOR 
is a member of the type 1 cytokine receptor family characterised by a single transmembrane 
domain.27 Under normal circumstances EPO and EPOR have a relatively low expression in 
non-haematopoietic tissue,28 however, expression of EPO and EPOR is rapidly increased in 
response to hypoxia and a number of other metabolic stressors including pro-inflammatory 
cytokines, hypoglycaemia and increased reactive oxygen species.10,29,30 These stressors directly 
activate the HIF-1, -2 and -3 pathways, which in turn regulate the gene transcription of EPO 
and EPOR.31,32 Activation of the EPOR leads to downstream activation of intracellular pathways 
such as phosphoinositide 3 kinase (PI3K) / protein kinase B (Akt), mitogen activated protein 
kinase (MAPK) and signal transducers and activators of transcription (STAT). These pathways 
are associated with cell survival.33-38 These pathways originate with the binding of EPO to 
the EPOR to activate Janus-tyrosine kinase 2 (Jak2).39,40 Next, by phosphorylation, PI3K and 
Akt are activated.41 Activation of the specific gene product STAT5 can regulate EPO mediated 
cell  proliferation  and  protect  against  apoptosis,  which  are  direct  substrates  of  Jak2.  EPO 
maintains cellular integrity and prevents apoptosis through a number of pathways, such as 
the modulation of apoptosis protease activating factor-1 (Apaf-1), the release of cytochrome 
C, and the activation of caspases 1, 3 and 9.42,43 EPO also modulates cellular inflammation by 
inhibiting cellular phosphatidylserine membrane exposure and subsequent targeting of cells 
for phagocytosis.44-46 In two recent studies, EPO increased endothelial nitric oxide synthase 
(eNOS) expression and nitric oxide (NO) production in cardiomyocytes. Blocking eNOS activity 
significantly decreased the anti-apoptotic effects of EPO, suggesting that the anti-apoptotic 
effects of EPO in cardiomyocytes are, partially, mediated by eNOS-derived NO production and 
is crucial for the anti-apoptotic effects of EPO as well.47,48
As a result of this upregulation of the EPOR, EPO robustly protects the cell, mainly by inhibiting 
the  apoptotic  mechanisms  of  injury,  including  the  preservation  of  cellular  membrane 
asymmetry to prevent inflammation.49
Genetically engineered mice provided more in-depth insight into the importance of the EPOR. 
EPOR expression in the erythropoietic lineage cells is necessary for normal development of 
mammals. EPOR knock-out mice, lacking the EPOR in their erythroid lineage, die of severe 
anaemia between embryonic day 13 and 15.50-52 EPO and EPOR play an essential role in 
proliferation, survival and differentiation of erythroid progenitor cells.53,54 Wu et al. demonstrated 
that EPO and EPOR have a major function in embryonic heart development, since EPO-/- and 
EPOR-/- mice experience ventricular hypoplasia and defects in the intraventricular septum.55 In 
addition to these findings, Suzuki et al. developed a mouse model in which EPOR expression is 
restricted to the erythropoietic lineage, by targeted knock-in of the EPOR gene ligated to the        27
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GATA-1 promotor, a transcription factor exclusive to erythroid lineage cells (EPOR-/--rescued 
mice).56 These mice express the EPOR exclusively in their erythropoietic cells, while other 
organs lack the EPOR. These mice develop normally and are fertile, so that it appears that EPO 
and EPOR are dispensable for normal development. However, these mice were subjected to 
various acute and chronic models of cardiovascular disease, and EPO and EPOR seem to play 
a major role in protection to cardiovascular damage. A deficiency of the endogenous EPO-
EPOR system deteriorates cardiomyocyte survival after ischemia-reperfusion (I/R) injury and 
subsequent left ventricular remodelling.57 This effect is partially due to enhanced apoptosis of 
cardiomyocytes. In the setting of peripheral artery disease the EPOR system plays an important 
role  in  angiogenesis  in  response  to  hind  limb  ischemia  through  upregulation  of  vascular 
endothelial growth factor (VEGF) and the VEGF receptor (VEGFR), both directly by enhancing 
neovascularisation and indirectly by mobilising endothelial progenitor cells (EPCs).58 Asaumi 
et al demonstrated that the deletion of EPOR in non-haematopoietic cells results in enhanced 
Figure 1. Overview of the different pathways of the effects of erythropoietin (EPO) administration in cardiovascular 
disease. In healthy hearts, number of endothelial progenitor cells (EPCs) are upregulated, but do not improve cardiac 
function further. However, endothelial function is improved. In acute myocardial ischemia, EPO has cytoprotective 
effects,  preserving  heart  function.  In  chronic  heart  failure,  EPO  upregulates  the  number  of  EPCs,  providing 
neovascularisation and preserves cardiac function. Possible side effects are raised haematocrit, heightened blood 
viscosity, resulting in hypertension, lower cerebral and renal blood flow and (fatal) thrombotic complications, which 
in turn can result in myocardial infarction or other arterial and venous thrombotic events. VEGF: vascular endothelial 
growth factor; Jak2: Janus-tyrosine kinase 2; PI3K: phosphoinositide 3 kinase; Akt: protein kinase B; STAT: signal 
transducers and activators of transcription.                 28
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susceptibility to the development of heart failure (HF) in mice with pressure overload of the left 
ventricle. The enhanced susceptibility to left ventricular failure was associated with impaired 
phosphorylation of STAT3 and p38, decreased expression of VEGF and impaired left ventricular 
neovascularisation.59 In pulmonary hypertension, mobilisation of EPCs from the bone marrow 
and their incorporation into the pulmonary endothelium are impaired in EPOR-/--rescued mice, 
with a resultant potentiation of pulmonary hypertension and pulmonary vascular remodelling 
in response to chronic hypoxia.60 EPO treatment was also associated with less cardiac and 
pulmonary  vascular  remodelling  in  flow-associated  pulmonary  hypertension.  Molecular 
studies in this model suggested that the VEGF-VEGFR system may be involved in mediating 
these effects of EPO.61 Upregulation of VEGF results in angiogenesis in hypoxic tissue.62-65 The 
group of Folkman et al has shown that angiogenesis in the atherosclerotic plaque can lead 
to instability of the plaque and at a final stage rupture of the plaque. When inhibiting this 
angiogenesis in the atherosclerotic plaque, intimal neovascularisation and plaque growth are 
diminished.66,67 This process of VEGF mediated angiogenesis might be a side effect of prolonged, 
chronic use of EPO (figure 1). Together, current evidence supports a pivotal role of the EPOR in 
the complex cascades of acute and chronic hypoxic damage in the body and, more specifically, 
the cardiovascular system.
EPo TREATmEnT foR ACuTE myoCARdIAl IsCHEmIA
Apoptosis  and  necrosis  are  the  major  forms  of  cell  death  contributing  to  the  extent  of 
damage after myocardial infarction (MI) and are a major determinant of the final infarct 
size.68-71 Furthermore, apoptosis contributes to the final injury size during injury caused by 
revascularisation.72 It is postulated that this reperfusion injury might contribute up to 50% of 
the final size of damage,73 in turn suggesting a large potential for therapeutical interventions.
Ischemia-reperfusion injury
In  several  experimental  studies  it  has  been  established  that  EPO  exerts  cytoprotective 
effects.74-84 The anti-apoptotic effect of EPO is the acute protecting mechanism of EPO during 
ischemia (figure 2).85,86 Clearly, this effect is independent from haematocrit-increasing effects of 
EPO, but is rather exerted via distinct apoptotic pathways. EPO exerts its potent anti-apoptotic 
effects in a number of cellular systems, including cultured endothelial cells and neonatal rat 
cardiomyocytes.87,88 Cavillo et al. administered a high-dose of EPO (5.000 IU/kg) for seven 
consecutive days in an I/R injury model in rats. This reduced cardiomyocyte loss by 50%, an 
extent sufficient to normalise haemodynamic function within one week after reperfusion.89 
Other experimental in vivo studies using an I/R injury model showed decreased infarct size,90-
95 enhancement of left ventricular function,96,97 and less apoptosis,98,99 even when EPO was 
administered after the onset of reperfusion.100 We have shown a 16% reduction (measured at 
a random, given moment, thus underestimating the true number of apoptotic cells) in number 
of apoptotic cells in pre-treated animals with EPO in an I/R injury model.101,102 Furthermore, 
apoptosis was significantly attenuated in animals treated with EPO at the start of ischemia 
(29% reduction) and after the onset of reperfusion (38%).103 Importantly, these positive effects 
of EPO are observed both at a high-dose administration and at a low-dose administration of 
EPO.104,105        29
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Experiments using permanent occlusion of the left coronary artery to induce MI show smaller 
infarct size, prevention of left ventricular dilatation, improved left ventricular ejection fraction 
(LVEF) and increased capillary density.106,107 Amongst others, Moon et al. found a reduction of 
the infarct size up to 25% after permanent ligation of the coronary artery using a single dose of 
EPO (3.000 IU/kg) compared to untreated animals examined eight weeks later.108 From our own 
group, Lipsic et al. has recently shown that low-dose (0.4 μg/kg/3 weeks) EPO administration 
had no effect on haematocrit levels (figure 3A). Low-dose EPO significantly improved cardiac 
function, reflected by increased left ventricular developed pressure and improved contractility 
(dP/dtmax) and relaxation (dP/dtmin), indices of the left ventricle at nine weeks after MI 
(p<0.05 compared to MI) (figure 3B).105
In the above-mentioned studies, EPO was administered at different times before and after 
I/R injury and permanent occlusion of the coronary artery, and in different dosages. All show 
the beneficial effect of EPO administration, indicating a broad window of opportunity for the 
potential treatment of MI in the human setting. From these data, it becomes clear that EPO 
administration  represents  a  powerful  anti-apoptotic  and  pro-angiogenic  treatment.  These 
effects are seemingly irrespective of the dose and dosage interval chosen, so that it may be 
proposed to low-dose and use EPO-free interval in order to prevent undesired haematocrit 
increases.
Figure 2. Schematic view of the protective properties of erythropoietin in time after ischemic insult.Chapter 2
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Clinical studies
We performed a single centre, safety trial exploring the effects of low-dose EPO in the setting 
of acute MI. Only small and non-significant changes in haematocrit levels were observed, 
while EPCs were increased at 72 h (2.8 vs. 1.0 cells/μl in control group, p<0.01). No adverse 
events were recorded during the 30-day follow-up.109 Together with the available experimental 
data this we considered a promising role for EPO as a cytoprotective agent in the setting of 
an acute MI and reperfusion injury afterwards. To evaluate this strategy in patients, in The 
Netherlands the HEBE III trial is currently conducted in which the effect of a single bolus of 
EPO is evaluated in patients with acute MI on LVEF (Clinical Trials number NCT00449488). In 
total, 466 patients will be included. The REVEAL study, which has a somewhat similar design, is 
currently performed in the United States of America (Clinical Trials number NCT00378352).
Figure 3. A. Effect of erythropoietin (EPO) treatment on longitudinal changes in haematocrit (p<0.01 vs. sham) in a 
model of experimental heart failure in rats. B. Effects of myocardial infarction (MI) and high-dose and low-dose EPO 
treatment on haemodynamic parameters, dP/dtmax and dP/dtmin; * p<0.05 vs. MI, ** p<0.01 vs. MI. C. Representative 
pictures of the effect of EPO treatment on incorporation of endothelial progenitor cells after MI into new vasculature. 
Staining of three different groups: sham animals, MI animals and MI animals treated with EPO (green: hPAP, red: His 
52; endothelium and blue: DAPI; nucleus). More double positive cells are found in the EPO treated group, suggesting 
incorporation of bone marrow derived endothelial progenitor cells in ischemic tissue contributing to neovascularisation. 
Sham: sham operated animals; MI: myocardial infarction, placebo treated animals; MI-EPO high: myocardial infarction 
animals, treated with high-dose EPO; MI-EPO low: myocardial infarction animals treated with low-dose EPO. A and B 
reprinted from Lipsic et al, Eur J Heart Fail 2008;10:22-29. Copyright (2008), with permission from Elsevier. For colour 
figure, see supplement 1.Chapter 2 Erythropoietin in cardiac disease
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EPo TREATmEnT foR CHRonIC HEART fAIluRE
Sustained EPO signalling may also have salutary effects beyond erythropoiesis (figure 2): it 
brings about neovascularisation and recruitment of EPCs and improves cardiac function in rats 
with HF.110,111
Irrespective of epicardial coronary anatomy, perfusion of the myocardium in HF becomes 
insufficient due to disproportionate cardiomyocyte hypertrophy relative to (micro) vascular 
growth, resulting in ischemia and upregulation of the different HIFs.112,113 Therapies aimed at 
improving cardiac microvascularisation might therefore result in improvement of myocardial 
contractility and might favourably affect outcome in patients with chronic HF (figure 1). EPO 
has potent angiogenic properties, promoting proliferation and tube formation of endothelial 
cells  in  vitro  and  stimulating  angiogenesis  in  numerous  experimental  models  in  vivo.114-
116 In addition, EPO induces the proliferation, differentiation and adhesion of a subset of 
bone marrow derived progenitor cells with an endothelial phenotype in vitro and results 
in marked mobilisation of EPCs in vivo.117-119 EPCs have been shown to specifically home to 
ischemic tissues and stimulate neovascularisation by incorporating into newly formed vascular 
structures and by paracrine secretion of angiogenic factors.120,121 In patients with chronic HF, 
EPO levels are increased. This increase might be a protective but insufficient response to 
promote angiogenesis in the heart.122 Considering these angiogenic properties, we evaluated 
the therapeutic potential of darbepoetin alpha (long acting EPO analogue, 40 μg/kg/3 weeks) 
in rats with chronic myocardial dysfunction after MI.123 EPO treatment was initiated three 
weeks after the MI and although this did not result in a reduction of infarct size, left ventricular 
contractility and relaxation was significantly improved. As expected, the improvement of cardiac 
function was associated with increased capillary density and increased capillary-to-myocyte 
ratio, indicating neovascularisation. These beneficial effects of EPO on cardiac function and 
microvascularisation in post-MI left ventricular dysfunction has recently been confirmed by 
four independent studies.124-127
EPO-induced neovascularisation in HF is consistently associated with increased numbers of 
circulating EPCs.128 Therefore, we recently evaluated the contribution of EPCs to EPO induced 
neovascularisation by replacing bone marrow of rats with genetically labelled cells, which 
allowed us to quantify the contribution of EPCs and in situ proliferation of endothelial cells to 
neovascularisation.129 In our study, EPO significantly increased mobilisation and incorporation 
of EPCs into the myocardium, accounting for approximately 30% of the new vessels. The 
remaining 70% of the new vessels thus originated from in situ proliferation of myocardial 
endothelial cells, which was associated with a five-fold increase expression of VEGF. EPO-
induced neovascularisation in post-MI HF therefore relies on a combination of EPC recruitment 
from the bone marrow and increased myocardial expression of VEGF. Moreover, the presence 
of ischemia is pivotal for EPO induced myocardial regeneration, since EPO treatment in healthy 
rats does not affect cardiac function nor does it improve myocardial microvascularisation 
(figure 1).130 Interestingly, EPC-mediated endothelial cell turnover was significantly improved 
by EPO, associated with marked improvement of endothelial function suggesting a potential 
therapeutic role in endothelial dysfunction.131 The effects of EPO on EPCs seem mediated                 32
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through the Akt-eNOS pathway, whereas in situ endothelial proliferation has been linked to 
the Jak2-STAT3 and MAPK-p38 pathways.132
The  dosing  regimens  used  in  previous  studies,  all  resulted  in  a  significant  increase  in 
haematocrit levels. When applied to the clinical situation, this could lead to hypertension, 
seizures, vascular thrombosis and death, possibly related to abruptly increased haematocrit 
levels.133 Therefore, we recently evaluated the effect of a low-dose EPO bolus that had no 
effect on haematocrit. Similar to high-dose EPO, low-dose treatment resulted in statistically 
improved cardiac function and improved myocardial microvascularisation, although the effect 
was slightly less pronounced.105 These results do not only suggest that the beneficial effects 
of EPO on the heart may be independent of an increased haematocrit but also suggest that 
low-dose EPO might provide a safe and effective strategy in patients. Another option to avoid 
the potentially negative effects of chronic EPO therapy in haematocrit values could be the 
use of recently discovered non-erythropoietic derivates of EPO, retaining the tissue protective 
properties, without the undesired effect on erythropoiesis.134 Two independent studies have 
demonstrated that these non-erythropoietic EPOs retain their cardioprotective potential in 
models of acute MI.135,136 It is however uncertain whether these new EPOs will improve cardiac 
function in chronic HF.
sAfETy IssuEs
All dose regimens used in clinical studies resulted in a significant increase in haematocrit levels. 
Raised haematocrit levels have been linked to hypertension, vascular thrombosis, and (rarely) 
death (figure 1).137 In the case of EPO treatment in acute myocardial ischemia, this danger 
might not apply, because a single bolus does not seem to significantly raise haemoglobin and 
haematocrit levels.138 Nevertheless, the increase in haematocrit associated with the use of EPO 
may offset its beneficial effects. A possibility for future research is to use EPO derivates which 
only display the non-haematopoietic properties of EPO.139,140 These derivates have shown to 
be as effective in cardioprotection as recombinant human EPO in a model of acute MI.141,142 
Another possibility would be to use a low-dose, intermittent, dose regimen that does not elicit 
a substantial increase in haematocrit, yet does activate the pro-angiogenic and anti-apoptotic 
pathways of EPO.
To take the experimental findings for MI and chronic HF to the clinic, large multicentre, double 
blind, randomised, placebo controlled trials were designed (HEBE III (MI), REVEAL (MI), RED-
HF (chronic HF)) and results have to be awaited.143 Recent data from two randomised clinical 
trials using recombinant human EPO to correct anaemia in chronic kidney disease provided 
neutral to negative data. The CREATE study evaluated the effect of ‘complete’ haemoglobin 
correction (target haemoglobin 8.1 to 9.3 mmol/l) to ‘lower’ haemoglobin correction (target 
haemoglobin 6.5 to 7.1 mmol/l) in chronic kidney disease patients. In this study no change 
in  risk  on  cardiovascular  events  was  seen.144  Second,  the  CHOIR  study,  which  evaluated 
the  effect  on  cardiovascular  complications  of  achieving  ‘high’  haemoglobin  levels  (target 
haemoglobin 8.4 mmol/l) compared to ‘lower’ haemoglobin levels (target haemoglobin 7,0 
mmol/l) in chronic kidney disease patients. This study was terminated prematurely, because        33
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of an increased adverse event rate in the high haemoglobin group.145 Especially the CHOIR 
has fuelled the debate on the safety of recombinant human EPO. As a result, the Food and 
Drug Administration (FDA) has recommended “the lowest possible dose to slowly raise the 
haemoglobin concentration to the lowest level that will avoid the need for a blood transfusion”. 
A third study in anaemic chronic kidney disease patients is currently running (TREAT).146 This 
study evaluates the effect of recombinant human EPO treatment (to achieve haemoglobin 
levels of 8.1 mmol/l) on cardiovascular events in this patient group. The current data was 
evaluated by the Data and Safety Monitoring Board and till date there is no evidence to 
terminate this study prematurely.147
It may be that the beneficial effects of EPO in chronic HF patients are different from chronic 
kidney disease patients.148,149 Several randomised, double blind, placebo controlled studies 
showed improved quality of life in anaemic chronic HF patients receiving recombinant human 
EPO. More important, both studies do not show a difference in the incidence of adverse 
events.150,151 The main difference between EPO treatment in chronic HF and chronic kidney 
disease patients is the interval of treatment, i.e. chronic kidney disease patients are treated 
for a longer period of time and generally need higher dosages of EPO. Long term treatment 
with EPO resulting in angiogenesis in the atherosclerotic plaque could lead to instability of 
the plaque and finally to rupture. On the other hand, inhibiting angiogenesis reduces intimal 
neovascularisation  and  plaque  growth.152,153  Chronic  EPO  administration,  as  practiced  in 
chronic kidney disease patients may increase angiogenesis in the atherosclerotic plaque by 
increased VEGF production, which may be associated with plaque rupture and acute coronary 
syndromes, MI and death and this may explain the unexpected effects of EPO observed in trials 
with chronic kidney disease patients. For sure, current trials will be monitored carefully.
ConClusIons
The discovery of an EPOR outside the haematopoietic system has fuelled the research into 
the beneficial effects of EPO for various conditions, predominantly in cardiovascular disease. 
Experimental evidence has revealed the cytoprotective and angiogenic properties of EPO and 
it seems that the EPO-EPOR system provides a powerful backbone against acute and chronic 
myocardial ischemia, each gaining from the different properties of EPO.
However, clinical trials in which EPO was titrated to achieve certain haematocrit levels have 
generated equivocal results. It has been suggested that a (too) high haematocrit is undesirable 
in cardiovascular disease. We have shown that intermittent (low-dose) EPO administration, 
that does not increase haematocrit substantially, suffices to activate the beneficial downstream 
pathways  of  EPO.  We  postulate  that  intermittent  administration  of  EPO,  as  opposed  to 
continuous administration, will provide powerful cellular protection and will improve cardiac 
outcome, without the side-effects of EPO associated with increased haematocrit. Clinical trials 
in both acute and chronic myocardial ischemia are currently underway and results are eagerly 
awaited.                34
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Chapter 3
ABsTRACT
Aims
We intended to delineate the mechanisms of erythropoietin (EPO)-induced cardiac vascular 
endothelial growth factor (VEGF) production and to establish if VEGF is crucial for EPO-induced 
improvement of cardiac performance.
Methods and results
The effects of EPO on VEGF expression were studied in cultured cardiac cells and EPO-treated 
hearts. The role of VEGF in EPO-induced neovascularisation was studied with two distinct 
VEGF-neutralising antibodies or irrelevant control IgG in an aortic sprouting assay and in rats 
with heart failure (HF) after myocardial infarction (MI) treated with EPO. EPO-alpha (10 IU/
ml) was used in vitro and darbepoetin alpha (40 μg/kg/3 weeks, starting 3 weeks after MI) in 
vivo. EPO stimulated VEGF mRNA expression through the signal transducers and activators of 
transcription-3 (STAT3) pathway in neonatal rat cardiomyocytes, but not in endothelial cells 
or fibroblasts. Similarly, the direct effects of EPO on endothelial sprouting were modest and 
VEGF independent. In rats with HF, EPO increased VEGF protein expression predominantly 
in cardiomyocytes, associated with a 37% increase in capillary density and improved cardiac 
performance. Administration of VEGF-neutralising antibodies abrogated the salutary effects 
of EPO on cardiac microvascularisation and function. VEGF neutralisation attenuated EPO-
induced proliferation of myocardial endothelial cells and reduced myocardial incorporation 
of endothelial progenitor cells (EPCs) in rats with alkaline phosphatase-labelled bone marrow 
cells.
Conclusion
VEGF is crucial for EPO-induced improvement of cardiac function in HF. EPO fosters VEGF 
expression predominantly in cardiomyocytes, which in turn stimulates myocardial endothelial 
proliferation and incorporation of EPCs.       45
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InTRoduCTIon
Heart failure (HF) remains a prevalent medical condition with a poor prognosis. The development 
of new therapeutic strategies is therefore of utter importance.1
Insufficient microvascular adaptation in relation to the degree of cardiomyocyte hypertrophy 
is a key pathophysiological feature that contributes to progressive cardiac dysfunction in HF.2,3 
We and others have convincingly shown that treatment with erythropoietin (EPO) restores 
microvascular insufficiency, and improves cardiac performance in experimental and clinical 
HF.4-7 The mechanisms of EPO-induced neovascularisation in HF are however incompletely 
understood.
There are several reasons to believe that the activation of vascular endothelial growth factor 
(VEGF) is involved in the cardiac effects of EPO. First, EPO increases VEGF expression in various 
ischaemic tissues and cardiac VEGF levels are strongly correlated with new vessel formation.8-11 
Secondly, EPO only stimulates neovascularisation in the heart at sites where VEGF expression 
is increased.12 Thirdly, mice that lack an EPO-receptor (EPO R) in the heart, display defective 
VEGF expression, and dramatically accelerated development of left ventricular (LV) dysfunction 
during pressure overload.8 Although these findings suggest an important role for VEGF in EPO-
induced neovascularisation, the data are observational and it remains to be established whether 
augmented VEGF expression is crucial for EPO-induced improvement of cardiac function.
We  hypothesized  that  VEGF  upregulation  in  the  myocardium  is  crucial  for  EPO-derived 
restoration of cardiac microvascularisation and performance. We first identified that cell types 
and signal transduction pathways are operative for EPO-induced VEGF expression in the heart. 
Then, we established that abolishment of VEGF expression neutralises the effects of EPO 
administration, specifically improvement of cardiac microvascularisation and function, using a 
well-established in vivo model of HF.
mETHods
Recombinant human EPO and experimental antibodies
We  used  EPO-alpha  (EPREX,  Janssen-Cilag)  in  a  concentration  of  10  IU/ml  in  all  in  vitro 
experiments.  The  long-acting  EPO  analogue  darbepoetin  alpha  (Aranesp,  Amgen)  was 
administered once every three weeks in a calculated dose of 40 μg/kg bodyweight. Because 
we intended to explore the effect of EPO on established HF, the first Darbepoetin dose was 
given three weeks after the infarct when infarct healing has subsided. The VEGF-neutralising 
antibodies goat anti rat-VEGF affinity purified antibody (aVEGF1; R&D systems, catalogue# 
AF564) in a concentration of 5 μg/rat per three times per week and mouse anti-humanVEGF165 
(aVEGF2, production described by Tilton et al.13) in a concentration of 1 mg/rat three times 
per week or the irrelevant control antibody goat anti-mouse-IgG (R&D systems, catalogue# 
AF007) at a concentration of 5 μg/rat per three times per week were used for the experimental 
protocol. Both VEGF-neutralising antibodies recognize and neutralise all splice variants of rat 
VEGF.                46
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Effect of EPO on VEGF transcription in cardiac cells
Neonatal rat ventricular myocytes (NRVM, from Sprague Dawley rats, Harlan, The Netherlands) 
and human umbilical vein endothelial cells (HUVECs) were isolated and maintained as described 
previously.14,15 Human cardiac fibroblasts (HCF, ScienCell Research Laboratories) were cultured 
in RPMI 1640 medium with L-glutamin and 10% foetal bovine serum. Before the experiment, 
cultures with NRVM (105 cells/well) and HCF (100% confluence) were incubated without serum 
and HUVECs cultures were cultured with 2% foetal bovine serum for 22 hr. Because we have 
previously described that ischaemia is required for EPO-induced upregulation of VEGF in the 
heart, cells were pre-incubated with or without the hypoxia mimetic deferoxamine (100 μM, 
Sigma Aldrich) for 2 hr. The role of well-described EPOR signal transduction pathways was 
studied by additional pre-incubation with the phosphoinositide 3-kinase blocker wortmannin 
(1 μM, Sigma Aldrich), the Map-kinase kinase (MEKK) blocker PD98059 (25 μM, Sigma Aldrich), 
or the cell permeable signal transducers and activators of transcription-3 (STAT3) inhibiting 
peptide  (pPYLKTK-mts,  1  μM,  Calbiochem)  for  30  min.  After  preincubation,  EPO  (Eprex, 
Janssen-Cilag, final concentration of 10 IU/ml), was added to the wells and cells were lysated 
after 30, 60, or 120 min with TRIZOL-reagent (Invitrogen) and RNA was isolated according 
to the suppliers guidelines. For measurements of STAT3 phosphorylation cells were lysated 
after 30 min. with RIPA-buffer containing protease and phosphatase inhibitors (Invitrogen) 
as previously described.9 To confirm that the effects of deferoxamine reflected true hypoxia, 
we additionally performed an experiment where NRVM were placed in a humidified hypoxic 
chamber at 37°C with 1% O2, 5% CO2. We used an identical experimental design, with the 
exception that the cells were placed in the hypoxic chamber instead of adding deferoxamine to 
the wells. After the hypoxic pre-incubation wells were very briefly removed from the hypoxic 
chamber to administer EPO under laminar flow.
After reverse transcription with random primers (Promega), quantitative reverse transcriptase-
polymerase  chain  reaction  was  performed  with  PCR-master  mix  containing  Cyber  Green 
(AbGene) and specific primers or with TAM-labelled primer/probe sets according to the suppliers 
guidelines (Applied Biosystems). Beta-2-microglobulin (B2M) was used as a housekeeping gene 
in all analyses (expression of B2M was constant under our experimental conditions). Moreover, 
in random subsets of the data, we additionally corrected for the housekeeping genes beta-actin 
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), which revealed identical results as 
B2M (data not shown). Results are expressed as fold-difference compared with control and 
represent the average of 8-12 wells per group of at least three separate experiments, with cells 
from different donors.
Aortic ring assay
The  aortic  ring  assay,  which  is  a  co-culture  of  endothelial  cells,  fibroblasts,  and  vascular 
smooth muscle cells, was performed using the method of Nicossia and Ottinetti with slight 
modifications.16 Briefly, 0.6 mm long aortic rings of the thoracic aorta were embedded in growth 
factor reduced Matrigel (Becton Dickinson). The aortic rings were then cultured in endothelial 
cell culture medium [which contains endothelial cell growth factor (ECGF) and heparin15] with 
or without 10 IU/ml EPO or 1 μg/ml goat anti-rat VEGF (AF 564, R&D systems) for seven days.        47
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After five and seven days of culture, each quadrant of the aortic ring was photographed with 
an inverted microscope. Maximal sprout length, defined as the length of the perpendicular 
line between the external circumference of the aortic ring and the tip of the longest sprout per 
quadrant was measured with Image-Pro (Version 4.5.0.29) and is expressed in arbitrary units.
Animals and bone marrow labelling
Male  Sprague  Dawley  rats  (270-320  gr)  were  purchased  (Harlan).  For  bone  marrow 
transplantation experiments, we used male Fischer F344 rats (200-230 gr) purchased from 
Charles Rivers (France) as recipients and R26-hPAP donor rats (F344 background, ubiquitously 
expressing  human  placental  alkaline  phosphatase).  Details  on  transplantation  have  been 
described in detail previously.9 Briefly, whole R26-hPAP bone marrow cells were transfused to 
Fischer F344 recipients after total body irradiation and left to reconstitute for six weeks before 
commencing with the experimental protocol. Animals were fed and housed according to the 
institutional rules and regulations.
Experimental protocol in rats
HF was induced by permanent ligation of the left coronary artery to produce a myocardial 
infarction (MI) and control rats received a sham procedure.4 Three weeks after MI, rats were 
randomly assigned to treatment with darbepoetin alpha or vehicle, given once every three 
weeks i.p. as described above. Because we intended to explore the effect of EPO on established 
HF, the first darbepoetin dose was given three weeks after MI when infarct healing has subsided. 
The effects of VEGF in EPO-induced neovascularisation were studied by administering one of 
the VEGF-neutralising antibodies (aVEGF1 or aVEGF2) to rats with MI concomitantly treated 
with  EPO  or  vehicle.  Because  VEGF-signalling  is  crucial  for  the  normal  control  of  cardiac 
microvascularisation in HF,17 we only administered neutralising antibodies during the first 
week after EPO treatment to allow for a neutralisation-free interval. Reference and control 
rats in the sham, untreated MI and EPO-treated MI groups received equivalent doses of the 
irrelevant control IgG to control for the non-specific effects of antibody administration. This 
resulted in seven treatment groups: sham, untreated MI and EPO-treated MI group where 
control IgG was administered (sham + IgG; MI + IgG; MI-EPO + IgG); the untreated and EPO-
treated MI group where aVEGF-1 was administered (MI-EPO + aVEGF1; MI + aVEGF1) and the 
untreated and EPO-treated MI group where aVEGF2 was administered (MI-EPO + aVEGF2; MI 
+ aVEGF2). To evaluate the temporal characteristics of VEGF neutralisation, 400 μl of blood 
was drawn from the tail vein at weeks three, four, six and seven. After nine weeks, at sacrifice, 
haemodynamic measurements were performed with a microtip pressure transducer (Millar 
Instr., Inc., Houston, TX, USA) as described previously.4 Heart rate, LV systolic pressure, and LV 
end diastolic pressure (LVEDP) were measured. The maximal rates of increase and decrease in 
LV pressure (dPdtmax and dPdtmin) and the developed LV pressure (dLVP) were determined. 
Next, blood was drawn and hearts were rapidly excised and weighed. Myocardial tissue was 
dissected transversally and processed for immunohistochemistry or snap frozen for molecular 
analysis.                48
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VEGF-neutralising capacity of plasma
Ninety-six-well plates were coated with donkey anti-goat-IgG in PBS overnight. Next, plates 
were washed five times and incubated with plasma samples (n=4) from rats treated with the 
irrelevant control antibody and four rats that received aVEGF1. Recombinant human VEGF165 
(R&D systems) was added to the wells to reach a final concentration of 1000 pg/ml and 
incubated for 60 min. Hereafter, VEGF concentration was determined by ELISA according to 
the suppliers’ guidelines (R&D systems). Percentage neutralisation was determined as VEGF 
measured/VEGF added (1000 pg/ml) x 100%. The neutralising characteristics of aVEGF2 have 
been described elsewhere.13
Western blot
The expression of VEGF and GAPDH was determined in tissue homogenates of the viable LV-
free wall (non-infarcted area) by standard western blotting techniques as described previously.9 
For determination of STAT3 phosphorylation, we used the PhosphoPlus STAT3 antibody kit (Cell 
Signalling Technology, catalogue number 9130), according to the suppliers’ guidelines.
Circulating endothelial progenitor cell culture
Circulating endothelial progenitor cells (EPCs) were enumerated by culture of mononuclear 
cells in lineage selection medium (EndoCult medium, StemCell Technologies) according to the 
suppliers guidelines, as previously described.9
LV histology
Infarct  size,  cardiomyocyte  cross-sectional  area,  the  number  of  cardiomyocytes/mm2,  the 
number  of  capillaries  per  tissue  area  (mm2),  and  the  capillary/cardiomyocyte  ratio  were 
determined as described previously.4 Other immunohistochemical stainings were performed 
on transverse myocardial sections at the mid-papillary level. As primary antibodies, we used 
mouse anti-Troponin T (JLT-12, Sigma Aldrich), rabbit anti-VEGF (A20, Santa Cruz biotechnology), 
mouse anti-proliferating cell nuclear antigen (PCNA, PC10, Cell Signaling Technology), rabbit 
anti-hPAP  (Serotec),  and  mouse  anti-rat  His-52  (kind  gift  from  Dr.  J.L.  Hillebrands).9  The 
envision kit (Dako-Cytomation) with Mayers haematoxylin (Sigma) for nuclear staining was 
used  for  chromogenic  detection.  For  fluorescent  detection,  diamidino-2-phelylindole,  the 
biotynylrhodamine-TSA kit (Perkin Elmer) or isotype-specific anti-mouse-IgG, or anti-rabbit-
IgG antibodies labelled with FITC, TRITC, or Alexa555 were used. Analysis of VEGF expression 
was performed in the MI border zone. Cells positive for both lectin and PCNA were considered 
proliferating endothelial cells, and cells positive for both hPAP and His-52 were considered 
bone marrow-derived endothelial cells. Cells were quantified in four to five random high 
power fields of the non-infarcted LV-free wall remote from the infarction by blinded observers 
(BDW, LY).
Statistical methods
Data are expressed as mean ± standard error of the mean (SEM). Statistical analysis among 
groups was performed by ANOVA with the Bonferroni post hoc test, if distributed normally or        49
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with the Kruskall-Wallis test followed by Mann-Whitney U test when skewed distributed. All 
p-values are two-tailed, and a p-value of less than 0.05 was considered statistically significant. 
All analyses were performed using SPSS version 15.0 software (SPSS, Chicago, IL, USA).
Ethics
The investigation conforms to the principles outlined in the Declaration of Helsinki. In addition, 
the investigation conforms to the Guide for the Care and Use of Laboratory Animals published 
by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). For the use of 
HUVECs, approval was granted by the medical ethical review board of the University Medical 
Centre Groningen, University of Groningen, Groningen, The Netherlands. The experimental 
protocol was approved by the Animal Ethics Committee of the University of Groningen.
Figure 1. Differential effects of EPO on VEGF gene transcription in cardiac cells
(A) Temporal changes in VEGF mRNA expression after EPO treatment in NRVC in the presence or absence of hypoxia 
or the hypoxia inducing agent deferoxamine. (B) Temporal changes in VEGF mRNA expression after EPO treatment in 
HUVECs in the presence or absence of the hypoxia inducing agent deferoxamine. (C) Temporal changes in VEGF mRNA 
expression after EPO treatment in HCF in the presence or absence of the hypoxia inducing agent deferoxamine. (D) 
Effect of specific blockers for EPOR signal transduction pathways on VEGF mRNA expression in EPO-treated NRVM, 
measured at 60 min. # p<0.05 vs. EPO, * p<0.05 vs. control. Deferox = deferoxamine, EPO = erythropoietin, B2M = 
beta-2-microglobulin.                50
Chapter 3
REsulTs
Effects of EPO on VEGF transcription in cardiac cells
VEGF mRNA expression was significantly increased by EPO in NRVM. In accordance with our 
recent study in rats,9 EPO induced VEGF expression only in the presence of hypoxia or the 
hypoxia-mimicking agent deferoxamine (p<0.05, figure 1A). In endothelial cells and fibroblasts, 
VEGF expression was unaffected by EPO [p = non-significant (NS), figure 1B and C]. Extended 
incubation  with  deferoxamine  increased  VEGF  expression  in  NRVM,  HUVECs,  and  HCF 
compared with cultures without deferoxamine, but did not alter the effects of EPO on VEGF 
expression (data not shown). The effects of EPO on VEGF expression were blocked by STAT3 
inhibiting peptide, but not by wortmannin or PD98059 (figure 1D), suggesting that the JAK2/
STAT3 pathway is the dominant signal transduction pathway. To confirm that STAT-3 is activated, 
we additionally measured STAT3 phosphorylation, which confirmed that EPO induces STAT3 
signalling in our model (see supplementary data, figure S2).
Figure 2. Effects of VEGF inhibition on EPO-induced angiogenesis in vitro
(A) Maximal aortic sprout length after five and seven days in a Matrigel aortic implantation assay. Aortic rings were 
cultured in the presence or absence of EPO (10 IU/ml) or VEGF-neutralising antibody (1 μg/ml goat anti-rat VEGF). 
EPO significantly increased maximal sprout length compared with control cultures. The increase was however <10%. 
Neutralisation of VEGF did not inhibit the effects of EPO on aortic sprouting. (B) Typical examples of aortic sprouting 
in the different experimental groups after seven days in culture. C = control culture, E = EPO, aV = VEGF-neutralising 
antibody.
Role of VEGF in EPO-induced aortic sprouting
To corroborate the previous findings, we studied the effects of EPO in the aortic sprouting 
assay, which is a co-culture of vascular cells without parenchyma cells such as cardiomyocytes. 
EPO significantly increased maximal sprout length compared with control cultures, but the 
increase was <10% (p<0.05, figure 2). Neutralisation of VEGF did not inhibit the effects of EPO 
on aortic sprouting.       51
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Effect of EPO on VEGF production in failing hearts
Immunofluorescent  double  staining  of  EPO  treated  failing  rat  hearts  showed  that  VEGF 
expression was especially apparent in cardiomyocytes (figure 3A). In rats with post-MI HF, 
EPO treatment resulted in a three-fold increased protein expression of VEGF in the viable LV-
free wall (figure 3D). In addition to increased protein levels, EPO treatment also increased 
the VEGF-immunoreactive area, suggesting that EPO additionally increased the number of 
cells that produced VEGF (figure 3B and C). Importantly, administration of the neutralising 
antibodies did not quantitatively affect VEGF-protein levels at sacrifice (figure 3). Therefore, 
the results of the study were not biased by neutralisation-induced changes of VEGF expression 
and thus represent the effects of temporary blocking VEGF signalling.
Figure 3. Effect of EPO on VEGF immunoreactivity in the myocardium
(A) Immunofluorescent staining of rat myocardium at x100 magnification. Co-localization of VEGF (red) and troponin-T 
(green) indicates that VEGF is expressed in cardiomyocytes. (B) Typical examples of VEGF-immunohistochemistry 
of myocardial sections at x40 magnification. (C) Graphic representation of VEGF immunoreactive area. (D) Graphic 
representation of the VEGF protein expression in the LV-free wall. MI = myocardial infarction, EPO = erythropoietin, 
IgG = control IgG, aVEGF = VEGF-neutralising antibody. For colour figure, see supplement 1.                52
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Effect of VEGF neutralisation on EPO-induced improvement of cardiac function
General characteristics of the study groups are presented in table 1. Temporal characteristics 
of the VEGF-neutralising capacity of the plasma are presented in supplementary data. In brief, 
during the anti-VEGF antibody administration 78% of VEGF was neutralised. In the subsequent 
weeks without antibody administration, the neutralisation capacity was normalised to control 
values. These data indicate that intermittent administration of neutralising antibodies results 
in  temporary  neutralisation  of  VEGF  signalling.  Induction  of  MI  resulted  in  a  significant 
reduction in cardiac function, increased heart weight and increased cardiomyocyte cross-
sectional area in all MI groups (table 1 and figure 4). EPO treatment significantly increased LV 
contractility (dPdtmax, dLVP) and LV-relaxation (dPdtmin) and decreased LV filling pressures 
(LVEDP) compared with the untreated MI (all p<0.01, figure 3). Neutralisation of VEGF with 
both antibodies blocked the salutary effects of EPO on cardiac function parameters (p=NS vs. 
untreated MI, p<0.05 vs. MI-EPO, figure 4), whereas intermittent neutralisation itself did not 
further decrease cardiac function compared with the untreated MI (p=NS, figure 4). Correction 
of LV contractility and relaxation indices for instantaneous pressures did not alter the results 
(data not shown).
Figure 4. Effects of VEGF neutralisation on EPO-induced improvement of LV function
(A–D) Graphic representation of LV contractility (dPdtmax), relaxation (dPdtmin), LVEDP and dLVP. MI = myocardial 
infarction, EPO = erythropoietin, IgG = control IgG, aVEGF = VEGF-neutralising antibody.       53
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Effect of VEGF neutralisation on EPO-induced LV neovascularisation
Cardiac capillary density was reduced in all MI groups compared with sham (p<0.001, figure 
5). However, EPO treatment significantly increased cardiac capillary density by 37% (p<0.01 vs. 
MI, figure 5). VEGF neutralisation completely blocked the effects of EPO on capillary density 
(p=NS vs. untreated MI, p<0.01 vs. MI-EPO, figure 5), whereas neutralisation alone did not 
result in further reduction of capillary density (p=NS vs. untreated MI, figure 5). Capillary-to-
cardiomyocyte ratio was slightly but non-significantly increased in all MI groups compared with 
sham. EPO treatment resulted in a 42% increase in capillary-to-cardiomyocyte ratio compared 
with sham and MI, which was also blocked by VEGF inhibition (figure 5).
Effect of VEGF neutralisation on EPO-induced proliferation of endothelial cells
The number of proliferating endothelial cells in the viable LV-free wall was comparable between 
sham and MI groups (figure 6A and B). EPO treatment significantly increased the number of 
proliferating endothelial cells (p<0.001 vs. sham and MI). VEGF inhibition resulted in a 47% 
reduction in of EPO-induced endothelial cell proliferation (p=0.01 vs. MI-EPO), although the 
number of proliferating cells was still significantly higher than in the sham and MI-group 
(p<0.05 vs. sham and untreated MI).
Figure 5. Effects of VEGF neutralisation on EPO-induced neovascularisation
(A) Typical examples of capillary density in the experimental groups at x40 magnification. (B) Graphic representation 
of  capillary  density  expresses  as  the  number  of  capillaries/mm2.  (C)  Graphic  representation  of  the  capillary-to-
cardiomyocyte ratio. MI = myocardial infarction, EPO = erythropoietin, IgG = control IgG, aVEGF = VEGF-neutralising 
antibody. For colour figure, see supplement 1.                54
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Effect of VEGF neutralisation on myocardial homing of EPCs
EPO significantly increased circulating EPCs after EPO treatment and VEGF neutralisation did not 
affect the number of circulating EPCs (table 1). To evaluate whether EPO-induced myocardial 
VEGF upregulation is required for homing of EPCs to the myocardium, we replaced the bone 
marrow of rats with hPAP-labelled cells to allow tracking of EPCs. EPO significantly increased 
the number of bone marrow derived endothelial cells (BMDEC) in the LV-free wall compared 
with sham and MI (p<0.01, figure 6C and D). VEGF inhibition attenuated the number of BMDEC 
by 42% in the MI-EPO + aVEGF group (p=NS vs. untreated MI, p<0.01 vs. MI-EPO, figure 6C and 
D), whereas VEGF neutralisation alone did not further reduced the number of BMDEC (p=NS 
vs. untreated MI, figure 6C and D).
Figure  6.  Effects  of  VEGF  inhibition  on  EPO-induced  myocardial  endothelial  cell  proliferation  and  vascular 
incorporation of EPCs
(A) Typical example of immunofluorecent staining at x40 magnification showing PCNA-positive nuclei (purple, i.e. 
proliferating) in capillary endothelial cells (green) highlighted with an arrow. (B) Graphic representation of the number 
of proliferating endothelial cells in the LV-free wall of the experimental groups. (C) Representative fluorescent overlay 
of myocardial section at x40 magnification stained with hPAP (green), His-52 (endothelium, red), and DAPI (nucleus, 
blue) showing hPAP-positive (i.e. bone marrow derived) endothelial cells, which appears yellow and are highlighted 
with an arrow. (D) Graphic representation of the number of bone marrow-derived endothelial cells in the LV-free 
wall. MI = myocardial infarction, EPO = erythropoietin, IgG = control IgG, aVEGF = VEGF-neutralising antibody, EC = 
endothelial cells. For colour figure, see supplement 1.       55
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Variable SHAM 
+ IgG
MI
 + IgG
MI-EPO 
+ IgG
MI + EPO
+ aVEGF1
MI + EPO
+ aVEGF2
MI + 
aVEGF1
MI + 
aVEGF2
n 9 9 11 13 10 11 12
Infarct size (% of LV
circumference)
- 41±2.3 42±1.8 43±1.5 43±2.0 43±2.1 44±1.8
Body weight (g) 396±7 409±16 414±7 406±6 415±9 416±10 402±13
Haematocrit (%) 47±1.2 48±1.2 58±1.5†‡ 56±0.9†‡ 55±2.6*# 49±1.4 47±0.8
Circ. EPCs (n/field) 147±15 91±25* 280±62*‡ 224±34*‡ - 135±21 - 
Heart/body (g/g) 3.4±0.1 5.2±0.4† 4.9±0.3† 4.7±0.3† 4.4±0.1† 5.0±0.3† 5.4±0.8†
Cardiom-cross. (mm2) 405±28 771±46† 806±41† 756±24† 806±37† 781±47† 804±28†
Lung/body (g/g) 4.4±0.1 8.1±1.7† 8.0±1.3† 8.1±1.1† 8.4±1.1† 10.6±1.2† 7.9±1.0†
Haemodynamics
Heart rate (bpm) 298±6.5 303±19 317±6 292±8 300±13 293±8 291±5
LV-syst (mmHg) 119±4 102±2† 112±4†‡ 101±2† 105±4† 100±3† 98±2†
Aorta-syst (mmHg) 123±3 101±3† 112±3# 100±3† 103±3† 96±6† 98±2†
Aorta-diast (mmHg) 80±3 71±3 82±2 74±4 73±3 65±6 71±1
dIsCussIon
The  present  study  establishes  for  the  first  time  a  crucial  role  for  VEGF  in  EPO-induced 
neovascularisation and restoration of LV function. Under ischaemic conditions, EPO promoted 
VEGF transcription through the JAK2/STAT3 signal transduction pathway. In contrast, EPO did 
not stimulate VEGF transcription in fibroblasts or endothelial cells and the direct angiogenic 
effects of EPO in the aortic ring assay were modest and VEGF independent. In rats with post-MI 
HF, EPO also stimulated VEGF-production predominantly in cardiomyocytes. Most importantly, 
neutralisation of VEGF completely abrogated the salutary effects of EPO on cardiac function 
and microvascularisation. Likewise, neutralisation of VEGF blunted EPO-induced proliferation 
of myocardial endothelial cells and homing of EPCs to the myocardium.
Our  study  suggests  a  pivotal  role  of  VEGF  in  EPO-induced  neovascularisation  in  HF,  and 
underscores  the  crucial  role  for  the  paracrine  control  of  myocardial  angiogenesis  by 
cardiomyocytes. The results provide further evidence that the beneficial effects of EPO on 
cardiac function are at least in part haematocrit independent.
Table 1. General characteristics at sacrifice
Data are presented as mean±SEM, n = number of animals, circ EPCs = circulating endothelial progenitor cells, heart/
body = heart weight/body weight ratio, cardiom-cross = cardiomyocyte cross-sectional area, lung/body = lung weight/
body weight ratio, bpm = beats per minute, LV = left ventricle, syst = systolic, diast = diastolic. * p<0.05, † p<0.01 vs. 
sham, # p<0.05, ‡ p<0.01 vs. MI.
EPO restores cardiac function in HF by targeting the myocardium
In patients with HF, correction of anaemia with EPO has been associated with restoration of 
cardiac function for more than three decades.18 Moreover, in experimental HF without anaemia, 
EPO consistently results in sustained improvement of cardiac function and microvascularisation                 56
Chapter 3
even in a dose that does not increase haematocrit levels.19,20 These observations suggested 
that EPO mediates these beneficial effects by targeting cardiac cells instead of bone marrow 
progenitor cells. Our study importantly substantiates this hypothesis. First, EPO induces VEGF 
production by cardiomyocytes and inhibition of VEGF abolishes the beneficial effects of EPO. 
From this, we postulate that the EPO-induced VEGF production by cardiomyocytes conveys 
the beneficial effects of EPO on the heart. Secondly, EPO failed to improve cardiac function 
when VEGF was antagonized, despite markedly increased haematocrit levels, thus confirming 
that these cardiac effects of EPO are haematocrit independent. Thirdly, although EPO-induced 
mobilisation of EPCs was not affected by VEGF neutralisation, myocardial neovascularisation 
was significantly attenuated, which indicates that the stimulation of EPCs alone is not sufficient 
to improve cardiac function.
EPO stimulates the paracrine angiogenic response of cardiomyocytes
Disproportional (micro) vascular growth during cardiac hypertrophy causes an impaired vascular 
supply of cardiomyocytes.2,3 Exhaustion of VEGF release by cardiomyocytes during prolonged 
ischaemia has been proposed as an underlying mechanism.2 We show that EPO increases VEGF 
expression in cardiomyocytes strictly under ischaemic conditions. Therefore, EPO seems to 
restore the adequate paracrine angiogenic response of cardiomyocytes to cellular ischaemia.21 
Furthermore, we provide proof that EPO-induced VEGF gene transcription is mediated via the 
JAK2/STAT3 signal transduction pathway. STAT3 has been identified as a crucial transcription 
factor  for  growth  factor  and  hypoxia  mediated  VEGF  production  and  an  indispensable 
transcription factor for adaptive angiogenesis in cardiomyocytes.22,23 The important role for 
STAT3 in EPO-mediated VEGF gene transcription therefore provides additional support for the 
restoration of the paracrine response of cardiomyocytes. The ischaemia-specific kinetics of 
EPO-induced VEGF production in cardiomyocytes might be explained by ischaemia-dependent 
EPOR upregulation.24 Alternatively, this might indicate that other hypoxia sensing pathways are 
also operative in this signal. Further studies are required to delineate the mechanisms of the 
hypoxia-specific nature of EPO.
The finding that the angiogenic effects of EPO are at least partially mediated in a paracrine 
fashion  rather  than  through  direct  stimulation  of  endothelial  cells  seems  to  contradict 
previous studies which showed that EPO markedly stimulates endothelial cell proliferation 
and vascular tubule formation in in vitro models of angiogenesis.25 Indeed, we did observe 
significant stimulatory effects of EPO in the aortic sprouting assay. However, these effects 
of EPO were modest, whereas the angiogenic effects of EPO in vivo were more substantial 
and amenable to VEGF neutralisation, as evidenced by marked attenuation of PCNA-positive 
endothelial cells after VEGF inhibition. Our results confirm recent observations by Asaumi et 
al. whom also demonstrated that the angiogenic effects of EPO on top of VEGF were limited.8 
Thus, EPO elicits myocardial angiogenesis, more so than direct stimulation of endothelial 
cells. Finally, the fact that cardiac function is not altered by VEGF neutralization alone might 
seem counterintuitive, because VEGF has been identified as a main angiogenic factor in HF.17 
However, to avert intrinsic negative inotropic effects of VEGF neutralisation in our model, we 
only administered VEGF-neutralising antibodies in the first week after EPO administration.        57
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With this, we established intermittent VEGF neutralisation, only during the pharmacological 
window of EPO (see supplementary data, figure S1).
EPO-increased VEGF expression facilitates myocardial incorporation of EPCs
EPO mobilises EPCs from the bone marrow and we and others have therefore postulated an 
important role for EPCs in EPO-induced neovascularisation.26 We recently showed that EPO 
stimulates incorporation of EPCs into the myocardial microvasculature.9 However, the present 
study indicates that EPC mobilisation alone does not necessarily augment neovascularisation. 
We previously demonstrated that EPCs incorporate into healthy and diseased tissues, whereas 
neovascularisation  was  specifically  induced  in  the  presence  of  VEGF  upregulation  and 
ischaemia.12 Moreover, transplantation of normal bone marrow to EPOR null mice does not 
rescue VEGF expression nor does it restore neovascularisation.27 One might therefore suggest 
that EPCs are dispensable for EPO-induced neovascularisation. However, attenuated expression 
of VEGF in EPOR null mice is also associated with impaired homing of EPCs,4 which we also 
observed in our study. Thus, in addition to stimulation of local endothelial proliferation, VEGF 
seems to serve as an important chemotactic factor for EPO-mobilised EPCs.
Clinical implications
After several promising phase 2 studies,28,29 a phase 3 clinical trial is currently evaluating the 
effects of EPO on outcome in HF patients with anaemia. From our present and previous data,22 
we postulate that a trial using low-dose EPO, with intermittent administration (circumventing 
unwanted and potentially damaging elevation of haematocrit levels) would be most likely to 
yield a positive outcome. Ideally, EPO-derivatives that specifically target the cardiomyocytic 
EPOR should be developed, as such agents might restore cardiac function without undesirable 
haematopoietic or pro-thrombotic side effects.30 Possibly, (post)transcriptional cardiomyocyte-
specific modification of the EPOR occurs that might enable us to design cardiac specific EPO 
derivatives.  Alternative  drug  delivery  approaches  might  include  EPO-eluting  hydrogels.31 
However, we cannot completely exclude that the beneficial effects of EPO are in part dependent 
on direct effects on endothelial cells or EPCs. Hence, efficacy of novel compounds should be 
compared in an experimental setting before embarking onto clinical trials.
Conclusion
EPO improves cardiac function in HF by stimulating VEGF production in cardiomyocytes. EPO 
fosters VEGF expression in cardiomyocytes which in turn stimulates myocardial endothelial 
proliferation and incorporation of EPCs. These findings provide new evidence for the non-
haematopoietic, pro-angiogenic, and salutary effects of EPO in HF. 
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Supplemental data to “Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of 
cardiac function in heart failure”
Figure 1 
Temporal characteristics of VEGF neutralisation capacity of the plasma. Graphic representation of the percentage of 
VEGF-165 recovered from the plasma of rats treated with VEGF-neutralising antibodies, expressed as the percentage 
of  VEGF-165  recovered  from  the  plasma  of  control  animals  treated  with  control  IgG.  Red  arrows  indicate  the 
intraperitoneal administration of antibodies. Blue arrows indicate the intraperitoneal administration of erythropoietin 
(EPO).
Figure 2
Effect of EPO on STAT3 phosphorylation in Neonatal Rat Ventricular Myocytes (NRVM). Deferoxamine pre-incubated 
NRVM were stimulated with EPO (10 IU/ml) or vehicle (Control). At baseline and after 30 minutes cells were lysated. 
Figure is a graphic representation of phospho-STAT3 normalised to total STAT3 and expressed as fold difference 
compared to the baseline sample. Below typical examples of Western Blot results shown. p-STAT3 = phosphorylated-
signal transducers and activators of transcription-3. * p<0.05 vs. control.Erythropoietin receptor deficient
mice have impaired exercise
tolerance due to cardiac 
and muscle maladaptoin
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Chapter 4
ABsTRACT
Background
We have demonstrated that erythropoietin (EPO) exerts cardioprotective effects via its receptor 
(EPOR)  in  pathophysiological  hypertrophy  (e.g.  myocardial  infarction  and  heart  failure). 
Whether the EPO-EPOR signalling pathway exerts similar effects in physiological hypertrophy 
is, however, unknown.
Methods
We employed transgenic-rescued EPOR-null mutant mice (EPOR-/--rescued, EPOR) that express 
the EPOR exclusively in the haematopoietic cells. C57Bl/6 mice were used as controls (WT). 
Both groups had unlimited access to a running wheel for 28 days (ex). Furthermore, sedentary 
mice of both groups were studied (sed). We measured exercise performance: average distance, 
average daily speed and average running time. At sacrifice heart weights and haemodynamic 
parameters were measured. Furthermore, we measured myocyte size, capillary-to myocyte 
ratio and number of NADH-tetrazolium reductase (NADH-TR) positive cells.
Results 
WT mice ran 8.0±0.4 km/day, whereas EPOR mice ran 5.5±0.6 km/day (p<0.01). This was mainly 
due to a lesser average speed (WT-ex 1.6±0.1 km/hrs vs. EPOR-ex 1.3±0.1 km/hrs, p<0.01). The 
percentage increase in cardiac mass was 26±4% in the WT-ex group compared to 10±2% in the 
EPOR-ex group (p<0.01). Indices of contractility and relaxation were increased after exercise 
in both groups. Myocyte size and capillary-to-myocyte ratio were increased in both the left 
ventricle and skeletal muscle in the WT-ex group as compared to the WT-sed group. The EPOR-
ex group did not show any of these effects after exercise. The percentage of NADH-TR positive 
cells was increased in skeletal muscle of the WT-ex group as compared to the WT-sed group 
(78±2 vs. 54±2%, p<0.01). This increase was absent in the EPOR-ex group. 
Conclusions
We conclude that the absence of EPO-EPOR signalling leads to a lower exercise capacity upon. 
EPOR-/--rescued mice appear to have impaired exercise tolerance due to cardiac and muscle 
maladaptation. We suggest that EPO-EPOR signalling is important for physiological adaptation 
during exercise.        65
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InTRoduCTIon
Physiologic hypertrophy is characterised by an increase in capillary density and an increase in 
myocyte size, so called hypertrophy, and is thought to be a mechanism to adapt to increased 
physiologic demands.1-3 Physiologic hypertrophy may be caused by exercise training, such as in 
athletes and has both cardiovascular as non-cardiovascular effects. 
In contrast to physiologic hypertrophy, pathophysiologic hypertrophy has been extensively 
researched in the context of cardiovascular disease. Maladaptive remodelling in cardiovascular 
disease  is  characterised  by  excessive  myocyte  hypertrophy  and  apoptosis,  fibrosis  and  a 
decrease in the number of capillaries.4 This is in contrast with physiologic hypertrophy, in which 
myocyte hypertrophy leads to an increase in the number of capillaries. Growth (in number 
and size) of capillaries, which theoretically would be needed to supply the hypertrophic left 
ventricle (LV) with oxygen and nutrients, is insufficient in pathophysiologic hypertrophy, thus 
creating an imbalance between the number of capillaries and cardiomyocytes. This imbalance 
is thought to further contribute to the remodelling process as it causes chronic hypoxia and 
less flow reserve, with further tissue damage as a result.5 
The  processes  behind  the  angiogenic  response  in  LV  hypertrophy  are  not  completely 
understood.  Numerous  growth  factors  and  their  receptors  play  a  role,  such  as  vascular 
endothelial growth factor (VEGF),6,7 transforming growth factor (TGF),8 the estrogen receptor,9  
and the erythropoietin (EPO)-EPO receptor (EPOR) system.
We and others have shown that administration of EPO in ischemic heart failure stimulates 
neovascularisation.10-12 In pathological conditions, the endogenous EPO-EPOR system plays a 
pivotal role.13 It plays a role in recruitment of endothelial progenitor cells and prevents the 
development of pulmonary hypertension during chronic hypoxia in mice,14 it has a protective 
role  against  myocardial  ischemia  reperfusion  injury,15  and  plays  a  protective  role  against 
pressure overload-induced cardiac dysfunction in vivo.16 Furthermore, the EPO-EPOR system 
plays a role in angiogenesis in hind limb ischemia through upregulation of the VEGF-VEGFR 
by directly enhancing neovascularisation.17 This notion is further supported by observations 
made in a mouse strain that expresses the EPOR exclusively in the haematopoietic cells (EPOR-
/--rescued mice).18 These mice have accelerated maladaptive remodelling upon various stimuli, 
because of an insufficient angiogenic response.14-17
Whether the EPO-EPOR system plays a role in angiogenesis seen in physiologic hypertrophy 
remains  unknown.  We  hypothesized  that  EPO-EPOR  signalling  is  crucial  for  angiogenesis. 
Therefore,  we  evaluated  the  role  of  EPO-EPOR  signalling  in  a  model  of  physiologic 
hypertrophy.
mETHods
Animals
We employed transgenic-rescued EPOR-null mutant mice (EPOR-/--rescued mice) that express 
EPOR exclusively in the haematopoietic cells. These mice have been previously described.18 
These mice have normal development without clear cardiac phenotype. The EPOR-/--rescued                 66
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mice have a C57Bl/6J genetic background and were bred and housed at the central animal 
facility of the University of Groningen. C57Bl/6J (Harlan, The Netherlands) mice were used 
as controls. All mice had ad libitum access to food and water. Mice were conventionally but 
individually caged with a 12 hr. day-night cycle. The experimental protocol was approved by 
the Animal Ethical Committee of the University of Groningen.
Experimental protocol
Ten week old male EPOR-/--rescued mice (EPOR) and age and gender control mice (WT) were 
allowed to exercise in a model of voluntary wheel running (VWR); mice had unlimited access to 
a running wheel for four weeks (WT-ex, EPOR-ex). Furthermore, sedentary mice of all groups 
were studied (WT-sed, EPOR-ex). We tested two time periods: two weeks of VWR and four 
weeks of VWR. The current paper reports end-points of the four week period only; the two 
week outcomes were in concert with these data. The four week trial consisted of a total of 56 
mice. The running wheel was equipped with sensor and a computer that recorded exercise 
performance: average distance, average daily speed, maximum speed and average running 
time. After four weeks, mice were anaesthetised and the right carotid artery was dissected. A 
microtip pressure-volume transducer was inserted (Millar Instr. Inc., Houston, Texas, USA) as 
described previously.19 Systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate 
(HR), left ventricular end-diastolic pressure (LVEDP) and maximal rates of increase and decrease 
in left ventricular pressure (dP/dtmax and dP/dtmin) were measured. Thereafter, blood was 
drawn and hearts were rapidly excised and weighed. Myocardial tissue and muscle tissue (m. 
gastrocnemius) was dissected transversally and processed for immunohistochemistry or snap 
frozen for molecular analysis.
Echocardiography
Two days prior to sacrifice all mice were subdued to echocardiography (GE Vivid 7 Dimension, 
using a 13 MHz probe) under general anaesthesia (isoflurane 2%). We recorded parasternal 
long axis (PLAX), parasternal short axis (PSAX) and apical four chamber view (AP4CH). In 
PLAX, the left ventricular outflow tract diameter (LVOT) was measured. In PSAX, M-Mode was 
obtained to measure diameters of the septum and posterior wall in systole and diastole. PSAX 
was obtained at the height of the papillary muscles. Flow over the aortic valve was measured 
using colour Doppler and cardiac output (CO) was calculated. All echo measurements were 
obtained from the same researcher (RadB) to avoid inter observer variability.
Plasma EPO levels
Plasma EPO levels were analysed using a commercial Enzyme Linked Immunosorbent Assay 
according to the guidelines provided by the manufacturer (Mouse EPO Quantikine ELISA kit, 
#MEP00, R&D Systems Europe, Abingdon, UK).
Histology
Hearts and muscle were isolated, fixed with buffered 3.7% formalin and embedded in paraffin, 
or embedded in tissue tec and frozen in liquid nitrogen. Thereafter cut into three μm thick        67
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sections on a microtome and sections were mounted on slides. Hearts were cut at the mid-
papillary level and skeletal muscle was cut at the mid-belly.
Myocyte size
Deparaffinised thee μm thick sections were stained with a Gomori’s silver staining. Myocyte 
hypertrophy was measured as the cross-sectional area (CSA) of transversally cut myocytes 
as previously described.20 In each stained section, measurements were averaged from five 
different counting fields at 40x magnification.
Capillary density 
To assess capillary density and neovascularisation, endothelial cells were stained with CD31. 
Cryosections were fixed in acetone and air dried. Next, endogenous peroxidases were blocked 
(#K4008, EnVision kit, 1:2, Dako, Glostrup, Denmark). Slides were incubated with purified rat 
anti-mouse CD31 antibody (#550274, 1:100, BD Biosciences, San Diego, CA, USA) for 1 hr. After 
washing with PBS, slides were incubated with secondary antibody (Unconjugated rabbit anti-
rat IgG antibody, #AI-4001, 1:300, Vector Laboratories, Burlingame, CA, USA) for 1 hr. Slides 
were  washed  with  PBS  and  incubated  with  a  tertiary  antibody  (anti-rabbit  polymer-HRP, 
#K4008, EnVision kit, Dako, Glostrup, Denmark) for 30 minutes. Next, sections were developed 
with AEC+ solution (#K4008, Envision kit, Dako, Glostrup, Denmark) and counter stained with 
Mayers Haematoxylin. Slides were mounted and stored in the dark. Number of capillaries was 
counted in eight random chosen fields at 40x magnification. A size criterion of ten µm was 
used to exclude small arterioles and venules. Capillary density is expressed as the number 
of capillaries per tissue area (mm2). As a measure of neovascularisation, capillary-to-myocyte 
ratio was calculated dividing capillary with myocyte density, as previously described.21
Muscle fibre type 
To assess whether exercise causes a shift in fibre type, we assessed the muscle fibre type in 
muscle tissue with NADH-tetrazolium reductase (NADH-TR) staining as previously described.22 
Type  I  muscle  fibres  have  high  NADH-dehydrogenase  activity  in  mitochondria,  therefore, 
type I muscle fibres are stained dark blue and type II muscle fibres remains unstained. In 
short, cryosections were fixed in acetone and incubated with incubation solution (NADH: 
#10107735001, Roche, Basel, Switzerland, 0.2 M phosphate buffer solution, Nitro-BT solution: 
#N-6876, Sigma-Aldrich, St. Louis, MO, USA, and H2O2) for 45 minutes at 37°C. Slides were 
washed with PBS and fixated with 4% paraformaldehyde for 10 minutes. Slides were mounted 
and stored in the dark. Number of type I and type II muscle fibres were counted in four random 
chosen fields at 40x magnification and expressed as percentage of total number of myocytes.
Quantitative real-time PCR
Total RNA from LV tissue and skeletal muscle was extracted using the Nucleospin RNA II kit, 
according to manufacturer’s protocol (Machery-Nagel, Duren, Germany). cDNA synthesis and 
quantitative real time PCR (rtPCR) were performed as previously described with using 0.5 μg 
total RNA.23 mRNA levels were expressed in relative units based on a standard curve obtained 
with serial dilutions of a calibrator cDNA mixture. To normalise expression data, multiple 
internal control genes were used as described.24 Please see supplemental data for full protocol 
and list of primers.                68
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Statistical analyses
Results are reported as mean ± standard error of the mean (SEM) or otherwise if stated. For 
reasons of clarity, we only provided statistics on the differences between the WT-sed and WT-
ex groups and EPOR-sed and EPOR-ex groups. Statistical analysis among groups was performed 
by ANOVA with the Bonferroni post hoc test, if distributed normally or with the Kruskall-Wallis 
test followed by Mann-Whitney U test when skewed distributed. All p-values are two-tailed, 
and a p-value of less than 0.05 was considered significant. All analyses were performed using 
SPSS version 16.0 software (SPSS, Chicago, IL, USA).
Figure 1. Voluntary wheel-running values for wild type and EPOR-/--rescued mice
A. Average running distance (in km/day) over the four week study period. B. Average running time (in min/day) mice 
voluntary spent in the cage-wheel over the four week study period. C. Average speed (in km/hr) mice achieved in the 
cage-wheel over the four week study period. D. Total distance (in km) mice ran over the four week study period. E. 
Average distance (in km/day) per day for every 24 hrs over the four weeks of voluntary exercise. AUC = area under the 
curve, WT = wild type mice, EPOR = EPOR-/--rescued mice, ex = exercise. * p<0.05, ** p<0.01.       69
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WT-sed
(n=10)
WT-ex
(n=12)
EPOR-sed 
(n=13)
EPOR-ex
(n=11)
HR (bpm) 495±21 484±22 532±38 486±25
SBP (mmHg) 102±2 101±2 109±4 110±3
DBP (mmHg) 63±2 61±2 65±4 69±3
MAP (mmHg) 75±2 74±2 80±4 82±2
LVEDP (mmHg) 5.8±0.9 5.1±1.1 5.7±1.2 7.9±1.2
dPdtmax (mmHg/s) 8969±293 10611±366 * 8901±585 11115±572 ‡
dPdtmin (mmHg/s) -8318±484 -10057±467 * -8278±413 -11192±660 ‡
HW (mg) 155±3.6 195±6.6 * 167±5.4 182±5.0
BW (gr) 27.1±0.4 27.1±0.4 28.1±0.8 26.6±0.4
Ht (%) 45±1 45±1 45±2 44±1
EPO (pg/ml) 107±6 111±10 154±8 177±13
REsulTs
EPOR-/--rescued mice have impaired exercise capacity as compared to wild type mice
Mice were allowed to exercise in a model of voluntary wheel-running for four weeks. Figure 1 
shows the voluntary wheel-running values for WT and EPOR-/--rescued mice. Mice in the WT-ex 
group covered a larger distance per day compared to the EPOR-ex group (8.0±0.4 vs. 5.5±0.6 
km/day, p<0.01, figure 1A). Furthermore, mice in the WT-ex group also spent more time in 
the cage-wheel (290±12 vs. 237±20 min/day, p<0.01, figure 1B), had a higher average speed 
(1.6±0.1 vs. 1.3±0.1 km/hr, p<0.05, figure 1C) and in total ran significantly more kilometres 
(223±11 vs. 153±16 km, p<0.01, figure 1D) as compared to the EPOR-ex group. Figure 1E 
shows the average running distances per every 24 hrs for the complete four weeks of voluntary 
wheel-running. Predominantly in the first two weeks, WT-ex mice ran more kilometres per day 
compared to the EPOR-ex mice (area under the curve, p<0.01).
Table 1. Clinical characteristics at sacrifice after four weeks of exercise
Data is shown of exercise after four weeks. All values are mean±SEM. HR = heart rate, SBP = systolic blood pressure, 
DBP = diastolic blood pressure, MAP = mean arterial pressure, LVEDP = left ventricular end diastolic pressure, dPdtmax 
and dPdtmin = maximal rates of increase and decrease in left ventricular pressure, Ht = haematocrit, HW = heart 
weight, BW = body weight, WT = wild type mice, EPOR = EPOR-/--rescued mice, sed = sedentary, ex = exercise. * p<0.05 
vs. WT-sed, ‡ p<0.05 vs. EPOR-sed.
Wild type mice show a stronger cardiac adaptation than EPOR-/--rescued mice
The effects of voluntary exercise are reflected by the haemodynamic parameters as shown 
in table 1. dPdtmax and dPdtmin are increased in both exercise groups (WT-ex and EPOR-
ex). Other haemodynamic parameters are all similar between groups. LV pressures and blood 
pressures are comparable, as expected.
In figure 2, the heart weights are presented. We calculated ‘cardiac adaptation’ as a measure 
for the response of the heart on the performed exercise. Both the WT-ex as EPOR-ex group had 
a similar increased heart weight normalised for body weight as compared to WT-sed (5.7±0.1                 70
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vs. 7.1±0.2 mg/g, p<0.01) and EPOR-sed (5.9±0.2 vs. 6.8±0.2, p<0.01) respectively (figure 
2A). To provide better insight in the magnitude of hypertrophy, we calculated the percentage 
increase in cardiac mass (figure 2B). The increased exercise capacity resulted in a larger cardiac 
adaptation in heart weight in the WT-ex group as compared to the EPOR-ex group (26±4 vs. 
10±2%, p<0.01).
Echocardiography
Table 2 summarises the echocardiographic parameters. Only posterior wall thickness was 
increased in the WT-ex group (p<0.05) as compared to WT-sed group. This was not observed 
in the EPOR-ex group. Furthermore, CO and SV were both increased in the WT-ex group as 
compared to the WT-sed group, as expected in animals that exercise. This was not observed in 
the EPOR-ex group.
EPOR-/--rescued mice have increased EPO plasma levels but normal haematocrit values
To measure the influence of knock-out of the EPOR on EPO production, we measured EPO 
plasma  levels  and  Ht  (table  1).  EPO  plasma  levels  were  significantly  increased  in  EPOR-
/-r-rescued mice (both the EPOR-sed and EPOR-ex groups as compared to the WT controls, 
p<0.01). However, this increase did not cause an increase in Ht levels (p=NS in all groups). So, 
the lack of a functional EPO-EPOR system leads to a modest increase in EPO levels, without 
enhanced erythropoiesis.
Figure 2. Cardiac adaptation in sedentary and exercised wild type and EPOR-/--rescued mice
A. Heart weight (HW) normalised for body weight (BW) determined from sedentary (sed) and exercised (ex) wild type 
(WT) and EPOR-/--rescued (EPOR) mice. B. Cardiac adaptation expressed as percentage change from mean sedentary 
HW in exercised groups. ** p<0.01.       71
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WT-sed
(n=10)
WT-ex
(n=12)
EPOR-sed 
(n=13)
EPOR-ex
(n=11)
LVEDD (mm) 4,09±0,48 4,09±0,46 4,11±0,30 3,89±0,25
LVESD (mm) 2.88±0.54 2.80±0.48 2.72±0.32 2.52±0.34
IVSd (mm) 0.77±0.08 0.78±0.14 0.79±0.13 0.85±0.10
LVPWd (mm) 0.69±0.14 0.85±0.09 * 0.63±0.20 0.69±0.28
FS (%) 29.97±7.49 31.68±7.24 33.67±5.36 35.52±6.80
CO (ml/min) 21.57±6.04 28.10±5.47 * 24.41±3.53 24.69±7.73
SV (μl) 62.5±12.9 74.0±12.0 * 65.6±10.0 69.3±19.9
WT mice have myocyte hypertrophy and adapted capillary-to-myocyte ratio after exercise
We measured CSA of both cardiomyocytes and skeletal muscle fibres. CSA was increased in 
WT-ex mice as compared to WT-sed mice in cardiomyocytes (216±6 vs. 280±10 μm2, p<0.01, 
figure 3A), and in skeletal muscle myocytes (1366±45 vs. 1800±161 μm2, p<0.05, figure 3B). 
CSA of both cardiomyocytes and skeletal muscle myocytes was not significantly increased in 
EPOR-ex mice as compared to EPOR-sed mice (cardiomyocyte CSA: 218±18 vs. 242±15 μm2, 
p=NS, figure 3A; skeletal muscle: 1220±118 vs. 1509±201 μm2, p=NS, figure 3B).
As a sign of neovascularisation, we calculated the capillary-to-myocyte ratio. After exercise, 
the capillary-to-myocyte ratio in the left ventricle is increased in the WT-ex group compared to 
the WT-ex group (1.2±0.03 vs. 1.6±0.06, p<0.01, figure 3C). The capillary-to-myocyte in the left 
ventricle was increased to a lesser degree in the EPOR-ex group as compared to the EPOR-sed 
group, and this did not reach statistical significance (1.1±0.06 vs. 1.3±0.11, p=NS, figure 3C). 
The capillary-to-myocyte ratio in skeletal muscle showed similar results (WT-sed vs. WT-ex: 
0.9±0.11 vs. 1.4±0.16, p<0.05, figure 3D; EPOR-sed vs. EPOR-ex: 0.9±0.11 vs. 1.1±0.06, p=NS, 
figure 3D).
Skeletal muscle of exercised EPOR-/--rescued mice does not adapt to increased workload
To measure if skeletal muscle adapts to the increased workload with a shift in fibre type (from 
type II to type I), we measured the number of NADH-TR positive cells. Figure 3E shows the 
percentage of NADH-TR positive cells counted in skeletal muscle. Significantly more NADH-
TR positive cells were found in the WT-ex group compared to the WT-sed group (78±2 vs. 
54±2%, p<0.01). This was not observed in the EPOR-ex group compared to the EPOR-sed group 
(59±1 vs. 57±1%, p=NS), indicating that the EPOR-/--rescued mice have an impaired adaptive 
mechanism to increased workload.
Table 2. Echocardiographic parameters at sacrifice after four weeks
Data is shown of exercise after four weeks. All values are mean±SEM. HR = heart rate, LVEDD = left ventricular end 
diastolic diameter, LVESD = left ventricular end systolic diameter, IVSd = thickness of the left ventricular septum during 
diastole, LVPWd = thickness of the left ventricular posterior wall during diastole, FS = fractional shortening, CO = 
cardiac output, SV = stroke volume. WT = wild type mice, EPOR = EPOR-/--rescued mice, sed = sedentary, ex = exercise. 
* p<0.05 vs. WT-sed.                72
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mRNA expression of factors involved in structural, angiogenic and metabolic development
We measured expression of different genes involved in structural, angiogenic and metabolic 
development in both left ventricular tissue as in skeletal muscle (figure 4).
Structural
mRNA expression of atrial natriuretic peptide (ANP) in the ventricle was increased 1.6±0.1 times 
in the WT-ex as compared to the WT-sed group (p<0.01). ANP expression was also increased 
significantly in the EPOR-ex group (1.3±0.1 times vs. EPOR-sed, p<0.05), but to a lesser extent 
Figure 3. Expression of different genes involved in myocyte hypertrophy
A. cardiomyocyte cross sectional area (CSA) in sedentary and exercised mice. B. Skeletal muscle fibre CSA in sedentary 
and exercised mice. C. Capillary-to-myocyte ratio in left ventricle. D. Capillary-to-myocyte ratio in m. gastrocnemius. 
E. Percentage of NADH-TR positive cells in m. gastrocnemius. WT = wild type mice, EPOR = EPOR-/--rescued mice, ex = 
exercise. * p<0.05, ** p<0.01.       73
Chapter 4 EPOR deficient mice have impaired exercise tolerance
.................................................... 4
as in the WT-ex group. Actin, alpha-1, skeletal muscle (ACTA-1), is a conserved protein involved 
in cell motility, structure and integrity. Alpha actins are a major constituent of the contractile 
apparatus. ACTA-1 was increased in the ventricle of both the WT-ex (2.3±0.2 times vs. WT-sed, 
p<0.01) as EPOR-ex group (1.6±0.2 times vs. EPOR-sed, p<0.01), but not in skeletal muscle.
Angiogenic 
We measured mRNA levels of VEGF-A as a marker of angiogenic development. VEGF-A was 
slightly, but significantly increased in the ventricle of the WT-ex group (1.4±0.1 times vs. WT-
sed, p<0.01). This was not observed in the EPOR-ex group, and this effect was also absent in 
skeletal muscle.
Figure 4 A. mRNA expression of atrial natriuretic peptide (ANP). B. mRNa expression of actin, alpha-1, skeletal muscle 
(ACTA-1). C. mRNA expression of myocyte-enriched calcineurin interacting protein-1 (MCIP-1). D. mRNA expression 
of vascular endothelial growth factor-A (VEGF-A). E. mRNA expression of peroxisome proliferator activated receptor 
alpha (PPARα). F. mRNA expression of acyl-CoA dehydrogenase (MCAD). WT = wild type mice, EPOR = EPOR-/--rescued 
mice, ex = exercise. * p<0.05, ** p<0.01.                74
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Metabolic
Peroxisome proliferator activated receptor alpha (PPARα), involved in the regulation of cellular 
differentiation, development and metabolism, was not increased in the ventricle. In skeletal 
muscle on the other hand, PPARα was increased 1.9±0.2 times in the WT-ex group (vs. WT-
sed, p<0.01). However, also in the EPOR-ex group, PPARα was increased (1.8±0.3 vs. EPOR-
sed, p<0.01). mRNA expression of myocyte-enriched calcineurin interacting protein-1 (MCIP-1) 
was only increased in the ventricle of the WT-ex group (3.5±0.4 times vs. WT-sed, p<0.01) 
and not in the EPOR-ex group, and also not in skeletal muscle. mRNA expression of acyl-CoA 
dehydrogenase (MCAD) is decreased in the ventricle of both the WT-ex (with 8%, p<0.05) as the 
EPOR-ex group (with 4%, p<0.05). However in skeletal muscle, MCAD expression is increased 
1.3±0.1 times in the WT-ex group (vs. WT-sed, p<0.01). This was not observed in the EPOR-ex 
group. 
dIsCussIon
In a model of voluntary exercise, we show that EPOR-/--rescued mice have a reduced exercise 
capacity, which is associated with an impaired adaptation of cardiac and skeletal muscle. 
The increased exercise capacity seen in WT mice resulted in a larger cardiac adaptation in 
HW in the WT-ex mice (26%) as compared to the EPOR-ex mice (10%). This increased cardiac 
adaptation was accompanied by myocyte hypertrophy and neovascularisation as shown with 
the increase in CSA and capillary-to-myocyte ratio in both cardiomyocytes as skeletal muscle. 
EPOR-/--rescued did not show this adaptation to increased workload. Furthermore, exercised 
WT mice show a shift in muscle fibre type to adapt to the increased workload (from type II to 
type I), whereas EPOR-/--rescued mice do not show this adaptation al all.
 
The development of EPOR-/--rescued mice by the group of Yamamoto provided an interesting 
model to study the role of EPO-EPOR signalling.18 Where EPO and its receptor are indispensable 
to erythropoiesis, knock-out of the EPOR is lethal in utero. Exploiting a GATA-1 minigene cassette 
with haematopoietic regulatory domains, the group of Yamamoto established EPOR-/--rescued 
mice expressing EPOR exclusively in the haematopoietic lineage, but without expression of the 
EPOR in any other organ. Despite the lack of EPOR expression in non-haematopoietic tissues, 
these mice develop normally and are fertile.18 The group of Shimokawa showed that EPOR-/-
-rescued mice have an impaired angiogenic response in models of maladaptive hypertrophy, 
such as transverse aortic constriction and myocardial infarction.15-17 In the current study, we 
show that also in adaptive hypertrophy these mice have an impaired angiogenic response. The 
capillary-to-myocyte ratio is not significantly increased in both the left ventricle and in skeletal 
muscle, indicating the impaired angiogenic response.
A  functional  EPOR,  which  was  previously  thought  only  to  be  present  in  haematopoietic 
progenitor cells, is also expressed in non-haematopoietic systems, such as the cardiovascular 
system, skeletal muscle and the central nervous system.25 In WT mice, normal changes are 
observed in left ventricular and skeletal muscle as a response to exercise, such as the increase 
in CSA, capillary-to-myocyte ratio and, for skeletal muscle, a shift in fibre type. The diminished        75
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responses in the EPOR-/--rescued mice could indicate a vulnerable state of cardiomyocytes and 
skeletal muscle myocytes in EPOR-/--rescued mice, due to the absence of EPO-EPOR signalling.
Skeletal muscle fibres can be categorised to the degree of oxidative capacity of the fibre. 
Type I fibres appear red due to the high content of the oxygen binding protein myoglobin 
and  mitochondrial  cytochromes.  These  fibres  are  suited  for  endurance,  because  they 
use predominantly oxidative metabolism to generate ATP. Type II fibres are white and rely 
predominantly on glycolysis for energy production. These fibres are efficient for short bursts of 
speed and power and use both oxidative metabolism and anaerobic metabolism depending on 
the particular sub-type. These fibres cannot maintain contractions for longer periods. Increase 
in exercise, as in the WT-ex mice, causes a shift from type II fibres to more type I fibres, to 
adapt to the increased exercise. The absence of the EPOR signalling in skeletal muscle in the 
EPOR-/--rescued mice does not cause a shift in muscle fibre type, as determined by NADH-TR 
staining. This in clear contrast to the WT, in which we did observe a clear increase in type I 
fibres required for endurance exercise. It might well be possible that EPOR signalling plays a 
crucial role in this shift and that absence of this shift in fibre type causes the decreased exercise 
capacity as compared to the WT-ex mice.
As markers of hypertrophic response to exercise, we measured ANP and ACTA1. Both are 
increased in hypertrophy in the left ventricle.22,26 The differences in ANP and ACTA1 mRNA 
expression show that the cardiac adaptive response to exercise is less pronounced in the EPOR-
ex group than in the WT-ex group. This is in concert with the much larger cardiac adaptation 
in the WT-ex group. MCIP-1 is a downstream target of calcineurin and the nuclear factor of 
activated T-cells (NFAT) pathway. NFAT is involved in the development of cardiac and skeletal 
muscle.27 Activation of MCIP-1 in left ventricular tissue, and les pronounced in the skeletal 
muscle myocytes, in the WT-ex group strongly suggests that the NFAT pathway is activated. 
MCIP-1 inhibits NFAT in a negative feedback loop and suggests a cross talk between EPO and 
NFAT pathways.
We recently have shown that VEGF is crucial for EPO-induced improvement of cardiac function.6 
VEGF neutralisation resulted in reduced neovascularisation in a model of experimental heart 
failure, despite EPO treatment, suggesting that EPO exerts its effects partially via VEGF. The 
absence of VEGF-A increase in the EPOR-/--rescued mice after exercise is in concert with these 
data.
Analyses  of  metabolic  makers,  PPARα  and  MCAD,  show  that  exercise  has  effect  on  the 
metabolism, as expected.28 However, no clear differences were observed between the WT and 
EPOR-/--rescued mice and might not be the limiting factor in adaptive hypertrophy.
EPO is one of the most scrutinised doping drugs in endurance sports these days. Numerous 
professional athletes, most notably professional cyclists, have been using EPO as a doping drug 
for years, to enhance their endurance. It is thought that EPO, by its main erythropoietic effect, 
increases the number of erythrocytes, hence increasing the oxygen carrying capability of the 
blood en thereby have increased oxygen supply to the organs during endurance sports. This 
would only be the case with (very) high haematocrit values. Nowadays, haematocrit values 
are critically monitored; not only absolute levels, but also variation (biological passport) and                 76
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athletes with suspicious haematocrit values are not allowed to enter competition. However, 
up to date, no clear scientific evidence exists if EPO usage is actually useful. Furthermore, 
athletes who use EPO (or CEPO or ARA), only take low amounts of EPO (1000-4000 IU), not 
enough to increase haematocrit levels significantly.29 Current anti-doping strategies with the 
use of biometrical passports clearly do not exclude the use of low-dose EPO. From our data, 
we postulate that it might well be possible that the supposed effects of EPO as a doping drug 
might not be the exclusively erythropoietic but rather the non-erythropoietic properties of 
EPO.
As this is an animal model, always precaution is needed to translate the current findings to the 
clinical situation. Furthermore, this is a model of voluntary wheel-running. Mice still could run 
less, not because of less exercise capacity, but of other mechanisms. To investigate whether the 
absence of the EPO-EPOR signalling could lead to dysfunction heart and muscles, prolonged or 
forced exercise, for example swimming, should be used. We conclude that the absence of EPO-
EPOR signalling leads to a lesser exercise capacity upon voluntary wheel-running. We suggest 
that EPO-EPOR signalling is important for physiological adaptation during exercise.
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Real-time PCR primer, 5’ to 3’
Gene name Forward Reverse
Cyclo G CTT CAT ACC AGC GAC GAT TC ATG TGG AGG AGT CTC ACT TC
GAPDH CAT CAA GAA GGT GGT GAA GC ACC ACC CTG TTG CTG TAG
ANP ATG GGC TCC TTC TCC ATC AC TCT ACC GGC ATC TTC TCC TC
ACTA1 TGC CAT GTA TGT GGC TAT CCA TCC CCA GAA TCC AAC ACG AT
MCIP1 GCT TGA CTG AGA GAG CGA GTC CCA CAC AAG CAA TCA GGG AGC
VEGF-A ACT GGA CCC TGG CTT TAC TG CAG TAG CTT CGC TGG TAG AC
PPARα TAT TCG GCT GAA GCT GGT GTA C CTG GCA TTT GTT CCG GTT CT
MCAD GCA GCC AAT GAT GTG TGC TTA C CAC CCT TCT TCT CTG CTT TGG T
Supplemental  data  to  “Erythropoietin  receptor  deficient  mice  have  impaired  exercise 
tolerance due to cardiac and muscle maladaptation”
suPPlEmEnTAl mETHods
Plasma EPO levels
Plasma EPO levels were analysed using a commercial Enzyme Linked Immunosorbent Assay 
according to the guidelines provided by the manufacturer (Mouse EPO Quantikine ELISA kit, 
#MEP00, R&D Systems Europe, Abingdon, UK). Samples were 2 times diluted and incubated 
for 2 hrs at room temperature. After several wash steps, substrate solution was added and 
incubated for 30 minutes at room temperature in the dark. After incubation, the reaction was 
stopped with specific stop solution and the optical density was read 450 nm, with a wavelength 
correction of 540 nm (Microplate Spectrophotometer, Bio-Rad Laboratories, Hercules, CA, 
USA). Plasma EPO levels were determined against a standard curve using specific software 
(Microplate manager 5.2.1, Bio-Rad Laboratories).
Supplemental table 1. List of primers used for real-time PCR
GAPDH = Glyceraldehyde 3-phosphate dehydrogenase, ANP = atrial natriuretic peptide, ACTA1 = actin, alpha-1, skeletal 
muscle, MCIP-1 = myocyte-enriched calcineurin interacting protein-1, VEGF-A = vascular endothelial growth factor-A, 
PPARα = peroxisome proliferator activated receptor alpha, MCAD = acyl-CoA dehydrogenase. CHAPTER Apoptosis during CABg surgery with 
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Chapter 5
ABsTRACT
Objectives
We  aimed  to  compare  the  rate  of  apoptosis  after  cardiopulmonary  bypass  (CPB)  and 
cardioplegic arrest during coronary artery bypass grafting (CABG) surgery between atrial and 
ventricular tissue.
Methods 
During CABG surgery with CPB and cardioplegic arrest, sequential biopsies were taken from 
the right atrial appendage and left ventricular anterior wall before CPB and after aortic cross 
clamp release. Change in number of apoptotic cells and biochemical markers of myocardial 
ischemia and renal dysfunction were assessed.
Results 
CPB was associated with a transient small, but significant increase in CK (1091±374%), CK-MB 
(128±38%), troponin-T (102±13%) and NT-proBNP (1308±372%) levels (all: p<0.05). A higher 
number of apoptotic cells as assessed by caspase-3 staining was found in the ventricular 
biopsies taken after aortic cross clamp release compared to the biopsies taken before CPB 
(5.3±0.6 vs. 14.0±1.5 cells/microscopic field, p<0.01). The number of apoptotic cells in the 
atrial appendage was not altered during CPB. Correlation between the duration of aortic 
cross clamp time and the change in caspase-3 positive cells in the left ventricular wall was of 
borderline significance (r of 0.58, p=0.08). Similar results were obtained from TUNEL staining 
for apoptosis.
Conclusion 
CABG surgery with CPB and cardioplegic arrest is associated with an elevated rate of apoptosis 
in ventricular but not in atrial myocardial tissue. Ventricular tissue may be more sensitive to 
detect changes than atrial tissue, and may be more useful to investigate the protective effects 
of therapeutic intervention.       83
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InTRoduCTIon
Coronary  artery  bypass  grafting  (CABG)  surgery  with  cardiopulmonary  bypass  (CPB)  and 
cardioplegic arrest is the most commonly used cardiac surgery procedure in the western 
world.1  This  procedure  is  associated  with  periods  of  oxygen  deprivation  and  possibly  a 
damaging effect to the heart. Restoration of coronary blood flow after release of the aortic 
cross clamp leads to ischemia-reperfusion injury. Subsequent production of reactive oxygen 
species result in cardiomyocyte death due to apoptosis.2-4 These changes may cause (transient) 
cardiac dysfunction,5,6 and therefore limiting the duration of cardioplegic arrest may reduce 
cell injury.
We  hypothesised  that  CPB  and  cardioplegic  arrest  (in  the  setting  of  CABG)  would  cause 
considerable increase in number of apoptotic cells in the heart. We therefore studied the 
presence of apoptosis in hearts of patients undergoing CABG surgery with CPB and cardioplegic 
arrest and we aimed to compare the rate of apoptosis after CPB and cardioplegic arrest during 
CABG surgery between atrial and ventricular tissue.
mETHods
Patients
Patients were eligible for this study when aged between 18 and 80 years, when admitted for 
elective CABG surgery with CPB and cardioplegic arrest for the first time for two or more vessel 
coronary artery disease, and who met all the other inclusion and none of the exclusion criteria 
as listed in table 1. This study was approved by the Institutional Review Board of the University 
Medical Centre Groningen. Each participating patient has signed informed consent.
Anaesthesia
General anaesthesia was provided according to a fixed protocol.7 Premedication consisted of 
oral diazepam 10-15 mg two hours preoperatively. After insertion of peripheral venous and 
arterial cannulae under local anaesthesia, general anaesthesia was induced with sufentanil 0.5-
1 μg/kg and midazolam 0.05-0.1 mg/kg. Tracheal intubation was achieved with pancuronium 
0.1 mg/kg and the lungs were ventilated with air and oxygen (fraction of inspired oxygen [FiO2] 
= 0.4). Anaesthesia was maintained with sufentanil, pancuronium and infusion of midazolam 
0.1 mg/kg/hr. A flow-directed continuous cardiac output catheter was inserted in the right 
internal jugular vein, and an indwelling bladder catheter was used for urine collection. After 
induction of anaesthesia the patients received cefuroxim 1500 mg (clindamycin 600 mg when 
allergic to penicillin).  
Fluid management: Hydroxyethyl starch 6% and saline were used to maintain mean arterial 
pressure  >60  mmHg  and  to  maintain  filling  pressure  and  cardiac  output.  Transfusion  of 
packed RBC were administered at haemoglobin levels <5.0 mmol/l. According to standard 
care in our clinic intravenous insulin therapy was started at serum glucose levels >8.0 mmol/l. 
Before institution of CPB, activated clotting time of greater then 400 seconds was produced 
by administration of heparin (starting dose 3 mg/kg). Patient characteristics were recorded 
prospectively. Diuretics, mannitol and aprotinin were not used during the entire study period.                84
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CPB:  CPB  was  provided  using  a  Stockert  roller  pump  with  an  open  reservoir,  a  hollow 
fibre oxygenator (Cobe optima), an arterial filter (Affinity, Medtronic) and an inline blood 
monitoring system (CDI500, Terumo). The CPB flow was maintained at 2.4 l/min/m2 and the 
circuit was primed with 1000 ml Ringers-lactate, 500 ml Haes 200/0.5 10% and 50 mg heparin. 
Nasopharyngeal temperature was lowered to 32°C. MAP was maintained between 60 and 90 
mmHg. Deviations were corrected with phenylephrin and nitroglycerin.
Surgery and biopsies
Surgery was performed by experienced cardiothoracic surgeons. All patients underwent CABG 
surgery with mild hypothermia (32-34°C). Cardioplegia in all patients was standardized to the 
crystalloid St. Thomas solution. The atrial biopsies were taken from the right atrial appendage 
and closed with prolene 4.0. Care was taken not to squeeze the biopsy places with forceps. 
Ventricular tissue samples were collected from the left anterior ventricular wall parallel to the 
left anterior descending artery, each from separate sites. Under an angle of approximately 
30 degrees using a 24 Gauge tru-cut needle ventricular biopsies were taken. Part was put 
in 4% paraformaldehyde for 24 hrs, after which it was processed for paraffin embedding for 
immunohistological assessment. The second part was snap frozen in liquid nitrogen for RNA 
isolation. The ventricular biopsy site was closed using prolene 4.0 suture with teflon pledges. 
Before closure of the chest, biopsy sites were checked for bleeding.
Figure 1. Study design
The figure shows the study design as described in the text.
Study design and mode of sampling biopsies
Tissue  samples  were  collected  at  three  different  time  points  during  surgery  (figure  1). 
Immediately after opening the chest, a baseline atrial biopsy was collected. During placement 
of the venous cannula (20 to 40 minutes later) a second atrial biopsy was collected. Immediately 
after initiation of bypass the first ventricular biopsy was obtained. Ten minutes after aortic 
cross clamp release, the second ventricular biopsy was taken. Finally, a third atrial biopsy was 
obtained  immediately  after  harvesting  the  second  ventricular  tissue  sample.  Additionally 
plasma and urine was collected for up to five days post-procedure to examine release of 
markers of both myocardial ischemia and of renal function.       85
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Monitoring and measurements during surgery
Blood  pressure,  heart  rate,  electrocardiogram,  cardiac  output  and  mixed  venous  oxygen 
saturation were monitored according to routine clinical practice. Blood and urine samples were 
collected at different time point. One day before surgery, blood and urine was collected for 
screening. Furthermore, pre-surgery, post-surgery, and at 2, 5, 12, 24, 48, 72 and 120 hours after 
surgery, blood and urine samples were collected. Markers of myocardial ischemia (creatinine 
kinase (CK), CK-myoglobin (CK-MB), troponin-T, N-terminal-pro Brain Natriuretic Peptide (NT-
proBNP)) and renal function (creatinine) were determined. In urine samples microalbiminuria 
and creatinine was determined. The estimated glomerular filtration rate (eGFR) was calculated 
using the modification of diet in renal disease (MDRD) formula. All markers were analysed in 
the hospital laboratory.
Histology
For apoptosis detection, we stained for caspase-3 and TUNEL. Formalin fixed paraffin sections 
were incubated with an antibody that specifically recognizes the active form of caspase-3 as 
previously reported.8,9 TUNEL staining was performed as previously described.8 For quantitative 
analysis, active caspase-3 positive cells or TUNEL-positive cells were counted in six random 
fields per section (80-120 cells per field) counted at high-power magnification (40x).
Statistics
Results are reported as mean ± standard error of the mean (SEM) or otherwise if stated. 
Because of small samples sizes, comparisons of differences between groups were analysed 
by Wilcoxon or Friedman test when appropriate. The correlation between aortic cross clamp 
time and the rate of apoptosis in ventricular tissue was assessed using Spearman coefficient. 
A p-value of less than 0.05 was considered significant. All analyses were performed using SPSS 
version 16.0 software (SPSS, Chicago, IL, USA).
REsulTs
Patient characteristics
We included ten patients, undergoing elective CABG surgery with CPB and cardioplegic arrest 
for 2- and 3-vessel disease. All patients were male, and their age ranged from 39 to 73 years. Two 
patients had 2-vessel disease, and eight patients had 3-vessel disease. Baseline characteristics 
are summarized in table 1. Mean duration of the complete procedure was 222±19 minutes 
with a mean perfusion time of 80±80 minutes and a mean aortic cross clamp time of 46±5 
minutes. All patients recovered well from their surgery. No rethoracotomies for postoperative 
bleeding were performed. Post-operative atrial fibrillation was seen in two patients. Average 
stay after surgery at the intensive care unit was 1.2 days. Patients were discharged from the 
hospital at a mean of eight days after surgery.                86
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Inclusion criteria
Accepted  for  CABG  surgery  with  CBP  and  cardioplegic  arrest  for  2-  and  3-vessel  coronary  artery 
disease
Primary CABG-surgery
Haemoglobin concentration ≥7.2 mmol/l and ≤9.7 mmol/l
Man or woman 
between 18 to 80 years of age
Exclusion criteria
Off-pump CABG surgery
Previous MI of the anterior wall
LVEF ≤40%
Chronic kidney disease (serum creatinine >106 mmol/ml for all females, >133 mmol/ml for black males, 
>115 mmol/ml for non-black males
Atrial fibrillation
Grand mal seizure within 1 year of enrolment
Malignant hypertension
Previous treatment with rhEPO
Blood transfusion <12 weeks before randomisation
Polycythaemia vera
Pregnancy/breast feeding
Severe valvular disease (including pulmonary and tricuspid) or left ventricular outflow obstruction, 
which requires surgery
Pulmonary hypertension
Concomitant inflammatory or malignant disease
Presence of other serious medical conditions
Participation in any investigational device or drug trial(s) or receiving other investigational agent(s) 
within 30 days prior to enrolment.
Table 1. Inclusion and exclusion criteria
CABG = coronary artery bypass graft surgery, CPB = cardiopulmonary bypass, MI = myocardial infarction, LVEF = Left 
ventricular ejection fraction, rhEPO = recombinant human erythropoietin.
Apoptosis in atria and ventricles
Figure 2A and B show the rate of apoptosis in right atrial appendage and left ventricular wall as 
determined by caspase-3 and TUNEL staining. In the left ventricle, significantly more caspase-3 
positive cells were counted in the biopsies taken after aortic cross clamp release compared 
to the number of caspase-3 positive cells found in the biopsies taken before the start of CPB 
(5.3±0.6 vs. 14.0±1.5 cells per microscopic field, p<0.01). Similar results were obtained from 
TUNEL staining (32.5±4.0 vs. 44.9±4.6 cells per microscopic field, p<0.05). In the atria, the 
number of caspase-3 positive cells was not altered during surgery (1.4±0.3 vs. 1.9±0.5 vs. 
1.8±0.6 cells per microscopic field; p=NS). This was confirmed by TUNEL staining (23.1±4.1 
vs. 22.2±2.1 vs. 25.3±3.8 cells per microscopic field; p=NS). Correlation between aortic cross 
clamp time and the change in ventricular caspase-3 positive cells showed a trend towards a 
positive correlation with an r of 0.58 (p=0.08; figure 2F). Similar results were obtained from the 
TUNEL staining (data not shown).       87
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Cardiac enzymes and renal function
CPB was associated with a transient small, but significant increase in CK, CK-MB, troponin-T 
and NT-proBNP levels (all: p<0.05). CK-MB levels and troponin-T levels reached their maximum 
after two and five hours, respectively, and returned to baseline within 120 hours post-surgery 
(percentage change: 128±38% and 102±13%, respectively; figure 3A-B). CK levels peaked at 48 
hours post-surgery (percentage change: 1091±374%). Maximum NT-proBNP levels were found 
at 72 hours post-CABG (percentage change: 1308±372%; figure 3C-D). Serum creatinine levels 
decreased shortly after the procedure and returned to baseline after 120 hours. Accordingly, 
eGFR levels were higher at two hours post-surgery with a return to baseline at day five (figure 
3E-F). Other measurements showed no or very little fluctuation in time.
dIsCussIon
We demonstrate that CABG surgery with CPB and cardioplegic arrest causes an increased rate 
of apoptosis in ventricular but not in atrial myocardial tissue. Thus it seems that ventricular 
myocardium is more vulnerable to cardioplegic arrest. In addition, our data suggests that 
studies with pharmacological interventions aimed at salvaging apoptosis during cardioplegic 
arrest should use ventricular biopsies rather than atrial biopsies.
Different studies use either atrial or ventricular tissue to show apoptosis,10-12 but no comparison 
has been made. Our study shows clear differences in the rate of apoptosis between ventricular 
and  atrial  myocardial  tissue.  Furthermore,  manipulating  myocardial  tissue,  for  example 
with forceps, induces apoptosis. In our study, care was taken, to use only biopsies of non-
manipulated tissue to avoid induction of apoptosis by manipulation. 
Apoptosis has been considered as one of the mechanisms of cardiomyocyte loss during CPB 
and cardioplegic arrest, like in CABG surgery.13,14 Apoptosis during CPB and cardioplegic arrest 
can be triggered by several mechanisms, including ischemia-reperfusion injury,15 and release 
of cytokines and inflammatory factors.16 Longer aortic cross clamp time correlates, as shown 
in this and other studies, with an increase in number of apoptotic cells.17 This increased loss of 
cells might contribute to an impaired contractility of the heart.18 Several strategies are being 
tested to ensure a lower rate of apoptosis, by reducing aortic cross clamp time as much as 
possible, or using cytoprotective agents against ischemia-reperfusion injury.19,20
Prevention of apoptosis during CPB: proposal for an intervention trial
We postulate that apoptosis during CABG surgery is a maladaptive effect of CPB and cardioplegic 
arrest and might be amendable for intervention. Under normal circumstances EPO and EPOR 
have a relatively low expression in non-haematopoietic tissue.21 However, expression of EPO 
and EPOR is rapidly increased in response to hypoxia and increased reactive oxygen species.22,23 
Numerous studies have shown that EPO has cytoprotective effects,24-26 and EPOR signalling 
pathways are associated with cell survival.27-30 Since EPO reduces apoptosis, we postulate that 
EPO administration may have salutary effects on the heart in the setting of cardiac surgery 
employing CPB and cardioplegic arrest. We therefore started a prospective randomised clinical 
trial in which patients are randomised to EPO (60.000 IU) or placebo (clinical trials protocol ID                 90
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NCT00524901) before cardiac surgery employing CPB and cardioplegic arrest, which aims to 
prove the anti-apoptotic effects of EPO. Patients are included according to the inclusion and 
exclusion criteria summarised in table 1.
Conclusions
We  conclude  that  CABG  surgery  with  CPB  and  cardioplegic  arrest  is  associated  with  an 
elevated rate of apoptosis in ventricular tissue. Ventricular tissue may be more sensitive to 
detect changes than atrial tissue, and may be more useful to investigate the protective effects 
of therapeutic interventions. We speculate that the observed increase in apoptosis may be 
amendable to ant-ischemic and anti-apoptotic agents. EPO may be useful in this respect, as it 
has established anti-apoptotic effects and the EPOR is expressed in the heart.
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N=10
(ave±SEM)
General
Age (yrs) 60±3.4
Sex (% male) 100
Race (Caucasian, %) 100
No. of diseased vessels 2.8±0.1
Height (cm) 177±1.8
Weight (kg) 85.1±2.7
BMI (kg/mm2) 27±0.5
RR (mmHg) 146/73±6/3
HR (bpm) 70±5
Medical history
Previous myocardial infarction (%) 20
Previous CABG surgery (%) 0
Previous PCI (%) 20
Diabetes mellitus (%) 40
History of hypertension (%) 70
Obesity (%) 80
History of hypercholesterolemia (%) 20
Smoking (%) 10
Family history (a) 40
Renal dysfunction 0
Medication
Beta-blocker (%) 100
Ace-inhibitor (%) 20
Statin (%) 80
Diuretic (%) 10
Nitrate (%) 20
Calcium antagonist (%) 30
AT1-antagonist (%) 30
Acetylsalicylic acid (%) 100
Other anticoagulants (%) 10
Table 2. Baseline characteristics
Ave = average, SEM = standard error of the mean, BMI = body mass index, RR = blood pressure, HR = heart rate, CABG 
= coronary artery bypass graft surgery, PCI = percutaneous coronary intervention, AT1-antagonist = type I angiotensin 
II receptor antagonist, bpm = beats per minute.
(a)  a  positive  family  history  was  defined  by  the  presence  of  a  composite  endpoint  (myocardial  infarction, 
revascularisation, chronic heart failure, stroke and death) in first degree family members before the age of 50 (males) 
or 60 (females).                92
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Chapter 6
ABsTRACT
We investigated whether administration of estradiol to male mice augments mobilisation 
of  bone  marrow-derived  endothelial  progenitor  cells  (EPC)  and  incorporation  into  foci  of 
neovascularisation after hind limb ischemia, thereby contributing to blood flow restoration. 
Mice were randomised and implanted with placebo pellets or pellets containing low-dose 
estradiol  (0.39  mg)  or  high-dose  estradiol  (1.7  mg).  Hind  limb  ischemia  was  induced  by 
unilateral resection of the left femoral artery one week after pellet implantation, then EPC 
mobilisation and functional recovery was evaluated. EPC recruitment was assessed in mice 
transplanted with bone marrow from transgenic donors expressing β-galactosidase driven by 
the Tie-2 promoter. EPC culture assay performed two weeks after pellet implantation revealed 
a significantly greater (p<0.05) number of circulating EPCs in the high-dose estradiol group than 
in the low-dose estradiol and placebo groups. At three and four weeks after induction of hind 
limb ischemia, perfusion was significantly greater (p<0.05) in high-dose estradiol mice than in 
mice implanted with the low-dose estradiol or placebo pellets. At one and four weeks after hind 
limb ischemia surgery, more bone marrow-derived EPCs, identified as β-galactosidase-positive 
cells, were observed in ischemic regions from high-dose estradiol animals than in low-dose 
(p < 0.05) or placebo groups (p<0.05). These results indicate that estradiol dose-dependently 
increases the levels of EPCs in peripheral blood in male animals, improves the recovery of 
blood flow, and decreases limb necrosis after hind limb ischemia, and that this enhancement 
occurs, in part, through augmentation of EPC mobilisation and greater incorporation of bone 
marrow-derived EPCs into foci of neovascularisation.       99
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InTRoduCTIon
Since  the  discovery  of  endothelial  progenitor  cells  (EPCs)  in  1997,1  many  studies  have 
investigated their potential angiogenic capacity.2-6 The relationships between EPCs and various 
growth factors, cytokines, and hormones, including estrogen,7 have been studied in an effort 
to identify their potential for therapeutic angiogenesis. The emerging consensus of these 
studies is that blood-vessel regeneration evolves not only from the migration and proliferation 
of endothelial cells adjacent to the site of injury (a process called angiogenesis), but that 
circulating EPCs also contribute to the formation of new blood vessels.1,8-10 The mechanisms 
that regulate EPC-mediated neovascularisation are slowly being characterised.5,11,12
Oestrogen regulates angiogenesis by influencing the activity of endothelial cells. Under normal 
physiological conditions, angiogenesis in the uterus is associated with fluctuations of circulating 
estradiol (E2) and other sex steroids.13-17 The well established link between oestrogen and breast 
tumour invasiveness also suggests that oestrogen exerts a pro-angiogenic effect because the 
formation of metastases is dependent on angiogenesis.18 Studies in mice have revealed that 
E2 accelerates endothelial recovery after arterial injury,19,20 and E2 has been shown to prevent 
endothelial cell apoptosis 5,21,22 and to exert other positive effects on mature endothelial cells.
To date, experiments in animal models that have investigated the effects of E2 on EPCs have 
been performed exclusively in female animals,5,12,22 and it is not known whether these results 
can  be  extrapolated  to  males.  Furthermore,  the  potential  contribution  of  EPC-mediated 
neovascularisation to functional recovery at the ischemic site continues to be debated. This 
study sought to determine whether estrogen mobilises EPCs from the bone marrow after hind 
limb ischemia (HLI) in male animals, and whether the mobilised EPCs subsequently contribute 
to post-ischemic neovascularisation.
mETHods
Animal models
All experiments were conducted according to protocols approved by the Animal Care and 
Use Committee of St Elizabeth’s Medical Centre, Boston, MA and conform the Guide for the 
Care and Use of Laboratory Animals by the US National Institutes of Health. Experiments were 
performed in male FVB wild type (WT) mice (Jackson Laboratory, Bar Harbor, ME, USA), aged six 
weeks. HLI was induced by unilateral resection of the left femoral artery from the proximal end 
of the femoral artery up to the distal portion of the saphenous vein. The femoral artery and all 
side-branches were dissected and excised, then the overlying skin was closed using a surgical 
stapler. After surgery, the mice were kept on a warm plate until fully awake. For bone marrow 
transplant experiments, mice were irradiated (16 G) to destroy endogenous bone marrow and 
transplanted with a minimum of 3 × 106 bone marrow cells from age-matched male transgenic 
donors that expressed β-galactosidase; β-galactosidase transcription was regulated by the 
endothelial cell-specific Tie-2 promoter. Mice were anaesthetised by intraperitoneal injection 
with a mixture of ketamine (80 mg/kg) and xylazine (4 mg/kg) and sacrificed with an overdose 
of the same anaesthetic. Animals were housed under standard conditions with ad libitum food 
and water. Over the duration of the experiments, the mortality rate was 6% for intact mice,                 100
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10% for mice that underwent HLI surgery alone, and 33% for mice that underwent both bone 
marrow transplantation and HLI surgery.
Design
Three experiments were performed. For each experiment, non-castrated WT male mice were 
implanted with 90-day release E2 pellets containing high (1.7 mg/pellet) or low (0.39 mg/pellet) 
doses of E2 (17β-estradiol), or placebo (Innovative Research of America, Sarasota, FL, USA). In 
a previous study of experimental carotid artery injury, serum E2 levels were approximately 
300-fold greater in ovariectomised female mice implanted with the high-dose E2 pellet than in 
mice implanted with the placebo pellet.5 Pellets were implanted subcutaneously as described 
elsewhere.12
The first experiment was performed with 60 mice (n=20 in each treatment group). Mice were 
implanted at week 0, and five mice from each group were sacrificed at weekly intervals over the 
next four weeks. Blood was collected by intracardiac puncture, and the number of circulating 
EPCs was assessed via EPC culture assay.
In the second experiment, 60 mice (n=20 in each treatment group) were implanted at week –1, 
HLI was induced at week 0, and five mice from each group were sacrificed at weekly intervals 
over the next four weeks. At sacrifice, all ischemic, non-necrotic tissue was collected and 
stained with fluorescent CD31 antibodies to assess capillary density; blood was collected by 
intracardiac puncture, and the number of circulating EPCs was assessed via EPC culture assay. 
Functional recovery was evaluated from Laser Doppler Perfusion Imaging (LDPI) measurements 
taken before HLI surgery and at sacrifice, and limb necrosis was assessed visually as previously 
described.23
For the third experiment, 42 mice underwent bone marrow transplantation surgery at week 
–5, and the bone marrow was allowed to regenerate over four weeks. Surviving mice (n=14 
in each treatment group) were implanted at week –1, HLI surgery was performed at week 0, 
and mice were sacrificed at week one and week four. After sacrifice, all ischemic, non-necrotic 
tissue was collected and stained for expression of β-galactosidase (a specific marker for cells 
derived from donor bone marrow) and CD31 (a specific marker for endothelial cells) to identify 
bone marrow-derived EPCs at the sites of neovascularisation.
EPC culture assay
Total  mononuclear  cells  were  isolated  from  1  ml  of  arterial  blood  by  density  gradient 
centrifugation using a Histopaque-1083 (Sigma-Aldrich Inc., St Louis, MO, USA), then cultured 
in  phenol  redfree  endothelial  cell  basal  medium  (Clonetics  Corp.,  San  Diego,  CA,  USA) 
supplemented with 5% fetal bovine serum, antibiotics, and growth factors on four-well glass 
slides coated with rat plasma vitronectin (Sigma-Aldrich Inc.) in 0.5% gelatine solution. After 
four days, EPCs were recognized as attached spindle shaped cells and assayed by co-staining 
with acetylated LDL-DiI (Biomedical Technologies, Stoughton, MA, USA) and FITC-conjugated 
Bandeiraea simplicifolia lectin I (Vector Laboratories, Burlingame, CA, USA). Fifteen randomly 
selected fields on each slide were viewed with fluorescence microscopy at 20× magnification, 
and double-positive cells were identified as EPCs and counted;24 EPC counts were presented as 
the average number of EPCs/mm2.      101 
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Perfusion
Perfusion in both ischemic (left) and non-ischemic (right) limbs was quantified via LDPI (Moor 
Instruments Inc, Wilmington, DE, USA) before HLI surgery and at predetermined time points 
afterward. Three consecutive measurements were obtained over the affected region (leg and 
foot) for each time point. Colour-coded images were recorded, and the average perfusion in 
each (i.e. ischemic and non ischemic) foot was calculated. To account for variations in ambient 
light, temperature, and other conditions, perfusion was presented as the ratio of ischemic 
(left) to non-ischemic (right) measurements.
Capillary density
Tissue samples were mounted and stained for CD31 expression, and one slide for each mouse 
was examined with light microscopy at 20× magnification. Capillaries positively stained for 
CD31 (an endothelial cell-specific marker) were counted in five randomly chosen microscopic 
fields on each slide, and capillary density was presented as the average number of capillaries/
mm2.
Statistics
Results are reported as mean ± standard error of the mean (SEM), and statistical analyses 
were performed with SPSS 12.0 for Windows. Comparisons between groups were analysed via 
ANOVA with Dunnett’s correction, and a p-value of less than 0.05 was considered significant.
REsulTs
Circulating EPC counts
Within the low- and high-dose E2 treatment groups, mice with HLI displayed significantly 
greater EPC counts at all weeks than those measured in mice that did not undergo HLI surgery 
(p<0.05); EPC counts in animals implanted with the high-dose E2 pellet peaked at week two 
in both the presence and absence of HLI. In the absence of HLI, the number of circulating 
EPCs at weeks one and two was significantly higher in animals treated with the high-dose E2 
pellet than in the low-dose (p<0.05) or placebo treatment groups (p<0.05) (figure 1A), and 
the difference between the high-dose group and the placebo group remained significant at 
week three (p<0.05); there was no significant difference between EPC counts in the low-dose 
and placebo groups at any time point. After induction of HLI, EPC counts were significantly 
greater in mice that had received the high-dose pellet than in placebo treated mice at week 
two (p<0.05 vs. placebo) and week three (p<0.01 for high-dose and p<0.05 for low-dose vs. 
placebo); EPC counts in the high-dose animals were greater than those in the low-dose group, 
but the difference was not statistically significant (figure 1B).
Perfusion and limb necrosis
At  three  and  four  weeks  after  HLI  surgery,  high-dose  E2  treatment  was  associated  with 
significantly greater restoration of perfusion than was observed in animals implanted with 
either the low-dose E2 or placebo pellets (figure 2B). The ratio of perfusion in the ischemic and 
non-ischemic limbs was 0.82±0.03 in week three and 0.88±0.11 in week four among animals                 102
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that received the high-dose E2 pellet, compared to 0.44±0.03 (p<0.01) and 0.47±0.01 (p<0.05), 
respectively, in animals that received the placebo pellet. The differences between low-dose 
E2 and placebo treatment were not significant at any time point. High-dose E2 treatment was 
also associated with a lower proportion of limb necrosis at week four (0%) than was observed 
in animals implanted with the placebo pellet (50%); limb necrosis in the low-dose E2 group 
was 22%.
Figure 1. Endothelial progenitor cell (EPC) counts in mice implanted with pellets containing 1.7 mg estradiol (high 
dose), 0.39 mg estradiol (low dose), or placebo. (A) Intact mice were implanted at week 0 and EPC culture assay was 
performed one to four weeks later. (B) Mice were implanted at week –1, hind-limb ischemia was induced at week 
0, and EPC culture assay was performed one to four weeks later. * p<0.05 vs. low-dose group, ‡ p<0.05 vs. placebo 
group.     103
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Figure 2. Recovery of perfusion in mice implanted with pellets containing 1.7 mg estradiol (high-dose), 0.39 mg 
estradiol (low-dose), or placebo. Mice were implanted at week -1, hind-limb ischemia was induced at week 0, and 
laser Doppler perfusion imaging (LDPI) was performed one to four weeks later. (A) Representative LDPI images for 
each treatment group at various time points; severely restricted limb blood flow is indicated in blue, and red indicates 
normal limb perfusion. (B) The ratio of perfusion recorded in the ischemic and normal limbs. ‡ p<0.05 vs. placebo 
group. For colour figure, see supplement 1.                104
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Capillary density
At two, three and four weeks after induction of HLI, capillary density was significantly higher 
(p<0.05) in mice treated with a high-dose of E2 than in animals implanted with the placebo 
pellet (figure 3), and the differences between the high-dose and low-dose E2 treatment groups 
at weeks two and four were also significant (p<0.05).
Figure 3. Capillary density in mice implanted with pellets containing 1.7 mg estradiol (high-dose), 0.39 mg estradiol 
(low-dose), or placebo. Mice were implanted at week –1, and hind-limb ischemia was induced at week 0. Tissue 
samples were obtained from mice sacrificed one to four weeks later and stained for expression of CD31 (an endothelial 
cell-specific marker). * p<0.05 vs. low-dose group, ‡ p<0.05 vs. placebo group.
Bone marrow-derived cells
At one and four weeks after induction of HLI in mice that had undergone bone marrow 
transplantation surgery, animals implanted with the high-dose E2 pellet displayed significantly 
more β-galactosidase positive (i.e. bone marrow-derived) cells at the site of ischemia than were 
observed in either the low-dose group or placebo-treated animals (figure 4A); the difference 
between the low-dose E2 and placebo-treatment groups was significant at week one. The 
number of β-galactosidase-positive cells at the site of ischemia declined between weeks one 
and four in all treatment groups.
Cells that stained positive for both β-galactosidase and CD31 (representative of bone marrow-
derived capillary density) were significantly more common one week after induction of HLI in 
mice treated with a high-dose of E2 than in low-dose E2 or placebo-treated animals, but this 
difference abated by week four, when the prevalence of double positive cells was less than 
25 cells/mm2 in all groups (figure 4B). The prevalence of double positive cells did not differ 
significantly between the low-dose E2 and placebo groups.     105
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Figure 4. Incorporation of bone marrow-derived endothelial cells at the sites of neovascularisation in mice implanted 
with pellets containing 1.7 mg estradiol (high-dose), 0.39 mg estradiol (low-dose), or placebo. Mice underwent 
transplantation surgery at week –5, were implanted at week –1, and hind-limb ischemia was induced at week 0. 
Tissue samples were obtained from mice sacrificed one and four weeks later and stained for expression of CD31 (an 
endothelial cellspecific marker) and β-galactosidase (a specific marker for cells derived from donor bone marrow). (A) 
Representative slides quantitatively stained for β-galactosidase expression; positively stained cells are blue. (B) The 
prevalence of cells stained positive for β-galactosidase expression. (C) Representative slides quantitatively stained for 
CD31 and β-galactosidase expression; the three panels display (from top to bottom) endothelial cells (green), bone 
marrowderived cells (red), and bone marrow-derived endothelial cells (yellow). (D) The prevalence of cells stained 
positive for both CD31 and β-galactosidase expression. * p<0.05 vs. low-dose group, ‡ p<0.05 vs. placebo group. For 
colour figure, see supplement 1.                106
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dIsCussIon
Peripheral artery disease affects 8-12 million people in the United States.25,26 The prevalence 
of peripheral artery disease is lower in premenopausal women than in men,27 and one factor 
believed to contribute to this difference is hormonal status. The potential protective role of 
E2 in peripheral and cardiovascular disease is implied by results in animal models and findings 
from extensive observational human studies.28-30 Administration of E2 yields profound effects 
in  both  ischemia-reperfusion  and  chronic  heart  failure  models,31,32  and  high  doses  of  E2 
attenuated the development of heart failure in a rat model of myocardial infarction.33,34 The 
acute protective effects of E2 treatment likely evolve, at least in part, through the inhibition of 
apoptosis.21,35
To date, only female animals have been used in animal-model investigations of the potential 
beneficial effects of E2 for peripheral arterial disease, so we sought to extend these studies to 
male animals by administering E2 to male mice with HLI. Surgical induction of HLI is a common 
and reliable method for modelling peripheral arterial disease,36-40 and because ischemia occurs 
in the limb, rather than in the heart, functional recovery can be easily monitored by using 
LDPI to measure blood flow. Functional data is much more difficult to obtain in models of 
cardiovascular diseases such as myocardial ischemia-reperfusion injury.
Our results indicate that the beneficial effects of E2 administration observed in female animals 
with HLI are reproducible in males. Four weeks after HLI surgery, mice administered high 
doses of E2 had recovered nearly 90% of non-ischemic perfusion and displayed no necrosis, 
compared to 47% recovery and 50% necrosis in placebo-treated animals; capillary density 
was also greater with high-dose E2 treatment than with placebo. Furthermore, the effects 
appeared to be mediated by EPCs; E2 administration dose dependently mobilised EPCs from 
the bone marrow, and the mobilised EPCs participated in neovascularisation. The prevalence 
of bone marrow-derived cells in the ischemic region was greater in animals that received the 
high-dose E2 pellet than in the placebo group at weeks one and four, and cells expressing 
both β-galactosidase and CD31 were more common in the high-dose group at week one. 
The difference in double-positive cell prevalence abated by week four because the activity of 
β-galactosidase decreased over time.
The involvement of EPCs in angiogenesis has been a popular topic of research, and many studies 
indicate that strategies involving the use of EPCs for therapeutic angiogenesis are feasible. 
Many growth factors, cytokines, and hormones can influence EPC mobilisation and homing,41 
including vascular endothelial growth factor,4,24,42-44 stromal cell-derived factor 1,45 statins,46 and 
erythropoietin,47-49 and the therapeutic potential of these agents for enhancing EPC mediated 
angiogenesis is being evaluated. The effects of E2 are dependent on EPC incorporation into 
the sites of neovascularisation and are mediated by endothelial nitric oxide synthase,5 and 
matrix metalloproteinase-9.12 Estradiol also reduces myocyte apoptosis in vivo and in vitro via 
oestrogen receptor- and phospho-inositide-3 kinase/akt dependent pathways.21,34 Oestrogen 
receptors α and β have been extensively investigated and are vital for the incorporation of 
bone marrow-derived EPCs in ischemic tissue; the role of the α receptor appears to be more 
prominent.11,50     107
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We acknowledge that the EPC culture assay does not completely exclude cells of a non-
endothelial lineage, and that FACS analysis could provide additional specificity. However, the 
maximum amount of blood that can be taken from a mouse (1 ml) is not sufficient for both the 
EPC culture assay and FACS analysis, and this limitation can be overcome only by pooling blood 
samples from several mice, which would reduce the statistical power of subsequent analyses. 
The limited amount of blood obtainable from each mouse also precluded the measurement 
of circulating E2 levels. Finally, the small number of animals (five to seven per treatment 
group per time point) yielded a large distribution of measurements for each time point, which 
may have occasionally prevented the differences between treatment groups from reaching 
statistical significance.
In conclusion, our study shows that E2 dose dependently increases the level of circulating EPCs 
in the peripheral blood of both intact male mice and male mice with HLI, and that E2-mobilised 
EPCs home to the foci of neovascularisation during HLI to promote recovery. Furthermore, E2 
was also associated with improved blood-flow recovery, greater capillary density, and less limb 
necrosis, with optimal effects observed two to three weeks after the onset of HLI. These findings 
suggest that systemic E2 administration may increase EPC-mediated neovascularisation under 
ischemic conditions caused by peripheral artery disease.
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Chapter 7
ABsTRACT
Background
In experimental models of ischemia-reperfusion injury, activation of HO-1 attenuates ischemia-
reperfusion related damage. We conducted a pilot study to evaluate the safety and efficacy 
of an exogenous HO-1 inducer (heme arginate) in patients with non-ST-elevation myocardial 
infarction (NSTEMI).
Design
Patients with NSTEMI were open label randomised to a single dose of heme arginate (N=10) or 
placebo (N=5), infused within three hrs after hospital admission for NSTEMI. Blood, to assess 
different downstream markers of HO-1 activation and safety parameters (heart, kidney and 
liver function, electrolytes and general haematology), was taken at hospital admission and 3, 6 
and 12 hrs and 1, 2, 3, and 7 days after administration of heme arginate. 
Results
A single high dose of heme arginate after NSTEMI did not increase plasma ferritin and total, 
direct and indirect bilirubin concentrations or HO-1 mRNA expression and HO protein activity 
in peripheral blood mononuclear cells as compared to the placebo group. Safety parameters 
were all comparable between the two groups. Interestingly, NSTEMI itself did activate the HO-1 
system. Median total bilirubin levels were increased with 60% after NSTEMI (peak compared 
to baseline, p=0.001). Also, median HO-1 mRNA (17.5 times compared to baseline, p=0.001) 
and median HO protein activity (peak compared to baseline, 780%, p=0.003) were increased 
after NSTEMI.
Conclusions
NSTEMI causes an endogenous HO-1 response, while adding the exogenous HO-1 inducer heme 
arginate does not further increase downstream HO-1 markers. Heme arginate administration 
is safe in patients with NSTEMI. Clinicaltrials.gov identifier: NCT00483587.     115
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InTRoduCTIon
The ‘free radical hypothesis’ for vascular dysfunction originally postulated that reactive oxygen 
and nitrogen species (ROS and RNS, respectively) led to non-specific modification of lipids, 
proteins and nucleic acids, which then contributed to the aetiology of cardiac diseases.1,2 
Especially ischemia-reperfusion (I/R) injury is associated with increased production of ROS and 
subsequent cell death.3 Recently, degradation products of heme oxygenase-1 (HO-1) activity 
have been suggested to act as anti-oxidants.4-7 The inducible isoform of HO, named HO-1, can 
be activated in virtually all tissues and represents the rate limiting step in the degradation of the 
pro-oxidant heme molecule into biliverdin, carbon monoxide (CO), and iron.5 Biliverdin is then 
converted by biliverdin reductase (BVR) into bilirubin, whereas iron induces the expression 
of the iron sequestering molecule ferritin.5,8-10 At physiological concentrations, bilirubin, CO 
and ferritin all exhibit high anti-oxidant and cytoprotective properties.9,11-13 Moreover, during 
cardiovascular  disorders,  including  acute  myocardial  infarction  (MI),  bilirubin  undergoes 
oxidative modifications, probably due to the high levels of both ROS and RNS, originating 
specific products named biopyrrins. An increased concentration of biopyrrins was found in 
plasma and urine of subjects suffering from acute MI, coronary artery disease and chronic 
heart failure.14-17
Numerous animal studies in atherosclerotic, hypertensive, I/R-injury and MI models employing 
gene therapy or genetically engineered mouse models strongly suggested that HO-1 induction 
prevents cardiovascular damage.18-20 However, this approach in the human setting is clearly 
not feasible.
Heme  is  both  the  substrate  and  a  strong  pharmacological  inducer  of  HO-1  expression. 
Administration of hemin significantly decreased infarct size in experimental models of MI.21-23 
Furthermore, administration of hemin (up to 9 mg/kg/day, administered directly in the left 
atrium) attenuated myocardial stunning in dogs after ligation of the left ascending coronary 
artery.24
So, although a large body of evidence supports the beneficial effects of HO-1 activation, in 
particular by either hemin or heme arginate, in I/R-injury and other models, clinical data in 
cardiovascular patients are lacking to date. Therefore, we evaluated the safety and efficacy 
of a single dose of heme arginate in patients with a non-ST-elevation myocardial infarction 
(NSTEMI).
PATIEnTs And mETHods
Study design
This is a prospective, open label, placebo-controlled pilot study (EudraCT 2006-003689-40; 
NCT00483587). Figure 1A shows an outline of the study design. All patients gave written 
informed consent to the study procedures, which were approved by the Ethics Committee 
of the University Medical Centre Groningen, The Netherlands. This study conforms with the 
guidelines from the Declaration of Helsinki.                116
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Study patients
Fifteen (15) patients were recruited at the Department of Cardiology from the University 
Medical Centre Groningen, The Netherlands, between December 2007 and July 2008. Male 
and female patients were eligible for enrolment if they were admitted to the cardiac care 
unit with suspected diagnosis of NSTEMI confirmed by elevated creatinin kinase (CK) and/or 
troponin-T levels according to ESC guidelines for Management of acute coronary syndromes: 
acute coronary syndromes without persistent ST segment elevation.25,26 Exclusion criteria were: 
ST-elevation on the electrocardiogram, a clinical history of chronic kidney disease, any known 
hepatic disease and any known hypersensitivity or allergic reactions to one of the constituents 
of heme arginate (hemin, L-arginine, propylene glycol, ethanol).
Study treatment
Patients were randomly allocated in order of admission and randomised with a ratio 1:2 to 
either placebo (0.9% sodium chloride, N=5) or heme arginate (Normosang®, Orphan Europe 
SARL, 250 mg intravenously in 15 minutes, N=10). This dose of heme arginate is considered 
safe and used in patients with acute porphyria (instructions of manufacturer). Heme arginate 
or placebo was administered within three hours after admission. Regardless of allocation, all 
patients received standard therapy according to national and international guidelines.26 Blood 
Figure 1. A. Flowchart of the study. B. Heme breakdown pathway. CAG = coronary angiogram, NSTEMI = non-ST-
elevation myocardial infarction, HO-1 = heme oxygenase-1, CO = carbon monoxide, ROS = reactive oxygen species, 
RNS = reactive nitrogen species, Fe2+ = iron, NADP = nicotinamide adenine dinucleotide phosphate. For colour figure, 
see supplement 1.     117
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samples were drawn from the antecubital vein of the study subjects at baseline and 3, 6, 12 
hrs and 1, 2, 3 and 7 days after admission. A coronary angiogram (CAG) was made 6 to 12 hrs 
after admission for diagnostic purposes. After CAG, an independent team of cardiologists and 
thoracic surgeons decided the optimal treatment for the NSTEMI (medical treatment only, 
percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery) and 
patients were treated accordingly. Seven days after inclusion in this study, an echocardiogram 
was made to assess left ventricular function, including left ventricular ejection fraction.
Endpoints
The primary efficacy endpoint was to evaluate the modification of the HO/BVR pathway upon 
administration of heme arginate, and the following markers were determined: mRNA levels of 
HO-1 in peripheral blood mononuclear cells (PBMCs), in vitro HO protein activity in PBMC lysates 
and plasma levels of ferritin and total, direct and indirect bilirubin. Key secondary endpoints 
were the overall changes in the HO/BVR expression and activity in patients who underwent 
NSTEMI. Key safety endpoints were heart function (CK, CK-MB, troponin-T, NT-proBNP and 
echocardiogram),  kidney  function  (blood  urea  nitrogen,  creatinin,  estimated  glomerular 
filtration fraction), liver function (aspartate aminotransferase, alanine aminotransferase, lactate 
dehydrogenase, alkaline phosphatase), electrolytes (sodium, potassium), regular haematology 
(haemoglobin, leucocytes, thrombocytes). Furthermore, specific markers of cardiac disease 
were analysed using ELISA kits according to manufacturers’ protocol (IL-6: #D6050, Human IL-6 
Quantikine HS ELISA Kit; IL-10: #D1000B, Human IL-10 Quantikine ELISA Kit; #TNF-α: DTA00C, 
Human TNF-α Quantikine ELISA Kit, VEGF: #DVE00, Human VEGF Quantikine ELISA Kit, all R&D 
Systems Europe, Abingdon, UK). All samples were analysed at the general laboratory of the 
hospital.
Analytical assays
Isolation of mononuclear cells
PBMCs were isolated from eight ml of whole blood using a PBMC preparation tube (#362761, 
BD, New Jersey, USA) according to manufacturer’s protocol. Cells were kept at -80°C till further 
use.
RNA isolation, cDNA synthesis and Quantitative rt-PCR
Total RNA was isolated from snap frozen PBMCs using QIAschredder and RNeasy kits (QIAGEN) 
according to manufacturer’s recommendations. cDNA was created according to the Omniscript 
protocol (QIAGEN) using 1 μg RNA and random primers (Invitrogen). Subsequently, quantitative 
real time rt-PCR was conducted using Taqman Universal PCR Master Mix protocol and primer 
probe sets (all from Applied Biosystems) specific to detect human GAPDH (Hs99999905_m1) 
and HO-1 (Hs00157965_m1). For each experimental group, the Ct values of GAPDH were 
subtracted from the Ct values of the gene of interest (Delta Ct) and the average Delta Ct 
values of the duplicates were taken. A Delta Ct difference between the two independent PCR 
experiments of up to 0.6 was tolerated. See supplemental data for extended protocol.
HO protein activity assay
To  determine  whether  the  induced  HO  protein  was  active,  we  performed  an  HO-activity                 118
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assay.  Briefly,  100.000  cells  were  resuspended  in  lysis  buffer  and  subsequently  lysed  by 
three freeze-thaw cycles. To analyse the amount for bilirubin that was formed, 2 mM heme 
(Frontier scientific) was added and samples were incubated for 60 min. at 37°C in the dark. 
Next, methanol was added, samples were mixed well and centrifuged at 13.000 x g. Samples 
were run on a HPLC (Spectra-Physics Analytical, Spectrasystem SCM400) equipped with a 5 μm 
Discovery C18 column and a Discovery C18 Superguard Cartridge 5 μm particle size precolumn 
(both Sigma-Aldrich). Separation was done by a mixture of 80% solvent A (40% 100 mM 
NH4Ac, pH 5.5, 5% methoxy-ethanol and 50% methanol (all Sigma-Aldrich) and 20% solvent B 
(5% methoxy-ethanol and 95% methanol) over a 20 minute time interval at a flow rate of 1 ml/
min. Biliverdin and bilirubin were detected at a wavelength of 377 and 450 nm, respectively. 
Standards of biliverdin and bilirubin (both from Frontier Scientific) were also run in order to 
quantify the amount of biliverdin/bilirubin found in the samples. The HO protein activity is 
expressed as μmol/mg total protein/hour. See supplemental data for extended protocol.
Statistics
Summaries of quantitative continuous variables are presented as median and inter quartile 
ranges (IQR) or otherwise if appropriate. HO-1 mRNA expression and HO protein activity are 
presented as percentage change during the study (between baseline and peak values, peak is 
12 hrs for mRNA expression and one day for protein activity). Because of small samples sizes, 
comparisons of differences between groups were analysed by Wilcoxon signed-rank test and 
comparisons within groups were analysed by Mann-Whitney U test. All tests were done two-
sided. To assess if NSTEMI upregulates markers of the HO-1 pathway, groups were pooled. A 
p-value of less than 0.05 was considered significant. All analyses were performed using SPSS 
version 16.0 (SPSS, Chicago, IL, USA).
REsulTs
Patients
Clinical characteristics of the study patients are summarised in table 1. Median age of the heme 
arginate group was 63 (51-72) years, where the placebo group was slightly older (median 77 
(61-84) years, p=0.13). Predominantly male patients participated in this study (heme arginate 
group 80%, placebo group 60%, p=0.43. Medical history, medical treatment at admission 
and discharge, and echo parameters did not differ significantly between the two groups. 
Furthermore, we did not observe any differences in heart rate, blood pressure or cholesterol 
levels between the two groups. Patients in the heme arginate group had significantly more 
often hypertension (90% vs. 40%, p=0.046).
Coronary  angiography  was  performed  6  to  12  hrs  after  admission  and  afterwards,  an 
independent team of cardiologists and thoracic surgeons decided the optimal treatment (see 
supplemental data for table with diagnoses after CAG and the chosen treatments). All patients 
in the placebo group were treated with PCI, where 30% of the patients in the heme arginate 
group underwent CABG surgery, all these patients being diagnosed with 3-vessel disease. 
Patients in the heme arginate group tended to stay longer in the hospital than those in the 
placebo group (3 (2-4) vs. 6.5 (2-13.3) days, p=0.24), which can be largely ascribed to the 
chosen treatment after CAG (more often CABG).     119
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Figure 2.
A. Ferritin plasma concentration during the study. B. Total bilirubin plasma concentration during the study. C. Change 
of HO-1 mRNA expression, change between baseline and peak values (12 hrs after admission). D. Change in HO protein 
activity, change between baseline and peak values (1 day after admission). F. HO protein activity 1 day after admission. 
Base = baseline, hr = hour.                120
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Placebo
(N=5)
Heme arginate
(N=10)
p
Age (years) 77 (61-84) 63 (51-72) 0.13
Male (N, %) 3 (60) 8 (80) 0.43
Days in hospital 3 (2-4) 6.5 (2-13.3) 0.24
Medical history
None (N, %) 1 (20) 1 (10) 0.60
PCI (N, %) 0 1 (10) 0.48
CABG (N) 0 0 1.00
Other (N, %) 4 (80) 8 (80) 1.00
Risk factors
Hypertension (N, %) 2 (40) 9 (90) 0.046
Family (N, %) 1 (20) 5 (50) 0.28
Smoking (N, %) 3 (60) 5 (50) 0.72
DM (N, %) 1 (20) 1 (10) 0.60
Obesity (N, %) 1 (20) 1 (10) 0.60
Hypercholesterolemia (N, %) 1 (20) 3 (30)
Medication at admission
Beta-blocker (N, %) 0 1 (10) 0.48
ACEi (N, %) 0 3 (30) 0.19
Diuretics (N, %) 1 (20) 5 (50) 0.28
ARB (N, %) 0 2 (20) 0.30
Anti-coagulants (N, %) 1 (20) 2 (20) 1.00
Lipid lowering drugs (N, %) 1 (20) 1 (10) 0.60
Nitrates (N, %) 0 1 (10) 0.48
Ca-antagonist (N, %) 0 2 (20) 0.30
Other (N, %) 3 (60) 4 (40) 0.48
Medication at discharge
Beta-blocker (N, %) 5 (100) 8 (80) 0.30
ACEi (N, %) 3 (60) 6 (60) 1.00
Diuretics (N, %) 1 (20) 4 (40) 0.45
ARB (N, %) 0 2 (20) 0.30
Anti-coagulants (N, %) 5 (100) 9 (90) 0.48
Lipid lowering drugs (N, %) 4 (80) 9 (90) 0.60
Nitrates (N, %) 1 (20) 2 (20) 1.00
Ca-antagonist (N, %) 0 1 (10) 0.48
Other (N, %) 3 (60) 7 (70) 0.71
HR admission (bpm) 84 (61-92) 87 (81-94) 0.46
HR discharge (bpm) 67 (62-75) 68 (62-82) 0.76
Systolic BP (mmHg) 160 (144-177) 147 (129-152) 0.10
Diastolic BP (mmHg) 80 (75-90) 94 (75-102) 0.24
Table 1. Clinical characteristics     121
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Echocardiography
Placebo
(N=5)
Heme arginate
(N=10)
p
IVSd (mm) 10 (9-15) 10 (10-12) 0.92
LVPWd (mm) 10 (8-11) 9 (9-10) 0.49
LVEDD (mm) 44 (36-46) 52 (47-53) 0.05
LVESD (mm) 26 (21-32) 37 (33-38) 0.032
LVEF (%) 53 (45-60) 45 (45-60) 0.64
Cholesterol
Triglycerides (mmol/l) 2.0 (1.1-3.3) 1.5 (1.1-2.4) 0.71
Total cholesterol (mmol/l) 4.6 (4.2-6.2) 5.1 (4.4-6.0) 0.67
HDL-cholesterol (mmol/l) 1.2 (0.9-1.8) 1.3 (1.2-1.5) 0.66
LDL-cholesterol (mmol/l) 3.1 (2.5-4.0) 3.6 (2.9-4.1) 0.50
Table 1 shows the clinical characteristics of the two groups. Data is presented as median (IQR). PCI = percutaneous 
coronary intervention, CABG = coronary artery bypass graft, DM = diabetes mellitus, ACEi = ACE-inhibitor, ARB = 
angiotensin II receptor blockers, HR = heart rate, BP = blood pressure, IVSd = inter ventricular septum thickness in 
diastole, LVPWd = left ventricular posterior wall thickness in diastole, LVESD = left ventricular end systolic diameter, 
LVEDD = left ventricular end diastolic diameter, LVEF = left ventricular ejection fraction, HDL-cholesterol = high density 
lipoprotein cholesterol, LDL-cholesterol = low density lipoprotein cholesterol.
Efficacy endpoints
Blood ferritin levels (figure 2A) and total bilirubin concentrations (figure 2B) were measured, 
to assess downstream markers of HO-1 activation. Furthermore, changes in mRNA levels of 
HO-1 (figure 2C), changes in HO protein activity (figure 2D) and HO protein activity one day 
after admission (figure 2E) were analysed in PBMCs. None of the markers are upregulated after 
heme arginate administration as compared to placebo group in this study (median change in 
HO-1 mRNA expression: 103 (61-113)% vs. 83 (38-131)%, p=0.81, median change in HO protein 
activity: 680 (91-1086)% vs. 1221 (555-3481)%, p=0.36).
Because  heme  arginate  administration  did  not  upregulate  HO-1  pathway  markers,  we 
combined all patients and assessed whether NSTEMI did activate the HO-1 pathway. As shown 
in table 3, NSTEMI is associated with upregulation of some of the aforementioned markers. 
Total, direct and indirect bilirubin levels, HO-1 mRNA expression and HO protein activity were 
all significantly upregulated after NSTEMI.
Safety endpoints
To monitor patient safety after heme arginate administration, we evaluated different markers 
of heart function, kidney function, liver function, electrolyte status, regular haematology and 
specific markers of cardiac disease (table 2, only baseline values and values after one and 
seven days are shown). None of the measured markers differed significantly at any time point 
within the study between the two groups.
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Table 2. Clinical characteristics
Data  is  presented  as  median  (IQR).  Only  baseline  values  and  values  after  1  and  7  days  are  shown.  We 
compared the values of the placebo patients with the heme arginate treated patients for each time point; 
none of the comparisons were statistically significant different (p-values not shown). CK = creatinin kinase, NT-
proBNP = N-terminal pro-brain natriuretic peptide, BUN = blood urea nitrogen, eGFR = estimated glomerular 
filtration fraction calculated with the modification of diet in renal disease (MDRD) formula, AST = aspartate 
aminotransferase, ALT = alanine aminotransferase, LDH = lactate dehydrogenase, AP = alkaline phosphatase, Na+ 
= sodium, K+ = potassium, Hb = haemoglobin, hsCRP = high sensitive C-reactive protein, IL = interleukin, TNF = 
tumour necrosis factor, VEGF = vascular endothelial growth factor.     123
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All (N=15) p
Baseline Peak
Total bilirubin (μmol/l) 10.0 (9.0-12.0) 16.0 (12.0-18.0) 0.001
Direct bilirubin (μmol/l) 0.0 (0.0-1.0) 2.0 (1.0-3.0) 0.005
Indirect bilirubin (μmol/l) 9.0 (7.0-10.0) 14.0 (12.0-16.0) 0.001
HO-1 mRNA expression (Δ/ΔCt) 0.2 (1.0-2.1) 3.5 (3.2-4.3) 0.001
HO protein activity (μmol/mg total protein/hour) 0.5 (0.2-1.8) 3.9 (2.2-14.2) 0.003
dIsCussIon
This is the first study that describes the use of an exogenous HO-1 activator, such as heme 
arginate, to attenuate I/R-injury in human I/R-injury (here: NSTEMI). We show that NSTEMI 
itself is associated with an activation of the HO-1 pathway. Single dose administration of heme 
arginate did not further activate this pathway.
Indeed, heme and its derivatives (heme arginate and heme lysinate) act all as strong inducers 
and substrates for HO-1, the rate limiting enzyme in the breakdown of free heme. As an effect 
of HO-1 activation and heme degradation, an increase in CO and biliverdin/bilirubin occurs as 
well as the upregulation of the iron storing molecule ferritin. All these molecules have both 
cytoprotective and cytotoxic effects depending on their amount and the redox status of the 
cell (figure 1B).5,8-10,21
In  this  pilot  study,  a  single  (high)  dose  of  heme  arginate  after  NSTEMI  did  not  increase 
plasma ferritin and total, direct and indirect bilirubin concentrations, as well as HO-1 mRNA 
expression and HO protein activity in PBMCs as compared to the placebo group. However, 
our data demonstrate that heme arginate administration is safe in patients with NSTEMI: no 
significant adverse effects on heart, kidney and liver along with abnormalities related to main 
biochemical parameters (electrolytes, blood tests, markers of inflammation) appeared in these 
patients. These findings resemble and confirm previous studies showing that heme arginate 
is well tolerated and the infusion does not induce adverse effects on haemostasis in healthy 
volunteers.27,28
An important corollary of our study was the observation, for the first time, of a systemic 
activation of the HO-1/BVR system in NSTEMI as demonstrated by the significant increase in 
plasma total, direct and indirect bilirubin, HO-1 mRNA expression and protein activity in PBMCs. 
This is in good agreement with previous studies which demonstrated that the activation of 
the HO-1/BVR system in free radical-induced diseases, such as Alzheimer disease and type 
II diabetes mellitus, is not confined in target organs but becomes systemic and affects also 
immune cells.20,29 Taking into consideration previous studies showing a free radical-induced 
degradation of HO-1/BVR-derived bilirubin in acute MI, it is plausible to hypothesize that 
Data is presented as median (IQR). Groups are pooled. Total bilirubin, direct bilirubin and indirect bilirubin are measured 
in plasma, time to peak was 1 day. HO-1 mRNA expression and HO protein activity were measured in peripheral blood 
mononuclear cells; time to peak was 12 hrs and 1 day respectively. HO = heme oxygenase.
Table 3. Effects of NSTEMI on HO-1 pathway and its breakdown products                124
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the degree of activation of the HO-1/BVR system in NSTEMI is even higher than found in our 
study.14-17
MI resembles a state with high levels of cellular and oxidative stress and in several animal 
models  of  cardiovascular  diseases  HO-1  induction  was  shown  to  prevent  cardiovascular 
damage.18,30,31 HO-1 induction was thoroughly tested in animal MI models.21-24 Genetically 
engineered mice overexpressing HO-1 are protected against MI, whereas on the other hand 
HO-1 null mice have severe cardiac dilatation and enhanced infarct size.19,30 The group of 
Victor Dzau developed a model of gene therapy overexpressing HO-1, using adeno-associated 
virus-2 as the delivery vector, in an MI model in mice. In the acute setting, overexpression 
of HO-1 reduced apoptosis, prevented myocardial wall thinning, inflammation, fibrosis and 
deterioration of cardiac function.32 Also, there was a significant reduction in apoptosis. In the 
setting of post-MI remodelling and function, overexpression of HO-1 markedly reduced fibrosis 
and ventricular remodelling and restored left ventricular function and chamber dimensions 
after MI.33
Although these pre-clinical lines of evidence lend support to the therapeutic potential of HO-1 
upregulation in cardiovascular disease, our data in humans demonstrated inefficacy of a single 
dose of ‘exogenous’ heme arginate to further increase HO-1 in NSTEMI. It is established that in 
the presence of excess heme (a condition mimicked by the administration of heme arginate) 
and/or perturbations of the redox intracellular milieu as during I/R-injury, HO-1 undergoes 
transcriptional  repression, rather than upregulation.  This  could be a possible  explanation 
for our findings.34,35 Another explanation could be that the dose was too low to elicit further 
or sustained activation of the HO-1 pathway. Alternatively, single dose is not the preferred 
regimen and one should rather administer repeated dosages of heme arginate or another 
heme derivative.
Our study has several limitations. Firstly, the sample size only allows for a first insight in the use 
of exogenous HO-1 inducers in patients with MI. Secondly, we only administered a single dose 
of heme arginate. Multiple infusions with heme arginate could well induce the downstream 
HO-1 markers. Thirdly, the dose administered is derived from the dose administered in patients 
with acute porphyria, which is considered safe. A dose-finding study should be carried out, 
in order to determine the optimal dose for patients with MI.36 Furthermore, in experimental 
models, HO activity was maximal at the time of infarction. In our study, we measured HO 
activity hours after onset of complaints.
In conclusion, this is the first study that describes the use of an exogenous HO-1 inducer in 
patients with cardiovascular disease. We conclude that NSTEMI induces HO-1, as shown by 
the increase of HO-1 mRNA expression, HO-1 protein activity and increase of total, direct and 
indirect bilirubin levels. A single high dose of heme arginate does not affect these parameters. 
So, although there is an endogenous HO-1 response to NSTEMI, adding an exogenous HO-1 
inducer does not increase downstream HO-1 markers further. Heme arginate administration 
seems safe in patients with NSTEMI.     125
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Chapter 8
ABsTRACT
Heart failure (HF)-associated anaemia is common and has a poor outcome. Because bone 
marrow (BM) dysfunction may contribute to HF-associated anaemia, we first investigated 
mechanisms of BM dysfunction in an established model of HF, the transgenic REN2 rat, which 
is characterised by severe hypertrophy and ventricular dilatation and SD rats as controls. 
Secondly, we investigated whether stimulation of haematopoiesis with erythropoietin (EPO) 
could restore anaemia and BM dysfunction. After sacrifice, erythropoietic precursors (BFU-E) 
were isolated from the BM and cultured for ten days. BFU-E were quantified and transcript 
abundance of genes involved in erythropoiesis were assayed. Number of BFU-E were severely 
decreased in BM of REN2 rats compared to SD rats (50±6.2 vs. 6.4±1.7, p<0.01). EPO treatment 
increased haematocrit in the SD-EPO group (after six weeks: 49±1 vs. 58±1%, p<0.01), however 
in the mildly anaemic REN2 rats, there was no effect (43±1 vs. 44±1%). This was parallelled 
by a 67% decrease in BFU-E in BM of REN2 rats compared to SD (p<0.01). EPO significantly 
improved BFU-E in both SD and REN2, but could not restore this to control levels in the REN2 
rats. Expression of several genes involved in differentiation (LMO2), mobilisation (SDF-1) and 
iron incorporation (transferrin receptor) of the BM were differentially expressed in REN2 rats 
compared to SD rats, and EPO did not normalise this. Altogether, these results suggest that 
BM dysfunction is an important contributor to HF-associated anaemia and that EPO is not an 
effective agent to treat HF-associated anaemia.     131
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InTRoduCTIon
Anaemia as a co-morbidity in heart failure (HF) is associated with a poor outcome.1,2 The 
prevalence of anaemia in HF is reported to be over 40% in patients with advanced HF.3 The 
causes of anaemia in HF are only partially understood, although several mechanisms have 
been implicated,4 including treatment with ACE-inhibitors,5 a blunted erythropoietin (EPO) 
production due to renal dysfunction,6 congestion,7 and iron deficiency.8 However, these causes 
only partially explain the severity of anaemia and are difficult to target.
Recent publications pointed towards bone marrow (BM) dysfunction as a potential contributing 
factor  to  anaemia  in  HF.  Iversen  et  al.  showed  decreased  haematopoiesis  in  BM  in  an 
experimental (murine) model of post myocardial infarction HF.9 Our group recently provided 
the first clinical proof for the existence of BM dysfunction in human ischemic HF.10 We showed 
that HF is associated with a profound and general BM dysfunction, simultaneously affecting 
multiple haematopoietic lineages. Very recently, the group of Iversen provided further evidence 
that HF is associated with general BM dysfunction by showing that anaemia occurs in both 
ischemic and non-ischemic murine HF models.11 Apparently, the mechanisms of anaemia in HF 
are dependent of aetiology and are possibly caused by general HF factors, like overproduction 
of neurohormones or hypoperfusion.11 Importantly, data as to whether pro-erythropoietic 
therapy could restore anaemia and BM function in HF is lacking.
Figure  1.  Overview  of  different  factors  involved  in  differentiation  and  mobilisation  during  different  stages  of 
erythropoiesis, which expression was measured (results shown in figure 5). Adapted from Koury et al,12 according to 
Hanson et al,29 Ohneda et al,31 and Jin et al.32 Factors highlighted in green are positive regulators, factor highlighted 
in red is a negative regulator. HSC = haematopoietic stem cell, BFU-E = burst forming unit-erythroid, CFU-E = colony 
forming unit-erythroid, RET = reticulocyte, RBC = red blood cell, LMO = LIM domain only 2 protein, TAL = T-cell acute 
lymphocytic leukemia protein, GATA = GATA binding protein, FOG = friend of GATA, MMP = matrix metallopeptidase, 
SDF = stromal cell-derived factor. For colour figure, see supplement 1.                132
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Therefore, we evaluated the severity and mechanisms of anaemia and BM dysfunction in 
an established experimental model of hypertensive HF, the transgenic TGR(mREN2)27 rat. 
Furthermore, we investigated if stimulation of haematopoiesis with EPO administration could 
restore, at least in part, HF-associated anaemia and BM function. Finally, we studied in detail 
well established factors of erythroid differentiation (LMO2, GATA-1) and mobilisation (MMP9, 
SDF-1) (figure 1, adapted from Koury et al.12). LMO2 and GATA-1 are both differentiation 
factors, where MMP9 mobilises erythroid precursors from the BM into the peripheral blood 
and SDF-1 is a negative regulator of erythroid mobilisation. Furthermore, we analysed factors 
involved in iron incorporation in the BM (transferrin receptor and ferroportin, both involved 
in maintaining cellular iron homeostasis) and studied if expression of these factors is changed 
during EPO administration.
mATERIAls And mETHods
Animal model
We employed six week old, male, homozygous TGR(mREN2)27 rats.13 See supplemental data 
for detailed description. Rats were fed with ad libitum regular chow that contains sufficient 
amounts of vitamin B and iron (RMH-B 2181, AB Diets, The Netherlands). Over the course of the 
experiment, the mortality rate of REN2 rats was 20% (as reported; mortality was 0% for control 
(Sprague Dawley, SD) rats). The experimental protocol was approved by the Animal Ethical 
Committee of the University of Groningen, The Netherlands, and conducted in accordance 
with existing guidelines for the care and use of laboratory animals.
Experimental protocol
To stimulate erythropoiesis, rats were randomised to treatment with the long-acting EPO 
analogue  darbepoetin  alpha  (40  μg/kg,  Aranesp®,  Amgen  Inc.,  Thousand  Oaks,  CA,  USA) 
administered subcutaneously every three weeks (baseline, three and six weeks) or saline 
(used as control). The dose of EPO was based on our extensive experience with this compound 
and previous data that this dose effectively raises haematocrit (Ht) in SD rats.14-19 Rats were 
sacrificed at week seven of the experimental protocol (when aged 13 weeks). In total four 
groups  were  studied:  SD-PL  (placebo;  n=12),  REN2-PL  (n=12),  SD-EPO  (n=12),  REN2-EPO 
(n=15). At baseline, three weeks and six weeks, blood was drawn from the tail vein for a 
full blood count. At sacrifice, we analysed serum iron status. Blood pressure via tail cuff and 
haemodynamic data at sacrifice were measured as described.20,21 Furthermore, to monitor the 
development of HF, echocardiography was performed at baseline, three weeks and six weeks. 
For details, see supplemental data.
Bone marrow isolation and MACs sorting
BM was isolated from tibia and femurs as previously described.22 C-kit positive (c-kit+) cells 
were isolated as described in the supplemental data. Briefly, the cell pellet was washed twice 
with PBS to remove platelets. Cells were labelled with polyclonal rabbit anti c-kit antibody, 
followed by goat anti-rabbit IgG Microbeads. Anti c-kit-labelled cells were sorted by using mini-     133
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magnetic activated cell sorting columns in a magnetic field. Effluent was collected in chilled 
IMEM medium. C-kit+ cells were collected with 1 ml chilled IMEM medium and cell number 
was counted.
Cell proliferation assay
After MACs column sorting, 1×104 c-kit+ BM cells were plated in 1 ml semi-solid medium 
(MethoCult, Stem Cell Technologies, Köln, Germany) in 35 mm Petri dishes in duplicate. The 
dishes were incubated at 37°C with 5% CO2 and 95% humidity for two weeks. Colonies were 
scored using an inverted phase-controlled microscope (Leica 090-135002, Leica Microsystems, 
CMS GmbH, Germany). Burst-forming units-erythroid (BFU-E) were defined as consisting of 30 
or more cells. Colony-forming units (CFU) were defined as consisting of 50 or more cells. 
FACS analysis
BM mononuclear cells were harvested from tibia and femur of experimental animals and frozen 
in liquid nitrogen with 10% DMSO in medium in assay. FACS analysis was performed on an LSRII 
cytometer (BD Biosciences, San Jose, CA, USA). For phenotypic analysis by flow cytometry, 2-5 
× 107 cells were dissolved in 10 ml cold DMEM with 10% FBS. Cell pellet were resuspended 
in 80 μl PBS/0.5% BSA. Samples were subsequently stained with rabbit polyclonal anti c-kit 
antibody (1 μg/106 cells, Santa Cruz Biotechnology, Heidelberg, Germany) on ice for 30 min. 
After washing twice with 2 ml PBS/0.5% BSA, cells were incubated with Alexa Fluor® 647 (1 
μg/106 cells, Invitrogen, OR, USA) and FITC rat anti-mouse IgG (1 μg/106 cells, BD Biosciences 
Pharmingen, Breda, The Netherlands) as secondary antibodies. Cells were then suspended 
in 0.5 ml PBS/0.5% BSA and analysed within one hour. Unstained cells and cells stained with 
second antibody only were used as a negative control. Data were analysed by FlowJo software 
(V7.5.5, Ashland, OR, USA). 
Quantitative real-time PCR
Total RNA from c-kit+ cells and left ventricular (LV) tissue was extracted using the Nucleospin 
RNA II kit, according to manufacturer’s protocol (Machery-Nagel, Düren, Germany). cDNA 
synthesis and quantitative real time PCR (RT-qPCR) were performed as previously described 
with using 0.5 µg total RNA.23 mRNA levels were expressed in relative units based on a standard 
curve obtained with serial dilutions of a calibrator cDNA mixture. To normalise expression 
data, multiple reference genes were used as described.24 Please see supplemental data for full 
protocol and list of primers.
Statistical analyses
Results are reported as means ± standard errors of the mean (SEM). Number of BFU-E, CFU and 
c-kit+ cells were normalised to SD-PL group. Statistical analysis among groups was performed 
by ANOVA with the Bonferroni post hoc test if distributed normally, or with the Kruskall-Wallis 
test followed by Mann-Whitney U test when skewed distributed. All p-values are two-tailed, 
and a p-value of less than 0.05 was considered significant. All analyses were performed using 
SPSS version 16.0 software (SPSS, Chicago, IL, USA).                134
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Hypertensive REN2 rats develop heart failure
REN2 and SD rats were treated with or without EPO and monitored for six weeks and sacrificed 
at an age of 13 weeks. As expected, REN2 rats suffered from severe hypertension (figure 2), 
providing the substrate for HF development. Heart weight (adjusted for tibia length), LV end 
diastolic  pressure  (LVEDP)  and  atrial  natriuretic  peptide  (ANP)  mRNA expression  were  all 
significantly increased in the REN2-PL and REN2-EPO groups, indicative for HF (figure 2). Table 
1 shows the haemodynamic data at sacrifice. Indices of maximal contraction and relaxation 
of the LV (dPdtmax and dPdtmin) were both significantly decreased in the REN2 groups, 
compared to the SD groups, indicating development of HF. Cardiac output (CO), assessed with 
echo Doppler prior to sacrifice, is decreased in both REN2 groups compared to the SD groups. 
Echocardiographic data during the experiment confirmed development of LV hypertrophy and 
LV dilatation in REN2 rats (shown in supplemental data). 
Figure 2. Figure 2 shows that the used animal model is a model of hypertensive heart failure. A. Mean arterial pressure 
(MAP) during the experiment. MAP is significantly higher at all time points for REN2 groups compared to SD groups. 
B. Heart weight normalised to tibia length. C. Left ventricular end diastolic pressure (LVEDP) at sacrifice. D. mRNA 
expression of atrial natriuretic peptide (ANP) in left ventricular tissue. ANP is expressed as fold change. HW = heart 
weight, Base = baseline, Wk = week, PL = placebo. * p<0.05, ** p<0.01.     135
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SD-PL
(n=12)
REN2-PL
(n=12)
SD-EPO
(n=12)
REN2-EPO
(n=15)
LV weight (mg) 841±15 1105±44 * 809±17 1157±36 ‡
TL (mm) 38.3±0.3 38.1±0.2 38.6±0.2 38.2±0.3
Body weight (g) 367±6 309±7 * 360±8 316±9 ‡
Heart rate (bpm) 352±17 347±12 352±12 350±10
dPdtmax (mmHg/s) 7993±290 5625±356 * 8676±618 5785±295 ‡
dPdtmin (mmHg/s) -9211±666 -5730±335 * -10249±711 -6010±367 ‡
CO (ml/min) 145±4 112±10 * 138±6 121±11 ‡
REN2 rats are anaemic and have a limited response to EPO
Table 2 shows the full blood count for all experimental groups at sacrifice. As hypothesized, 
REN2 rats were mildly anaemic, and had mild to moderate reductions of other haematologic 
parameters  as  well  (except  platelet  and  reticulocyte  count,  which  were  increased). 
Administration of EPO increased Ht levels significantly in the SD-EPO group compared to the 
SD-PL group (57.8±1.1 vs. 49.3±0.8%, p<0.01), however EPO administration did only marginally 
increase Ht in the REN2-EPO group (44.0±0.6 vs. 42.7±0.5%, compared to REN2-PL, p=NS, 
figure 3). An identical pattern was observed for haemoglobin levels. Furthermore, RBC, MCV 
and MCH were all significantly decreased in both the REN2-PL and the REN2-EPO groups, 
providing further evidence of anaemia. We observed an increased reticulocyte count in the 
REN2 groups, which is commonly seen in anaemia. EPO plasma levels increased significantly in 
all EPO treated groups (measured with ELISA as before,17 see supplemental data). Deficiencies 
of iron, vitamin B12 and folic acid were ruled out and did not differ between SD and REN2 
groups (see supplemental data).
Bone marrow dysfunction in the REN2 rats
To provide mechanistic insight into the causes of anaemia, we studied the number of BFU-E and 
CFU colonies with a cell proliferation assay (figure 3B and 3C). REN2 rats (treated with placebo) 
had a severely decreased number of BFU-E colonies, compared to SD-PL (0.33±0.11 fold, 
normalised to SD-PL, p<0.05). This indicates either a reduced number or a limited proliferation 
capacity of erythroid precursors in the BM. EPO administration increased the number of BFU-E 
colonies, both in the SD-EPO group (1.92±0.33 fold vs. SD-PL, p<0.05) as well as in the REN2-
EPO group, albeit much less (0.88±0.21 fold vs. SD-PL, p<0.05).
To dissect abnormalities in the erythroid precursors only from general abnormalities in the BM, 
we also investigated number of CFU colonies. Number of CFU is only slightly, but significantly 
decreased in the REN2-PL group compared to SD-PL group.
Table 1. Data at sacrifice
Table shows weights and haemodynamic data at sacrifice. Cardiac output (CO) was assessed with echo Doppler at 
sacrifice in anesthetized animals. LV = left ventricle, TL = tibia length, PL = placebo. * p<0.05 vs. SD-PL, ‡ p<0.05 vs. 
SD-EPO.                136
Chapter 8
Low levels of haematopoietic stem cells in REN2 rats
To confirm the findings in the cell proliferation assay, we performed FACS analysis of c-kit+ cells 
in BM (figure 4). Compared to SD-PL, the number of c-kit+ cells is reduced in REN2-PL (with 
43%, p<0.05). In line with the BFU-E cell proliferation assay number, EPO treatment increased 
the number of c-kit+ cells measured by FACS in both the SD-EPO group (1.6 fold, p<0.05 vs. 
SD-PL) and the REN2-EPO group (to baseline, vs. SD-PL, p=NS). However, the response to EPO 
was less strong in the REN2 rats. 
Figure 3. A. Change in haematocrit (Ht) levels during experiment. EPO administration cannot increase Ht levels in REN2 
rats. B. Number of burst forming units-erythroid (BFU-E, normalised to SD-PL). C. Number of colony forming units 
(CFU, normalised to SD-PL). PL = placebo, BM = bone marrow, Wk = week, # p<0.05 vs. SD-PL, REN2-PL and REN2-EPO,       
     p<0.05 vs. REN2-PL and REN2-EPO, * p<0.05, ** p<0.01.     137
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SD-PL
(n=12)
REN2-PL
(n=12)
SD-EPO
(n=12)
REN2-EPO
(n=15)
Hb (mmol/l) 9.6±0.8 9.0±0.1 12.4±0.2 * 9.3±0.1 ‡
Ht (%) 49.3±0.8 42.7±0.5 * 57.8±1.1 * 44.0±0.6 ‡
WBC (x109/l) 14.6±0.5 11.4±0.3 * 14.8±0.6 11.6±0.5 ‡
RBC (x1012/l) 8.8±0.2 8.0±0.1 * 9.8±0.2 * 8.0±0.1 ‡
PLT (x109/l) 522±32 744±33 * 485±36 711±25 ‡
RET (promille) 27.5±6.1 31.1±2.4 * 7.0±1.4 * 33.2±2.7 ‡
MCV (fl) 57.0±0.7 53.2±0.3 * 58.2±1.2 54.8±0.4 †‡
MCH (atto mol) 1204±8 1127±12 * 1247±20 * 1082±83 ‡
MCHC (mmol/l) 21.1±0.2 21.2±0.2 21.5±0.2 22.2±1.0
mRNA  expression  of  factors  involved  in  erythroid  differentiation,  mobilisation  and  iron 
incorporation (figure 5)
LMO2 was significantly reduced in the REN2-PL group (34% vs. SD-PL, p<0.05). EPO treatment 
reduced the LMO2 expression in the SD-EPO group, but did not increase the LMO2 expression 
in the REN2-EPO group. Vice versa, expression of GATA-1 was 2.3 fold increased in the REN2-
PL group compared to the SD-PL group (p<0.01). Treatment with EPO increased the GATA-1 
expression in the SD-EPO group, but did not affect the GATA-1 expression in the REN2-EPO 
group. These data suggest that differentiation of erythrocyte-like BM precursors is inhibited in 
HF and that EPO treatment partially restores this.  
Expression of MMP9 was reduced with 60% in the REN2-PL group compared to the SD-PL group 
(p<0.05). Treatment with EPO did not exert substantial effects on MMP9 expression in neither 
SD nor REN-2 rats. In contrast, SDF-1 expression was significantly increased in the REN2-PL 
group (3.5 fold vs. SD-PL, p<0.05). Treatment with EPO further increased the expression of 
SDF-1 (5.6 fold vs. SD-EPO, p<0.01). These data suggest that mobilisation of erythrocyte-like 
BM precursors is inhibited in HF and that this cannot be restored by EPO treatment.
mRNA expression of ferroportin was not statistically different between the four groups, albeit 
that ferroportin is slightly less expressed in both REN2 groups. mRNA expression of transferrin 
receptor was comparable between the SD-PL vs. REN2-PL groups (1.6±0.2 fold vs. SD-PL, p=NS). 
However, after treatment with EPO, the expression of transferrin receptor was increased in the 
SD-EPO group (2.8±0.7 fold vs. SD-PL, p<0.05), where the expression was not increased in the 
REN2-EPO group, indicating a reduction in iron incorporation in the erythroid cells in REN2 rats 
after EPO administration.
Table 2. Haematology
Table shows full blood count at sacrifice. Hb = haemoglobin, Ht = haematocrit, WBC = white blood cell count, RBC = red 
blood cell count, PLT = platelet count, RET = reticulocytes, MCV = mean corpuscular volume, MCH = mean corpuscular 
haemoglobin, MCHC = mean corpuscular haemoglobin concentration, PL = placebo. * p<0.05 vs. SD-PL, † p<0.05 vs. 
REN2-PL, ‡ p<0.05 vs. SD-EPO.                138
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dIsCussIon
In hypertensive REN2 rats with progressive HF we observed mild anaemia and a profound 
dysfunction of the erythroid lineage in the BM. Treatment with EPO with the aim to rescue 
this anaemia did not diminish the anaemia. Apparently, HF-associated BM dysfunction is a 
rather complex phenomenon that may require other treatment options. In concert with this, 
we observed that along the entire line of maturation of the erythroid lineage, multiple genes 
associated with differentiation, mobilisation and iron incorporation were abnormally expressed 
in BM from HF rats. Figure 6 provides an overview of the mechanisms of BM dysfunction 
involved in HF-associated anaemia.
Figure 4. A-D. Typical examples of FACS analysis. Every dot is a single cells count. The x-axis (Comp-APC-A) is the gate 
for fluorescent cells, the y-axis (SSC-A) is the cell size. Red color is high density of cell count; blue color is lower density 
of cell count. E. Number of the erythroid c-kit+ cells in bone marrow. PL = placebo, BM = bone marrow. * p<0.05, ** 
p<0.01. For colour figure, see supplement 1.     139
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We  used  a  monogenetic  rat  model  with  overexpression  of  the  renin  gene,  resulting  in 
hypertension and concomitant HF development. These rats also develop mild anaemia, which 
is in line with the observations of Iversen et al., who described for the first time the existence 
of HF-associated anaemia in mice.9 Our results extend this observation of Iversen to another 
species (rat) and moreover show that this also occurs in animals in which hypertension is the 
sole source for HF development. 
Since HF-associated anaemia has a dramatic impact on prognosis in humans,1-3,25 we tried to 
restore this by EPO treatment. As expected, EPO treatment resulted in a clear increase in Ht 
Figure 5. mRNA expression of different factors involved in differentiation (A+B) and mobilisation (C+D) of c-kit+ cells. 
mRNA expression of different factors involved in iron metabolism (E+F). LMO2 = LIM domain only 2 protein, GATA-1 = 
GATA binding protein, MMP9 = matrix metallopeptidase, SDF-1 = stromal cell-derived factor, PL = placebo. * p<0.05, 
** p<0.01.                140
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in the control rats. Surprisingly, however, EPO did not rescue anaemia in the REN2 rats and 
only showed marginal effects on Ht values. Since the main action of EPO is the regulation 
of erythropoiesis, this is apparently not the single culprit in HF-associated anaemia. Several 
clinical observations from our group suggested that EPO levels in HF are disconcordant with the 
(expected) levels of haemoglobin,26-28 and our current observations that EPO cannot rescue HF-
associated anaemia are in concert with this. This dysbalance between EPO and haemoglobin 
levels is related to an increased mortality risk. Mechanistically, this may be explained by a 
diminished response of the BM to high plasma EPO levels in HF, a phenomenon we confirm 
Figure 6. Schematic overview of the mechanisms of bone marrow dysfunction involved in HF-associated anaemia. 
Different triggers of anaemia in heart failure such as insensitivity of EPO, iron deficiency and neurohormonal activation 
have a negative effect on the haematopoietic stem cells in the bone marrow. Furthermore, impaired proliferation, 
differentiation, mobilisation and iron incorporation in haematopoietic stem cells contribute to the bone marrow 
dysfunction, causing anaemia and adding to the heart failure syndrome, which in turn triggers anaemia in heart 
failure, etc. EPO treatment does not rescue the dysfunction of the erythroid lineage and does not improve heart 
failure-associated anaemia. SNS = sympathetic nervous system, RAS = renin-angiotensin system. For colour figure, see 
supplement 1.     141
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in our present study. Together, this indicates that in HF-associated anaemia other treatment 
options will be needed.
To obtain further insight in the cause of this anaemia we analysed the BM. We observed a 
profound (43%) decrease in BM haematopoietic progenitor cells (c-kit+ cells) in REN2 rats as 
compared to control animals. This is in line with the observation of Iversen et al. who observed 
a reduction of up to 60% of similar CD34+ cells in mice with HF.9 Although not investigated in 
our rat model, they suggested that the mechanisms of HF-associated anaemia may depend on 
the etiology of the cardiac disease, where inflammation seems to be dominant in ischemic HF, 
while neurohormonal factors seem the player in non-ischemic HF.11
To further characterize BM dysfunction and the irresponsiveness to EPO in the REN2 rat model 
of HF, we performed RT-qPCR analysis to measure the expression of markers of differentiation 
(LMO2, GATA-1) and mobilisation (MMP9, SDF-1) of the erythroid lineage and incorporation 
of iron in these cells (ferroportin, transferrin receptor) (figure 5). LMO2, a positive regulator 
of erythroid differentiation,29 was downregulated in the REN2-PL group, which may contribute 
to the decreased number of BFU-E. GATA-1 is a transcription factor playing a key role in 
gene  regulation  during  erythroid  differentiation.30  This  factor  is  strictly  controlled  during 
development and differentiation of erythroid cells and essential for the survival of erythroid 
progenitors.31 GATA-1 mRNA expression is 2.3 fold increased in our experiments in the REN2-
PL group, indicating that survival of the erythroid progenitors is promoted in this weakened 
erythropoietic system.
Furthermore, impaired mobilisation of erythroid progenitors from the BM could contribute to 
the lack of increase in Ht upon EPO stimulation. Degradation of BM SDF-1 by MMP9 contributes 
to increased mobilisation of erythroid progenitors.32 So, decreased levels of MMP9, which 
result in increased levels of BM SDF-1 could in turn lead to impaired mobilisation of erythroid 
progenitors from the BM in REN2 rats. 
Analysis of factors involved in iron transportation yielded some interesting results. mRNA 
expression of ferroportin, involved in iron transportation from inside of a cell to the outer 
surface,  was  not  different  between  any  group.  mRNA  expression  of  transferrin  receptor, 
involved in maintaining cellular iron homeostatis, was comparable between the SD-PL vs. 
REN2-PL groups. However, after treatment with EPO, expression was increased in the SD-
EPO group, where expression was not increased in the REN2-EPO group. We speculate that 
the lower expression of transferrin receptor in REN2 rats treated with EPO is associated with 
lesser iron incorporation in erythroid cells, which may explain in part the lesser response to 
EPO. In general, we observed a changed expression profile of genes involved in differentiation, 
mobilisation and incorporation of iron in BM.
Besides defects in the erythropoietic lineage of the BM (reduction in c-kit+ cells and BFU-E), 
we also observed a reduction in number of CFU (with 27%) compared to control animals. EPO 
treatment did not improve these values in the REN2 rats. We recently showed that human HF 
is associated with a profound and general BM dysfunction, simultaneously affecting multiple 
haematopoietic lineages.10 Since all these patients obtained optimal HF treatment and were 
obviously  more  heterogeneous,  our  confirmation  in  this  monogenetic  rat  model  further 
confirms these observations in a human population and show that it is treatment independent.                 142
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Moreover, HF-associated anaemia appears to be a general phenomenon in mammals.
dPdtmax, dPdtmin and CO were all significantly decreased in the REN2 groups, compared to 
the SD groups indicating development of HF. Hypoperfusion of the bone marrow by reduced 
CO could potentially affect erythropoiesis in HF.8 However, we believe that hypoperfusion is 
not (yet) a critical factor, as we have sacrificed the REN2 rats before overt (decompensated) 
HF had ensued.
Because the REN2 transgene is expressed ubiquitously and thus also in the haematopoietic 
cells, we cannot exclude that the effects of the transgene mediate the phenotype at least 
to some extent. However, the sequel of events in the development of HF in the REN2 rat 
(hypertrophy, diastolic dysfunction, systolic dysfunction, overt HF, death) are very much alike 
the human situation. Furthermore, the mild anaemia and bone marrow dysfunction associated 
with HF in the REN2 rat are also comparable to what we observed in earlier human studies. So, 
although this model (like any rodent model) has limitations, the phenotype we study herein is, 
at least to a large extent, comparable to the human situation.
In  conclusion,  in  REN2  rats  with  progressive  HF  there  is  mild  anaemia  and  a  profound 
dysfunction of the erythroid lineage of the BM. Response to EPO is diminished in REN2 rats and 
does not rescue the dysfunction of the erythroid lineage. Multiple genes appear to be involved 
in this process. This does, however, not exclude EPO as a treatment option in HF, because we 
and others have shown that EPO has also direct positive effects on the heart, including anti-
apoptotic, pro-angiogenic and anti-ischemic actions.14-19 Therefore, EPO can be beneficial in 
HF, but does not improve HF-associated anaemia. The latter, probably needs a more complex 
treatment regimen.
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Supplemental data to “Heart failure-associated anaemia: Bone marrow dysfunction and 
response to erythropoietin”
suPPlEmEnTAl mETHods
Animal model
We employed 6 week old, male, homozygous TGR(mREN2)27 rats. These rats over express the 
mouse renin gene (ren-2d), and have a phenotype of severe hypertension and left ventricular 
(LV) hypertrophy, which culminates into heart failure (HF) over the course of 12-16 weeks.1 
The rats were obtained from the Max Delbrück Centre for Molecular Medicine, Berlin Buch, 
Germany (Prof. Dr. M. Bader). Age-matched Sprague Dawley (SD) rats were used as controls 
(Harlan, The Netherlands). Animals were housed under standard condition.
Experimental protocol
At baseline, three weeks and six weeks, blood was drawn from the tail vein for a full blood 
count: haemoglobin (Hb), haematocrit (Ht), white blood cell count (WBC), red blood cell count 
(RBC), red blood cell indices [mean corpuscular volume (MCV), mean corpuscular haemoglobin 
(MCH) and mean corpuscular haemoglobin concentration (MCHC)], platelet count (PLT) and 
reticulocytes (RET) were measured. In a subset of rats, we analysed serum iron status at 
sacrifice to rule out deficiencies. To assess hypertension, each week systolic blood pressure 
(SBP) and diastolic blood pressure (DBP) were measured in conscious rats using a noninvasive 
blood pressure monitoring system (CODA-6, Kent Scientific Corporation, Torrington, CT) as 
described before.2 Mean arterial pressure (MAP) was calculated ((2xDSP+1xSBP)/3). Rats were 
trained for blood pressure measurement two weeks prior to the start of the experiment. Prior 
to sacrifice haemodynamic function was assessed invasively by introducing a 2-French microtip 
pressure-volume transducer (Millar Instr. Inc., Houston, TX, USA) in the right carotid artery and 
the left ventricle (LV).3 Heart rate (HR), LV end diastolic pressure (LVEDP) and maximal indices 
of contraction and relaxation of the LV (dPdtmax and dPdtmin) were measured. Thereafter, 
blood was drawn, and hearts were rapidly excised and weighed. Heart tissue was processed 
for analysis by snap-freezing in liquid nitrogen at -80°C.
Cardiac function was prospectively assessed by echocardiography at baseline, three weeks 
and six weeks (Vivid 7, GE Healthcare, Chalfont St Giles, UK; equipped with a 10-MHz phase 
array linear transducer). The echocardiographic measurements were performed under general 
anaesthesia with 2% isoflurane. Both 2-dimensional (2D) images in parasternal long-axis and 
short-axis view and 2-D guided M-mode tracing were obtained. Long-axis views were obtained, 
ensuring that the mitral and aortic valves and the apex were visualized. Short-axis views were 
recorded at the level of mid-papillary muscles. LV end-systolic diameter (LVESD) and LV end-
diastolic diameter (LVEDD) were measured from the M-mode. LV fractional shortening was 
(automatically) calculated as (LVEDD − LVESD)/LVEDD × 100%. Cardiac output was obtained by 
echo Doppler measurements over the aortic valve.
EPO plasma levels prior to sacrifice were measured with ELISA according to protocol (Quantikine 
EPO Immunoassay MEP00, R&D Systems Inc, Minneapolis, MN, USA).                146
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Bone marrow isolation and MACs sorting4
BM was isolated from tibia and femurs of REN2 and SD rats by flushing bone marrow cavity 
with Dulbecco’s phosphate buffered saline (PBS). Mononuclear cell fraction was obtained 
by density gradient centrifugation on lympholyte-rat (CEDARLANE, Sanbio BV, Canada). C-kit 
positive (c-kit+) cells were isolated according to protocol. Briefly, the cell pellet was washed 
twice with PBS containing 2 mM EDTA and 1% fetal bovine serum (FBS) to remove platelets. 
Cells were labelled with polyclonal rabbit anti-c kit antibody (Santa Cruz Biotechnology, CA, 
USA; SC-5535; 1:25 dilution) followed by goat anti-rabbit IgG Microbeads (Miltenyi Biotech, 
Bergisch Gladbach, Germany, 1:5 dilution) for 30 min. at room temperature. The anti-c-kit-
labelled cells were sorted by using Mini-magnetic activated cell sorting columns (MS-MACs, 
Miltenyi Biotech, Bergisch Gladbach, Germany) in a magnetic field. The effluent was collected 
in chilled IMEM medium and combined with effluents from three washes. C-kit+ cells were 
collected into a 5 ml polystyrene round-bottom tube with 1 ml chilled IMEM medium and cell 
number was counted.
Quantitative real-time PCR5
Total RNA from c-kit+ cells and LV tissue was extracted using the Nucleospin RNA II kit, according 
to manufacturer’s protocol (Machery-Nagel, Düren, Germany). cDNA synthesis was performed 
with 0.5 µg total RNA using a specific cDNA synthesis kit according to manufacturer’s protocol 
(Quantitect Rev. Transcriptase kit, Qiagen, Venlo, The Netherlands). Quantitative real-time PCR 
(RT-qPCR) was performed using SYBR Green mix according to protocol (Absolute SYBR Green 
ROX mix, Thermo Scientific, Breda, The Netherlands, on C1000 Thermal Cycler CFX384 Real-
Time PCR Detection System, Bio-Rad Laboratories, Veenendaal, The Netherlands). All targets 
were evaluated under the same reaction conditions: 95°C for 15 minutes, then 36 cycles of 
95°C for 15 seconds and 60°C for 30 seconds. Samples were analysed by quantification software 
(Bio-Rad CFX Manager 1.6). mRNA levels were expressed in relative units based on a standard 
curve obtained with serial dilutions of a calibrator cDNA mixture. To normalise expression 
data, multiple reference genes were used as described by Vandesompele et al.6 Reference 
genes were chosen with little sample-to-sample variability (B2M and GAPDH). Please table S2 
for a list of primers used for RT-qPCR.     147
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SD-PL
(n=8)
REN2-PL
(n=5)
Iron (μmol/l) 30.9±1.5 27.2±1.7
Folic acid (nmol/l) >45 >45
Vitamin B12 (pmol/l) >1476 >1476
RT-qPCR primer, 5’ to 3’
Gene name Forward Reverse
B2M CTC GGT GAC CGT GAT CTT TC AGT TGG GCT TCC CAT TCT CC
GAPDH CAT CAA GAA GGT GGT GAA GC ACC ACC CTG TTG CTG TAG
ANP ATG GGC TCC TTC TCC ATC AC TCT ACC GGC ATC TTC TCC TC
LMO2 TGC AGG CGA GAC TAT CTC AGG CGC GCA TCG TCA TCT CAT AGG
GATA-1 ATG CCT GCG GCC TCT ACT AC CAG ATG CCT TGC GGT TCC TC
MMP9 CGG GAA CGT ATC TGG AAA TTC G CATG GCA GAA ATA GGC CTT GTC
SDF-1 CCG ATT CTT TGA GAG CCA TGT C TTC GGG TCA ATG CAC ACT TGT C
Ferroportin GCT GTT TGC AGG AGT CAT TG TGG AGT TCT GCA CAC CAT TG
TFR CTT CCG TGC TAC TTC TAG AC ACA TAG GGT GAC AGG AAG TG
SD-PL
(n=12)
REN2-PL
(n=12)
SD-EPO
(n=12)
REN2-EPO
(n=15)
EPO levels (pg/ml) 13±3 10±4 44±18 * 35±5 †
S1. Iron status
Table shows serum iron levels at sacrifice. Data are expressed as mean±SEM. PL = placebo. Folic acid and vitamin 
B12 serum levels were both above upper detection limit. There was no insufficiency in iron, folic acid or vitamin B12 
status.
S2. List of primers used for RT-qPCR
B2M = β2-microglobulin, GAPDH = glyceraldehyde 3-phosphate dehydrogenase, ANP = atrial natriuretic peptide, LMO 
= lim-domain partner of TAL, GATA = zinc finger factor that binds GATA sequences, MMP = matrix metalloproteinase, 
SDF = stromal cell-derived factor, TFR = transferrin receptor.
S3. Plasma EPO levels
Table shows the plasma EPO levels. PL = placebo. * p<0.05 vs. SD-PL, † p<0.05 vs. REN2-PL. Data is expressed as 
mean±SEM.                148
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S4. Echocardiographic data during experiment
IVSd = thickness of the interventricular septum in diastole (A). LVIDd = left ventricular internal diameter in diastole 
(B), LVPWd = thickness of the left ventricular posterior wall in diastole (C), Fractional shortening (D). PL = placebo, 
Wk = week. # p<0.05 REN2-PL vs. SD-PL and SD-EPO,    p<0.05 REN2-EPO vs. SD-PL and SD-EPO. Data is expressed as 
mean±SEM.     149
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Chapter 9
summARy
Heart failure (HF) is a clinical syndrome, involving not only the heart, but many other vital 
organs as well, including the brain, muscles, kidney and bone marrow.1 HF is associated with 
an increased serious risk of hospitalisation and mortality, and the economic burden of HF for 
health care systems and society is enormous.2 Atherosclerotic coronary disease is an important 
risk factor for the development of HF. New treatment options to preserve left ventricular 
function  after  myocardial  infarction  are  therefore  warranted.  Furthermore,  by  increasing 
our understanding of the pathophysiological processes involved in HF, we may be able to 
improve pharmacological treatment options. Therefore, we studied the extra-haematopoietic 
mechanisms of erythropoietin (EPO) and the EPO-EPO receptor system in HF. Furthermore, we 
studied downstream pathways of erythropoietin and potential targets for intervention, to gain 
further insight in the pathophysiological processes involved in HF. 
Extra-haematopoietic mechanisms of EPO and the EPO-EPO Receptor system
In the first part of this thesis, we explored the extra-haematopoietic mechanisms of EPO and 
the role of the EPO-EPO receptor system in HF. We intended to delineate the mechanisms of 
EPO-induced cardiac vascular endothelial growth factor (VEGF) production. Furthermore, we 
established if VEGF is crucial for EPO-induced improvement of cardiac performance (chapter 
3).  We  studied  the  effects  of  EPO  on  VEGF  expression  in  cultured  endothelial  cells  and 
cardiomyocytes and EPO-treated hearts. The role of VEGF in EPO-induced neovascularisation 
was studied with two distinct VEGF-neutralising antibodies (or irrelevant control IgG) in an 
aortic sprouting assay and in rats with HF after myocardial infarction (MI) treated with EPO. EPO 
stimulated VEGF mRNA expression through the STAT3 signal transduction pathway in neonatal 
rat cardiomyocytes, but not in endothelial cells or fibroblasts. Similarly, the direct effects of EPO 
on endothelial sprouting were modest and VEGF independent. In rats with HF, EPO increased 
VEGF protein expression predominantly in cardiomyocytes, associated with a 37% increase 
in capillary density and improved cardiac performance. Administration of VEGF-neutralising 
antibodies  abrogated  the  salutary  effects  of  EPO  on  myocardial  microvascularisation  and 
function. VEGF neutralisation attenuated EPO-induced proliferation of myocardial endothelial 
cells and reduced myocardial incorporation of endothelial progenitor cells (EPCs) in rats with 
alkaline phosphatase-labelled bone marrow cells. We conclude that VEGF is crucial for EPO-
induced improvement of cardiac function in HF. EPO fosters VEGF expression predominantly in 
cardiomyocytes, which in turn stimulates myocardial endothelial proliferation and incorporation 
of EPCs.
The role of the EPO receptor in physiologic hypertrophy was studied next (chapter 4). We have 
demonstrated that EPO via its receptor exerts cardioprotective effects in pathophysiological 
hypertrophy (e.g. MI and HF).3,4 It is unknown however if the EPO-EPOR signalling pathway 
exerts similar results in physiological hypertrophy. EPO receptor rescued knock-out mice (EPOR-
/--rescued mice) are mice that express the EPO receptor exclusively in the haematopoietic 
cells.5 These mice have accelerated maladaptive remodelling upon various stimuli, because 
of an insufficient angiogenic response.6-9 Mice had unlimited access to a running wheel for      153
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four weeks. We show that EPOR-/--rescued mice have a reduced exercise capacity, which is 
associated with an impaired adaptation of cardiac and skeletal muscle. The increased exercise 
capacity seen in WT mice resulted in a larger cardiac adaptation in HW in the WT-ex mice (26%) 
as compared to the EPOR-ex mice (10%). This increased cardiac adaptation was accompanied 
by myocyte hypertrophy and neovascularisation as shown with the increase in cross sectional 
area and capillary-to-myocyte ratio in both cardiomyocytes as skeletal muscle. EPOR-/--rescued 
did not show this adaptation to increased workload. Furthermore, exercised WT mice show a 
shift in muscle fibre type to adapt to the increased workload (type II to type I), where EPOR-/--
rescued mice do not show this adaptation al all. We concluded that the absence of EPO-EPOR 
signalling leads to a lesser exercise capacity upon voluntary wheel-running. We suggest that 
EPO-EPOR signalling is important for physiological adaptation during exercise. 
Studies in animal models of acute myocardial infarction suggest that ischemia-reperfusion (I/R) 
injury accounts for up to 50% of the final size of an MI, and in I/R models, a number of strategies 
have been shown to ameliorate lethal reperfusion injury.10 Of note, the translation of these 
beneficial effects into the clinical setting has been disappointing.11 To corroborate our data we 
collected in animal studies, we evaluated a human model of I/R injury and compared the rate 
of apoptosis after cardiopulmonary bypass (CPB) and cardioplegic arrest during coronary artery 
bypass grafting (CABG) surgery between atrial and ventricular tissue (chapter 5). During CABG 
surgery with CPB and cardioplegic arrest, sequential biopsies were taken from the right atrial 
appendage and left ventricular anterior wall before CPB and after aortic cross clamp release. 
We assessed the change in number of apoptotic cells and biochemical markers of myocardial 
ischemia and renal dysfunction. CPB was associated with a transient small, but significant 
increase in CK, CK-MB, troponin-T and NT-proBNP levels. A higher number of apoptotic cells 
as assessed by caspase-3 staining was found in the ventricular biopsies taken after aortic cross 
clamp release compared with the biopsies taken before CPB. The number of apoptotic cells in 
the atrial appendage was not altered during CPB. Correlation between the duration of aortic 
cross clamp time and the change in caspase-3 positive cells in the left ventricular wall was of 
borderline significance. We concluded that CABG surgery with CPB and cardioplegic arrest is 
associated with an elevated rate of apoptosis predominantly in ventricular tissue. Ventricular 
tissue may be more sensitive to detect changes than atrial tissue, and may be more useful to 
investigate the protective effects of therapeutic intervention.
Downstream pathways of erythropoietin: feasible targets for intervention
In the second part of this thesis, we focused on feasible targets for intervention to ameliorate 
the effects of ischemia in the heart. In chapter 6, we investigated whether administration of 
estradiol to male mice augments mobilisation of bone marrow-derived EPC and incorporation 
into foci of neovascularisation after hind-limb ischemia, thereby contributing to blood flow 
restoration.  EPC  culture  assay  performed  two  weeks  after  estradiol  pellet  implantation 
revealed a significantly greater number of circulating EPCs in the high-dose estradiol group 
than in the low-dose estradiol and placebo groups. Three and four weeks after induction of 
hind limb ischemia, perfusion was significantly greater in high-dose estradiol mice than in 
low-dose estradiol or placebo treated mice. At one and four weeks after hind-limb ischemia                 154
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surgery, more bone marrow-derived EPCs, identified as β-galactosidase-positive cells, were 
observed in ischemic regions from high-dose estradiol animals than in low-dose or placebo 
groups. These results indicate that estradiol dose-dependently increases the levels of EPCs 
in peripheral blood in male animals, improves the recovery of blood flow, and decreases 
limb necrosis after hind-limb ischemia, and that this enhancement occurs, in part, through 
augmentation of EPC mobilisation and greater incorporation of bone marrow-derived EPCs 
into foci of neovascularisation.
I/R-injury, for example in acute myocardial infarction, is accompanied by an severely increased 
production of reactive oxygen species and subsequent cell death, contributing to the loss 
of viable myocardial tissue after sustained MI.10 In chapter 7 we evaluated the safety and 
efficacy of an exogenous heme oxygenase (HO)-1 inducer (heme arginate) in patients with a 
non-ST-elevation myocardial infarction (NSTEMI) to scavenge these reactive oxygen species. 
Degradation products of HO-1 activity have been suggested to act as anti-oxidants.12-15 The 
inducible isoform of HO, named HO-1, can be induced in virtually all tissues and represents the 
rate limiting step in the degradation of the pro-oxidant heme molecule into biliverdin, carbon 
monoxide (CO), and iron.12 Biliverdin is then converted by biliverdin reductase (BVR) into 
bilirubin, whereas iron induces the expression of the iron sequestering molecule ferritin.12,16-18 
At  physiological  concentrations,  bilirubin,  CO  and  ferritin  all  exhibit  high  ant-oxidant  and 
cytoprotective properties.18-21 In our study, patients with NSTEMI were open label randomised 
to a single dose of heme arginate or placebo. Heme arginate or placebo was infused within 
three hours after hospital admission for NSTEMI. A single high dose of heme arginate after 
NSTEMI did not increase plasma ferritin and total, direct and indirect bilirubin concentrations, 
HO-1 mRNA expression and HO protein activity in peripheral blood mononuclear cells as 
compared to the placebo group. Safety parameters were all comparable between the two 
groups. However, NSTEMI itself did activate the HO-1 system. Median total bilirubin levels 
were increased with 60% after NSTEMI. Also, median HO-1 mRNA (17.5 times compared to 
baseline) and median HO protein activity (780% compared to baseline) were increased after 
NSTEMI. We concluded from this study that although there is an endogenous HO-1 response 
to NSTEMI, adding an exogenous HO-1 inducer does not increase downstream HO-1 markers 
further, however, heme arginate administration is safe in patients with NSTEMI. We suggest 
that before embarking on larger sized trials, a dose-finding study should be carried out, in 
order to determine the optimal dose for patients with MI (NSTEMI of STEMI).
One of the common co-morbidities in HF Is anaemia, which presence is associated with a 
particularly poor outcome.22-24 The causes of anaemia in HF are only partially understood, 
although several mechanisms have been implicated.25-29 Because bone marrow dysfunction 
may contribute to HF-associated anaemia, we investigated mechanisms of BM dysfunction in an 
established model of HF (chapter 8), the transgenic REN2 rat, which is characterized by severe 
hypertrophy and ventricular dilatation and Sprague Dawley (SD) rats as controls. Secondly, we 
investigated whether stimulation of haematopoiesis with EPO could restore anaemia and BM 
dysfunction. Number of burst forming units-erythroid (BFU-E) was severely decreased in BM 
of REN2 rats compared to SD rats. EPO treatment increased haematocrit in the SD-EPO group, 
however in the mildly anaemic REN2 rats, there was no effect. This was paralleled by a 67%      155
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decrease in BFU-E in BM of REN2 rats compared to SD. EPO significantly improved BFU-E in 
both SD and REN2, but could not restore this to control levels in the REN2 rats. Expression of 
several genes involved in differentiation and mobilisation of the BM is deregulated in REN2 
rats, and EPO did not normalise this. Altogether, these results suggest that BM dysfunction is 
an important contributor to HF-associated anaemia in the hypertensive REN2 rat and that EPO 
is not an effective agent to treat HF-associated anaemia, at least in this model.
TRAnslATIonAl REsEARCH
Before discussing what future experiments could help to unravel the pathways of EPO and the 
potential clinical applicability of EPO or its derivatives, I would like to share some thoughts on 
translational research.
To improve human health, scientific discoveries must be translated into practical applications. 
Such discoveries typically begin at ‘the bench’ with basic research - in which scientists study 
disease at a molecular or cellular level - then progress to the clinical level, or the patient’s 
‘bedside.’ Often, preclinical researchers are doing the ‘why and how’, where clinical researchers 
are looking for the best ways to treat their patients. Knock-out and overexpression models 
are used to unravel the mechanisms behind diseases. However, this approach in the human 
setting is clearly not feasible. Scientists are however increasingly aware that this bench-to-
bedside approach to translational research is really a two-way street. Basic scientists provide 
clinicians with new tools for use in patients and for assessment of their impact, and clinical 
researchers make novel observations about the nature and progression of disease that often 
stimulate basic investigations. Translational research has proven to be a powerful process that 
drives the clinical research engine. Unfortunately, as is common in translation research, results 
found in experimental models, are not necessarily translated to the human setting. Preclinical 
and clinical research are two distinct worlds and often there is a disappointing consistency 
between these two worlds. Growing barriers between clinical and basic research, along with 
the ever the increasing complexities involved in conducting clinical research, are making it 
more difficult to translate new knowledge to the clinic - and back again to the bench.
However, a stronger research infrastructure could strengthen and accelerate this critical part 
of the clinical research enterprise. Of pivotal importance is the doctor-scientist (MD, PhD), 
who is able to bridge the gap between basic and clinical science. Their increasing awareness 
that not only the ‘why and how’ is of major importance, but also the feasibility of these new 
findings for their patients should bring health care forward.
fuTuRE PERsPECTIVEs
Now the results of the HEBE III are published,30 two more large-scale randomised EPO trials 
still have to reveal their results. First, the results of second study evaluating the effect of 
EPO in first ST-segment elevation MI (REVEAL) are awaited in the fourth quartile of 2010.31 
Second, the results of first large randomised study to evaluate the effects of EPO in HF (RED-
HF) are awaited in 2011.32 Results of both should give a definitive answer on the use of EPO in 
cardiovascular disease. However, regardless of these results, the search for cellular protection 
against ischemia and I/R-injury continues.                156
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The dosing regimens used in previous HF studies, all resulted in a significant increase in 
haematocrit levels. When applied to the clinical situation, this could lead to hypertension, 
seizures, vascular thrombosis and death, possibly related to abruptly increased haematocrit 
levels.33 Therefore, our group recently evaluated the effect of a low-dose EPO bolus that had 
no effect on haematocrit. Similar to high-dose EPO, low-dose treatment resulted in statistically 
improved cardiac function and improved myocardial microvascularisation, although the effect 
was slightly less pronounced.3 These results do not only suggest that the beneficial effects of 
EPO on the heart may be independent of an increased haematocrit but also suggest that low-
dose EPO might provide a safe and effective strategy in patients.
Another option to avoid the potentially negative effects of chronic EPO therapy in haematocrit 
values  could  be  the  use  of  recently  discovered  carbamylated  EPO,34-39  and  other  non-
Figure 1. Overview of the potential mechanisms of cytoprotection of erythropoietin (EPO). Activation of the EPO 
receptor by EPO leads to downstream activation of intracellular pathways, such as PI3K/akt, ERK1/2, and STAT. These 
pathways originate with the binding of EPO to the EPO receptor to activate JAK2. Subsequently, PI3K and Akt are 
activated by downstream phosphorylation. Activation of STAT can regulate EPO-mediated cell protection and protect 
against apoptosis. EPO maintains cellular integrity and prevents apoptosis through a number of pathways, such as the 
modulation of apoptosis protease activating factor-1, the release of cytochrome c, and the prevention of activation of 
caspases 9 and 3. Dotted lines, suppressed pathways; solid lines, activated pathways. For colour figure, see supplement 
1.     157
Chapter 9 Summary and future perspectives
.................................................... 9
Con-PL
(n=5)
Con-EPO
(n=4)
MI-PL
(n=5)
MI-EPO
(n=5)
BW (gr) 359±7 433±22 397±9 403±9
HW (mg) 1181±37 1650±172* 1959±297* 1598±89*
HW/BW (mg/gr) 3.28±0.11 3.82±0.23 4.91±0.70* 3.97±0.20*‡
MAP (mmHg) 90.8±3.8 97.0±3.1 91.0±4.5 89.6±2.9
HR (bpm) 384±36 321±13 325±13 333±9
dPdtmax (mmHg/s) 9900±764 10556±976 6225±1126* 9518±247
dPdtmin (mmHg/s) -10775±462 -9753±743 -5737±830* -8456±274
LVEDP (mmHg) 2.8±0.5 2.7±1.8 19.8±7.1* 12.8±2.5*‡
Ht (%) 51±1.9 63±5.2* 47±1.9 59±3.5*‡
ANP (fold change) 1.00±0.12 1.78±0.40 7.65±1.23* 5.17±1.06*‡
Table 1. Baseline characteristics
Table shows the baseline characteristics of the groups used in the micro-array. Sprague Dawley rats were used. HF 
was induced by permanent ligation of the left ascending coronary artery to produce a myocardial infarction (MI) and 
control rats received a sham procedure. Three weeks after MI, rats were randomly assigned to treatment with the long-
acting erythropoietin darbepoetin alfa (EPO, 40 μg/kg) or placebo (PL), given once every three weeks subcutaneous. 
Con = control rats, BW = body weight, HW = heart weight, MAP = mean arterial pressure, HR = heart rate, dPdtmax 
and dPdtmin are indices of maximal contraction and relaxation, LVEDP = left ventricular end diastolic pressure, Ht = 
haematocrit. To determine if true heart failure existed, we measured atrial natriuretic peptide (ANP, shown as fold 
change vs. SD). Data is presented as mean±SEM. *p<0.05 vs. Con-PL, ‡ p<0.05 vs. MI-PL
erythropoietic derivates of EPO,40,41 retaining the tissue protective properties, without the 
undesired effect on erythropoiesis.42 Two independent studies have demonstrated that these 
non-erythropoietic EPOs retain their cardioprotective potential in models of acute MI.43,44 It is 
however uncertain whether these new EPOs will improve cardiac function in chronic HF. Large 
randomised trials have to be conducted to answer this question.
Another possibility is to better understand downstream EPO signalling (figure 1). We conducted 
a micro-array to elucidate the transcriptomic changes that occur after EPO treatment in post-
MI HF. For this micro-array, we applied ventricular hypertrophic mRNA from tissue obtained 
from a post-MI HF model as previous described.4,45,46 A micro-array is a multiplex technology 
used in molecular biology. It consists of an arrayed series of thousands of microscopic spots 
of DNA oligonucleotides, known as probes. Probe-target hybridisation is usually detected 
and quantified by detection of fluorophore-, silver-, or chemiluminescence-labelled targets 
to determine relative abundance of nucleic acid sequences in the target. Since an array can 
contain tens of thousands of probes, a micro-array experiment can accomplish many genetic 
tests in parallel, in our study, the entire genome of a rat. We attempted to identify a set of key 
genes which are differentially regulated by EPO and can provide us with new possible targets 
for research.
Table 1 shows the baseline characteristics of the groups that were analysed with the micro-array 
technique. Among other things, we compared the transcriptome of rats that had ischemic HF                 158
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by permanent ligation of the left ascending coronary artery vs. rats with ischemic HF treated 
with EPO. Seven genes were identified that were up- or downregulated after EPO treatment.
Upregulated genes
Upregulated during skeletal muscle growth 5 (Usmg5), also known as diabetes-associated 
protein in insulin-sensitive tissues (Dapit), is a protein that is expressed in skeletal muscle. 
One study found it is downregulated in insulin-sensitive tissues in streptozotocin-induced 
diabetes.47 It is also associated with ATP synthase in heart mitochondria.48,49 Little is known 
about the exact function of Usmg5. Upregulation in response to active stretching of skeletal 
muscle and downregulation of Dapit mRNA in insulin-sensitive rat tissues upon induction 
of streptozotocin-induced diabetes may point to a role in the energy metabolism of cells, in 
glucose metabolism, and/or in oxidative phosphorylation.
The second upregulated gene, myosin regulatory light chain 2, ventricular/cardiac muscle 
isoform, or Myl2, encodes the regulatory light chain associated with cardiac myosin beta 
heavy  chain.  Calcium  triggers  the  phosphorylation  of  regulatory  light  chain  that  in  turn 
triggers  contraction.  Mutations  in  Myl2  are  associated  with  left  ventricular  hypertrophic 
cardiomyopathy.50-53 Upregulation by EPO could mean that Myl2 has a role in preventing left 
ventricular hypertrophy, however not much is known about the role of Myl2 in HF.
Downregulated genes
Carbonic anhydrase 3 (Ca3) is part of a family of enzymes that catalyze the rapid conversion of 
CO2 and H2O to bicarbonate and protons, a reaction that occurs rather slowly in the absence 
of a catalyst. The primary function of Ca3 in animals is to maintain acid-base balance in blood 
and other tissues, and to help transport CO2 out of tissues. Only one study describes a role 
for  Ca3  in  the  emergence  of  cardiac  hypertrophy.54  Apparently,  activation  of  the  plasma 
membrane Na+-H+ exchanger (NHE1) and Cl- -HCO3- exchanger (AE3) has emerged as a central 
point in the hypertrophic cascade. Both NHE1 and AE3 bind carbonic anhydrase (Ca3), which 
activates their transport flux, by providing H+ and HCO3-, their respective transport substrates. 
Treatment of cardiomyocytes in vitro with phenylephrine to induce hypertrophy, increased 
the expression of Ca3, where a specific inhibitor of Ca3 prevented the phenylephrine-induced 
hypertrophy.  Possibly,  the  expression  of  Ca3  is  downregulated  in  our  in  vivo  model  as  a 
protective mechanism.
The second downregulated gene, Eukaryotic translation elongation factor 1 alpha 1, Eef1α1, 
encodes a ribosomal protein and plays a role in inflammation. For example, it is identified 
as an auto-antigen in 66% of patients with Felty syndrome, a syndrome characterised by the 
combination of rheumatoid arthritis, splenomegaly and neutropenia. The role of Eef1α1 in HF 
is not known and calls for speculation. HF is often characterised by increases in circulating pro-
inflammatory cytokines (TNFα, interleukin (IL)-6, IL-1, and IL-2) and their soluble receptor or 
receptor antagonists that become more pronounced as myocardial function deteriorates.55-60 
In  addition,  increased  production  of  pro-inflammatory  cytokines  and  other  inflammatory 
markers may identify patients at increased risk of developing HF in the future.61,62 Furthermore, 
a cause-and-effect relationship may contribute to the development of HF, as excess TNFα and 
IL-6 have a deleterious effects on cardiac function. Eef1α1 might play a role in the downstream 
effects of inflammatory cytokines.     159
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Upregulated
Description Fold change p Symbol
Upregulated during skeletal muscle growth 5 2,4 0,03 Usmg5
Myosin regulatory light chain 2, ventricular/cardiac muscle isoform 1,7 0,03 Myl2
Ribosomal protein L22 like 1 1,5 0,04 RPL22L1
Thioesterase superfamily member 2 1,5 0,04 Them2
Downregulated
Description Fold change p-value Symbol
Carbonic anhydrase 3 8,1 0,02 Ca3
Eukaryotic translation elongation factor 1 alpha 1 1,6 0,01 Eef1a1
WW domain binding protein 5 1,5 0,003 Wbp5
Table 2. Up- and downregulated genes in MI compared to MI-EPO
Table describes the genes found in the micro-array. Depicted are the genes found comparing MI vs. MI-EPO, >1.5 fold 
change, p<0.05. 
Some limitations to this approach apply. First, we do not see any upregulation of known 
factors associated with the apoptotic and neovascularising properties of EPO, such as STAT3 
and VEGF.8,45,63,64 However, one of the limitations of a micro-array is that the association with 
protein levels remains unknown. Second, the tissue was harvested one week after the last 
administration of EPO. We cannot rule out that the effects of this last administration are not 
picked up at a transcriptional level.
Nevertheless, these factors provide additional insight in the downstream pathways of EPO 
signalling and could contribute towards new therapeutic possibilities.                160
Chapter 9
REfEREnCEs
Dickstein K, Co 1.  hen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen 
DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, De Caterina 
R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber 
S, Tendera M, Widimsky P, Zamorano JL. ESC Guidelines for the diagnosis and treatment of acute and chronic 
heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the 
European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) 
and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-442.
McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health  2. 
burden. Eur Heart J 1998;19 Suppl P:9-16.
Lipsic E, Westenbrink BD, van der Meer P, van der Harst P, Voors AA, van Veldhuisen DJ, Schoemaker RG, van  3. 
Gilst WH. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing 
haematocrit. Eur J Heart Fail 2008;10:22-9.
Westenbrink BD, Lipsic E, van der Meer P, van der Harst P, Oeseburg H, Du Marchie Sarvaas GJ, Koster J, Voors AA,  4. 
van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Erythropoietin improves cardiac function through endothelial 
progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 2007;28:2018-
27.
Suzuki N, Ohneda O, Takahashi S, Higuchi M, Mukai HY, Nakahata T, Imagawa S, Yamamoto M. Erythroid-specific  5. 
expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood 2002;100:2279-88.
Asaumi Y, Kagaya Y, Takeda M, Yamaguchi N, Tada H, Ito K, Ohta J, Shiroto T, Shirato K, Minegishi N, Shimokawa  6. 
H. Protective role of endogenous erythropoietin system in nonhematopoietic cells against pressure overload-
induced left ventricular dysfunction in mice. Circulation 2007;115:2022-32.
Nakano M, Satoh K, Fukumoto Y, Ito Y, Kagaya Y, Ishii N, Sugamura K, Shimokawa H. Important role of erythropoietin  7. 
receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res 2007;100:662-
9.
Satoh K, Kagaya Y, Nakano M, Ito Y, Ohta J, Tada H, Karibe A, Minegishi N, Suzuki N, Yamamoto M, Ono M,  8. 
Watanabe J, Shirato K, Ishii N, Sugamura K, Shimokawa H. Important role of endogenous erythropoietin system 
in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation 
2006;113:1442-50.
Tada H, Kagaya Y, Takeda M, Ohta J, Asaumi Y, Satoh K, Ito K, Karibe A, Shirato K, Minegishi N, Shimokawa H.  9. 
Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial 
ischemia/reperfusion. Cardiovasc Res 2006;71:466-77.
Yellon DM and Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357:1121-35. 10. 
Bolli R, Becker L, Gross G, Mentzer R, Jr., Balshaw D, Lathrop DA. Myocardial protection at a crossroads: the need  11. 
for translation into clinical therapy. Circ Res 2004;95:125-34.
Mancuso C and Barone E. The heme oxygenase/biliverdin reductase pathway in drug research and development.  12. 
Curr Drug Metab 2009;10:579-94.
Baranano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl  13. 
Acad Sci U S A 2002;99:16093-8.
Mancuso C, Bonsignore A, Capone C, Di Stasio E, Pani G. Albumin-bound bilirubin interacts with nitric oxide by a  14. 
redox mechanism. Antioxid Redox Signal 2006;8:487-94.
Mancuso C, Capone C, Ranieri SC, Fusco S, Calabrese V, Eboli ML, Preziosi P, Galeotti T, Pani G. Bilirubin as an  15. 
endogenous modulator of neurotrophin redox signaling. J Neurosci Res 2008;86:2235-49.
Foresti R, Goatly H, Green CJ, Motterlini R. Role of heme oxygenase-1 in hypoxia-reoxygenation: requirement of  16. 
substrate heme to promote cardioprotection. Am J Physiol Heart Circ Physiol 2001;281:H1976-H1984.
Balla J, Vercellotti GM, Jeney V, Yachie A, Varga Z, Eaton JW, Balla G. Heme, heme oxygenase and ferritin in  17. 
vascular endothelial cell injury. Mol Nutr Food Res 2005;49:1030-43.
Jeney V, Balla J, Yachie A, Varga Z, Vercellotti GM, Eaton JW, Balla G. Pro-oxidant and cytotoxic effects of circulating  18.      161
Chapter 9 Summary and future perspectives
.................................................... 9
heme. Blood 2002;100:879-87.
Morita T, Mitsialis SA, Koike H, Liu Y, Kourembanas S. Carbon monoxide controls the proliferation of hypoxic  19. 
vascular smooth muscle cells. J Biol Chem 1997;272:32804-9.
Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Higher serum bilirubin is associated with  20. 
decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1996;16:250-5.
Mancuso C, Pani G, Calabrese V. Bilirubin: an endogenous scavenger of nitric oxide and reactive nitrogen species.  21. 
Redox Rep 2006;11:207-13.
Ezekowitz JA, McAlister FA, Armstrong PW. Anaemia is common in heart failure and is associated with poor  22. 
outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 2003;107:223-5.
Anand I, McMurray JJ, Whitmore J, Warren M, Pham A, McCamish MA, Burton PB. Anaemia and its relationship  23. 
to clinical outcome in heart failure. Circulation 2004;110:149-54.
O’Meara E, Clayton T, McEntegart MB, McMurray JJ, Lang CC, Roger SD, Young JB, Solomon SD, Granger CB,  24. 
Ostergren J, Olofsson B, Michelson EL, Pocock S, Yusuf S, Swedberg K, Pfeffer MA. Clinical correlates and 
consequences of anaemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart 
Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation 2006;113:986-94.
Pfeffer MA. Anaemia treatment in chronic kidney disease: shifting uncertainty. Heart Fail Rev 2008;13:425-30. 25. 
van der Meer P, Lipsic E, Westenbrink BD, van de Wal RM, Schoemaker RG, Vellenga E, van Veldhuisen DJ, Voors  26. 
AA, van Gilst WH. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the 
occurrence of anaemia in heart failure. Circulation 2005;112:1743-7.
Westenbrink BD, Visser FW, Voors AA, Smilde TD, Lipsic E, Navis G, Hillege HL, van Gilst WH, van Veldhuisen  27. 
DJ. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin 
production, but to fluid retention as well. Eur Heart J 2007;28:166-71.
Westenbrink BD, de Boer RA, Voors AA, van Gilst WH, van Veldhuisen DJ. Anaemia in chronic heart failure:  28. 
etiology and treatment options. Curr Opin Cardiol 2008;23:141-7.
Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak  29. 
W,  Niegowska  J,  Kirwan  BA,  Mori  C,  Eisenhart  Rothe  B,  Pocock  SJ,  Poole-Wilson  PA,  Ponikowski  P.  Ferric 
carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-48.
Voors AA, Belonje AM, Zijlstra F, Hillege HL, Anker SD, Slart RH, Tio RA, ‘t Hof A, Jukema JW, Peels HO, Henriques  30. 
JP, Ten Berg JM, Vos J, van Gilst WH, van Veldhuisen DJ. A single dose of erythropoietin in ST-elevation myocardial 
infarction. Eur Heart J 2010;
Reduction of infarct expansion and ventricular remodeling with erythropoietin after large myocardial infarction  31. 
(REVEAL). 2009;
McMurray JJ, Anand IS, Diaz R, Maggioni AP, O’Connor C, Pfeffer MA, Polu KR, Solomon SD, Sun Y, Swedberg K,  32. 
Tendera M, van Veldhuisen DJ, Wasserman SM, Young JB. Design of the Reduction of Events with Darbepoetin alfa 
in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail 2009;11:795-
801.
Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of  33. 
normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis 
and epoetin. N Engl J Med 1998;339:584-90.
Adembri C, Massagrande A, Tani A, Miranda M, Margheri M, De Gaudio R, Pellegrini-Giampietro DE. Carbamylated  34. 
erythropoietin is neuroprotective in an experimental model of traumatic brain injury. Crit Care Med 2008;36:975-
8.
Imamura R, Okumi M, Isaka Y, Ichimaru N, Moriyama T, Imai E, Nonomura N, Takahara S, Okuyama A. Carbamylated  35. 
erythropoietin improves angiogenesis and protects the kidneys from ischemia-reperfusion injury. Cell Transplant 
2008;17:135-41.
Imamura R, Isaka Y, Ichimaru N, Takahara S, Okuyama A. Carbamylated erythropoietin protects the kidneys from  36. 
ischemia-reperfusion injury without stimulating erythropoiesis. Biochem Biophys Res Commun 2007;353:786-
92.
Wang Y, Zhang ZG, Rhodes K, Renzi M, Zhang RL, Kapke A, Lu M, Pool C, Heavner G, Chopp M. Post-ischemic  37.                 162
Chapter 9
treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological 
outcome in a rat model of focal cerebral ischemia. Br J Pharmacol 2007;151:1377-84.
Xu X, Cao Z, Cao B, Li J, Guo L, Que L, Ha T, Chen Q, Li C, Li Y. Carbamylated erythropoietin protects the myocardium  38. 
from acute ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Surgery 2009;146:506-14.
Doggrell SA. A neuroprotective derivative of erythropoietin that is not erythropoietic. Expert Opin Investig Drugs  39. 
2004;13:1517-9.
Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M, Erbayraktar Z, Erbayraktar S, Sepodes B, Thiemermann  40. 
C, Ghezzi P, Yamin M, Hand CC, Xie QW, Coleman T, Cerami A. Nonerythropoietic, tissue-protective peptides 
derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A 2008;105:10925-30.
Ueba H, Brines M, Yamin M, Umemoto T, Ako J, Momomura S, Cerami A, Kawakami M. Cardioprotection by a  41. 
nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin. Proc Natl Acad Sci U 
S A 2010;107:14357-62.
Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P, Larsen  42. 
AK, Helboe L, Christensen S, Pedersen LO, Nielsen M, Torup L, Sager T, Sfacteria A, Erbayraktar S, Erbayraktar Z, 
Gokmen N, Yilmaz O, Cerami-Hand C, Xie QW, Coleman T, Cerami A, Brines M. Derivatives of erythropoietin that 
are tissue protective but not erythropoietic. Science 2004;305:239-42.
Fiordaliso F, Chimenti S, Staszewsky L, Bai A, Carlo E, Cuccovillo I, Doni M, Mengozzi M, Tonelli R, Ghezzi P, Coleman  43. 
T, Brines M, Cerami A, Latini R. A nonerythropoietic derivative of erythropoietin protects the myocardium from 
ischemia-reperfusion injury. Proc Natl Acad Sci U S A 2005;102:2046-51.
Moon C, Krawczyk M, Paik D, Coleman T, Brines M, Juhaszova M, Sollott SJ, Lakatta EG, Talan MI. Erythropoietin,  44. 
modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther 
2006;316:999-1005.
Westenbrink BD, Ruifrok WP, Voors AA, Tilton RG, van Veldhuisen DJ, Schoemaker RG, van Gilst WH, de Boer RA.  45. 
Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart 
failure. Cardiovasc Res 2010;87:30-9.
Westenbrink BD, Oeseburg H, Kleijn L, van der Harst P, Belonje AM, Voors AA, Schoemaker RG, de Boer RA, van  46. 
Veldhuisen DJ, van Gilst WH. Erythropoietin stimulates normal endothelial progenitor cell-mediated endothelial 
turnover, but attributes to neovascularization only in the presence of local ischemia. Cardiovasc Drugs Ther 
2008;22:265-74.
Paivarinne  H  and  Kainulainen  H.  DAPIT,  a  novel  protein  down-regulated  in  insulin-sensitive  tissues  in  47. 
streptozotocin-induced diabetes. Acta Diabetol 2001;38:83-6.
Chen R, Runswick MJ, Carroll J, Fearnley IM, Walker JE. Association of two proteolipids of unknown function with  48. 
ATP synthase from bovine heart mitochondria. FEBS Lett 2007;581:3145-8.
Meyer B, Wittig I, Trifilieff E, Karas M, Schagger H. Identification of two proteins associated with mammalian ATP  49. 
synthase. Mol Cell Proteomics 2007;6:1690-9.
Girolami F, Ho CY, Semsarian C, Baldi M, Will ML, Baldini K, Torricelli F, Yeates L, Cecchi F, Ackerman MJ, Olivotto  50. 
I. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene 
mutations. J Am Coll Cardiol 2010;55:1444-53.
Kaski JP, Syrris P, Esteban MT, Jenkins S, Pantazis A, Deanfield JE, McKenna WJ, Elliott PM. Prevalence of sarcomere  51. 
protein gene mutations in preadolescent children with hypertrophic cardiomyopathy. Circ Cardiovasc Genet 
2009;2:436-41.
Moller DV, Pham TT, Gustafsson F, Hedley P, Ersboll MK, Bundgaard H, Andersen CB, Torp-Pedersen C, Kober L,  52. 
Christiansen M. The role of Lamin A/C mutations in Danish patients with idiopathic dilated cardiomyopathy. Eur 
J Heart Fail 2009;11:1031-5.
McLeod CJ, Bos JM, Theis JL, Edwards WD, Gersh BJ, Ommen SR, Ackerman MJ. Histologic characterization of  53. 
hypertrophic cardiomyopathy with and without myofilament mutations. Am Heart J 2009;158:799-805.
Alvarez BV, Johnson DE, Sowah D, Soliman D, Light PE, Xia Y, Karmazyn M, Casey JR. Carbonic anhydrase inhibition  54. 
prevents and reverts cardiomyocyte hypertrophy. J Physiol 2007;579:127-45.
Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced  55.      163
Chapter 9 Summary and future perspectives
.................................................... 9
heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001;103:2055-
9.
Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, Niebauer J, Hooper J, Volk HD, Coats  56. 
AJ, Anker SD. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 
2000;102:3060-7.
Mohler ER, III, Sorensen LC, Ghali JK, Schocken DD, Willis PW, Bowers JA, Cropp AB, Pressler ML. Role of cytokines  57. 
in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine 
Survival Evaluation. J Am Coll Cardiol 1997;30:35-41.
Testa M, Yeh M, Lee P, Fanelli R, Loperfido F, Berman JW, LeJemtel TH. Circulating levels of cytokines and their  58. 
endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease 
or hypertension. J Am Coll Cardiol 1996;28:964-71.
Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients  59. 
with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction 
(SOLVD). J Am Coll Cardiol 1996;27:1201-6.
Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, Cassani G, Visioli O. Tumor necrosis factor soluble  60. 
receptors in patients with various degrees of congestive heart failure. Circulation 1995;92:1479-86.
Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Wilson PW, D’Agostino  61. 
RB. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the 
Framingham Heart Study. Circulation 2003;107:1486-91.
Murray DR and Freeman GL. Proinflammatory cytokines: predictors of a failing heart? Circulation 2003;107:1460- 62. 
2.
Calo LA, Davis PA, Pagnin E, Bertipaglia L, Naso A, Piccoli A, Corradini R, Spinello M, Savica V, Dalla Libera L.  63. 
Carnitine-mediated improved response to erythropoietin involves induction of haem oxygenase-1: studies in 
humans and in an animal model. Nephrol Dial Transplant 2008;23:890-5.
George J, Goldstein E, Abashidze A, Wexler D, Hamed S, Shmilovich H, Deutsch V, Miller H, Keren G, Roth A.  64. 
Erythropoietin promotes endothelial  progenitor cell proliferative and adhesive properties in a PI 3-kinase-
dependent manner. Cardiovasc Res 2005;68:299-306.PoPulAR summARy In duTCH
(nEdERlAndsE sAmEnVATTIng)
.........................................................................................................................................................................................................                166
Nederlandse Samenvatting
InlEIdIng
Hartfalen is een klinisch syndroom. Dit syndroom omvat niet alleen het hart, maar treft ook 
vele andere vitale organen, inclusief de hersenen, spieren, nieren en het beenmerg. Hartfalen 
is geassocieerd met een sterk verhoogd risico op ziekenhuisopnames en een verhoogd risico 
op overlijden. De economische last van hartfalen op de gezondheidszorg en de samenleving 
is enorm groot. Coronairlijden is een belangrijke risicofactor voor het ontstaan van hartfalen. 
Nieuwe behandelopties ter behoud van de hartfunctie na een hartinfarct zijn daarom nodig. 
Daarnaast, door uitbreiding van onze kennis over de pathofysiologische processen die ten 
grondslag liggen aan hartfalen, zijn we in staat betere farmacologische behandelopties voor 
hartfalen te ontwikkelen. In dit proefschrift worden twee doelen beschreven. Als eerste hebben 
wij de extra-hematopoietische effecten van erythropoietine (EPO) en het EPO-EPO receptor 
systeem in hartfalen bestudeerd. Als tweede hebben wij de verschillende processen waarmee 
EPO zijn werkingsmechanisme tot stand brengt onderzocht en hebben we potentiële targets 
voor interventie onderzocht, om meer inzicht te krijgen in de pathofysiologische processen die 
een rol spelen in hartfalen.
Extra-hematopoietische effecten van EPO en het EPO receptor systeem 
In het eerste deel van dit proefschrift, hebben we de extra-hematopoietische effecten van 
EPO en de rol van het EPO receptor systeem in hartfalen bestudeerd. De intentie was om de 
achterliggende mechanismes van vascular endothial growth factor (VEGF) productie door EPO 
te ontrafelen. Verder hebben we vastgesteld dat VEGF van groot belang is voor de verbetering 
van de hartfunctie door EPO (hoofdstuk 3). We hebben de effecten van EPO op VEGF expressie 
onderzocht in gekweekte endotheliale cellen, in cardiomyocyten en harten behandeld met 
EPO. De rol van VEGF in neovascularisatie door behandeling met EPO werd bestudeerd met 
behulp van twee afzonderlijke VEGF neutraliserende antilichamen (en irrelevante controle) 
in een aorta sprouting essay en in ratten met ischemisch hartfalen behandeld met EPO. EPO 
stimuleerde  VEGF  mRNA expressie  in  neonatale  cardiomyocyten  van  de  rat  via  de  STAT3 
signaal transductie route, echter dit was niet het geval in endotheel cellen of fibroblasten. 
Vergelijkbaar  hiermee  waren  ook  de  directe  effecten  van  EPO  op  endotheliale  sprouting 
bescheiden en onafhankelijk van VEGF. In ratten met hartfalen verhoogde EPO de VEGF eiwit 
expressie voornamelijk in cardiomyocyten, wat geassocieerd was met een 37% vergroting van 
de capillaire dichtheid en een verbeterde hartfunctie. Toediening van VEGF neutraliserende 
antilichamen deed de effecten van EPO op de myocardiale microvascularisatie en hartfunctie 
teniet.  VEGF  neutralisatie  verzwakte  de  EPO  geïnduceerde  proliferatie  van  myocardiale 
endotheel cellen en verminderde de incorporatie van endotheel stamcellen (EPCs) in het 
hart van ratten met alkaline fosfatase gelabelde beenmerg cellen. We concluderen dat VEGF 
een belangrijke rol speelt in de verbetering van de hartfunctie door EPO in hartfalen. EPO 
bevordert de VEGF expressie voornamelijk in cardiomyocyten, wat vervolgens de proliferatie 
van de endotheel cellen en de incorporatie van EPCs in het hart stimuleert.
De rol van de EPO receptor in fysiologische hypertrofie werd vervolgens bestudeerd (hoofdstuk 
4). We hebben laten zien dat EPO, via zijn receptor, beschermende effecten heeft op het hart      167
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in  pathofysiologische  hypertrofie  (bijvoorbeeld  na  een  hartinfarct  en  in  hartfalen).  Het  is 
onbekend of EPO-EPO receptor activatie dezelfde effecten heeft in fysiologische hypertrofie. 
EPO receptor knock-out muizen (EPOR-/--rescued muizen) zijn muizen die de EPO receptor 
exclusief in de hematopoietische cellen tot uiting brengen. Deze muizen hebben een versnelde 
maladaptieve  aanpassing  op  verschillende  stimuli,  door  een  insufficiënte  angiogenetische 
respons. Muizen hadden vrije toegang tot een loop wiel voor vier weken. We laten zien dat EPOR-
/--rescued muizen een verminderde inspanningscapaciteit hebben, wat geassocieerd is met een 
verminderde adaptatie van zowel hart als spierweefsel. De verhoogde inspanningscapaciteit 
die gevonden werd in de controle muizen, resulteerde in een grotere aanpassing in hartgewicht 
in de controle muizen met inspanning (26%), vergeleken met de EPOR-/--rescued muizen met 
inspanning (10%). Deze verhoogde aanpassing van het hart ging samen met hypertrofie van de 
spiercellen en neovascularisatie, zoals aangetoond door een vergroot spiercel oppervlakte en 
een verhoogde ratio in het aantal capillairen ten opzichte van het aantal spiercellen in zowel 
het hart als skelet spieren. EPOR-/--rescued muizen lieten deze aanpassing bij inspanning niet 
zien. Daarnaast lieten de controle muizen een verschuiving zien in spiercel type om beter te 
kunnen voldoen aan de verhoogde werklast (type II naar type I), een verandering die EPOR-/--
rescued muizen niet lieten zien. We hebben geconcludeerd dat de afwezigheid van EPO-EPO 
receptor activatie leidt tot een verminderde inspanningscapaciteit bij vrijwillige inspanning 
en suggereren dat EPO-EPO receptor activatie belangrijk is fysiologische aanpassing tijdens 
inspanning.
Studies in diermodellen met een acuut hartinfarct suggereren dat ischemie-reperfusie (I/R) 
schade tot 50% van de uiteindelijke grootte van het hartinfarct kan bepalen. In I/R modellen 
zijn  een  aantal  strategieën  beschreven  die  de  schade  die  optreedt  bij  reperfusie  kunnen 
verbeteren. Helaas is de vertaling van deze strategieën naar de klinische praktijk teleurstellend. 
Om onze data die verzameld is in dierexperimentele modellen te kunnen bevestigen, hebben 
we een humaan model van I/R schade onderzocht, waarin het percentage apoptotische cellen 
na  cardiopulmonaire  bypass  (CPB)  en  cardioplegie  tijdens  een  coronaire  bypass  operatie 
(CABG) werd vergeleken tussen atriaal en ventriculair weefsel (hoofdstuk 5). Tijdens CABG 
operaties  met  CPB  en  cardioplegie,  werden  achtereenvolgende  biopten  genomen  van 
het rechter hartoor en de linker ventrikel voorwand. Dit werd gedaan voor CPB en na het 
opheffen van de aortale klem. Wij hebben de veranderingen in het aantal apoptotische cellen 
en biochemische markers van ischemie van het hart en disfunctie van de nier beoordeeld. 
CPB was geassocieerd met een kleine, weliswaar voorbijgaande, maar significante verhoging 
van CK, CK-MB, troponine T and NT-proBNP levels in het bloed. Een werd een hoger aantal 
apoptotische cellen gemeten in de ventriculaire biopten genomen na opheffen van de aortale 
klem,  vergeleken  met  de  biopten  genomen  voor  CPB.  Het  aantal  apoptotische  cellen  in 
het rechter hartoor veranderde niet tijdens CPB.  Correlatie tussen de duur van de aortale 
klemming en de verandering in apoptotische cellen in de linker ventriculaire voorwand was 
borderline significant. Wij hebben geconcludeerd dat CABG operaties met CPB en cardioplegie 
geassocieerd zijn met meer apoptose, wat voornamelijk in het ventriculair weefsel plaats 
vind. Ventriculair hartweefsel is mogelijk gevoeliger om veranderingen waar te nemen dan 
atriaal hartweefsel en is mogelijk beter bruikbaar om de beschermende effecten van een 
therapeutische interventie te beoordelen.                168
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Downstream  signaal  transductie  paden  van  erythropoietine:  mogelijke  targets  voor 
interventie
In het tweede deel van dit proefschrift hebben we ons gefocust op mogelijke targets voor 
interventie om de effecten van ischemie schade in het hart te reduceren. In hoofdstuk 6 
hebben we onderzocht of de toediening van oestradiol aan mannelijke muizen een verhoogde 
mobilisatie van EPCs uit het beenmerg tot stand brengt en of deze EPCs zich nestelen in haarden 
van neovascularisatie na ischemie in de achterpoot, en daardoor bijdragen aan het herstel 
van de bloeddoorstroming. EPC culture essay, uitgevoerd twee weken na oestradiol pellet 
implantatie, liet een groter aantal circulerende EPCs in het bloed zien in de hoge dosis oestradiol 
behandelde groep vergeleken met de lage dosis oestradiol behandelde groep of de placebo 
groep. Drie en vier weken na het ontstaan van de ischemie in de achterpoot, was de perfusie 
significant groter in de hoge dosis oestradiol behandelde groep, vergeleken met de lage dosis 
en placebo groepen. Één en vier weken na het ontstaan van ischemie in de achterpoot, werden 
meer  EPCs  afkomstig  uit  het  beenmerg,  aangetoond  als  β-galactosidase  positieve  cellen, 
aangetroffen in de ischemische gebieden van de hoge dosis oestradiol behandelde groep, dan 
in de lage dosis of placebo groepen. Deze resultaten laten zien oestradiol dosisafhankelijk het 
aantal EPCs in het perifere bloed in mannelijke dieren kan verhogen, dat oestradiol het herstel 
van de bloeddoorstroming bevordert, dat het zorgt voor minder necrose na ischemie van de 
achterpoot, en dat deze verbeteringen plaatsvinden door verbeterde mobilisatie en verbeterde 
nesteling in haarden van neovascularisatie van EPCs afkomstig uit het beenmerg.
I/R  schade,  bijvoorbeeld  door  een  acuut  hartinfarct,  gaat  vaak  samen  met  een  serieus 
verhoogde productie van vrije zuurstof radicalen, gevolgd door cel dood, wat weer bijdraagt 
aan het verlies van vitaal hartspierweefsel na een doorgemaakt hartinfarct. In hoofdstuk 7 
hebben we de veiligheid en effectiviteit van een exogene heme oxygenase (HO)-1 stimulator 
(heme  arginaat)  in  patiënten  met  een  non-ST-elevatie  hartinfarct  (NSTEMI)  onderzocht. 
Heme arginaat werd toegediend om deze vrije zuurstof radicalen weg te vangen, waarbij de 
afbraakproducten van HO-1 activiteit lijken te werken als anti-oxidanten. Het isoform van HO 
dat induceerbaar is, genaamd HO-1, kan in vrijwel alle weefsel gestimuleerd worden en is de 
snelheidsbepalende stap in de afbraak van het pro-oxidante heme molecuul in biliverdine, 
koolstofmonoxide  (CO)  en  ijzer.  Biliverdine  wordt  vervolgens  door  biliverdine  reductase 
omgezet  in  bilirubine,  terwijl  ijzer  de  aanmaak  stimuleert  van  het  molecuul  ferritine.  In 
fysiologische concentraties hebben bilirubine, CO en ferritine allemaal een hoog anti-oxidante 
werking en beschermende eigenschappen op cellen. In onze studie werden patiënten met 
NSTEMI open label gerandomiseerd naar een enkele dosis heme arginaat of placebo. Heme 
arginaat of placebo werden binnen drie uur na opname in het ziekenhuis voor een NSTEMI 
toegediend. Een enkele dosis heme arginaat verhoogde de plasma concentraties van ferritine 
en totaal, direct en indirect bilirubine niet. Tevens verhoogde dit niet de HO-1 mRNA expressie 
of de HO eiwit activiteit in perifere mononucleaire bloedcellen in vergelijking met de placebo 
groep.  Veiligheidsparameters  waren  vergelijkbaar  tussen  de  twee  groepen.  Daarentegen 
activeerde NSTEMI zelf wel het HO-1 systeem. Mediane totale bilirubine  waarden waren 
met 60% gestegen na NSTEMI. Tevens was de mediane expressie van HO-1 mRNA (17,5 keer 
vergeleken met de baseline waarden) en de mediane HO eiwit activiteit (780% vergeleken met      169
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de baseline waarden) verhoogd na NSTEMI. Uit deze studie hebben we geconcludeerd dat er 
een endogene HO-1 respons is op het doormaken van een NSTEMI, maar dat toevoeging van 
een exogene HO-1 stimulator geen extra effect heeft. Wel is het veilig om heme arginaat toe te 
dienen in patiënten met NSTEMI. Wij bevelen aan dat voordat er begonnen wordt aan grotere 
studies met heme arginaat, er eerst een studie wordt verricht om de optimale dosis te bepalen 
voor patiënten met een hartinfarct (zowel NSTEMI als STEMI).
Een frequent voorkomende comorbiditeit die optreedt bij hartfalen is anemie. De aanwezigheid 
van anemie bij hartfalen is geassocieerd met een slechte uitkomst. De oorzaken van anemie 
bij hartfalen worden slechts ten dele begrepen, alhoewel verschillende mechanismen worden 
genoemd. Omdat disfunctie van het beenmerg kan bijdragen aan het ontstaan van anemie bij 
hartfalen, hebben wij het mechanisme van beenmerg disfunctie onderzocht in een bekend 
model van hartfalen (hoofdstuk 8), de transgene REN2 rat, welke gekarakteriseerd wordt door 
ernstige hypertrofie en ventriculaire dilatatie. Sprague Dawley (SD) ratten zijn gebruikt als 
controle ratten. Verder onderzochten we of we met stimulatie van de hematopoiese met EPO 
de anemie en beenmerg disfunctie kon behandelen. Het aantal burst forming units-erythroid 
(BFU-E) was ernstig verlaagd in het beenmerg van REN2 ratten vergeleken met het beenmerg 
van de SD ratten. Behandeling met EPO verhoogde het hematocriet in de SD-EPO groep, maar 
in de (licht) anemische REN2 ratten was er geen effect van de behandeling met EPO op het 
hematocriet. Dit ging samen met een 67% verlaging van het aantal BFU-E in het beenmerg 
van de REN2 ratten vergeleken met de SD ratten. Behandeling met EPO verhoogde het aantal 
BFU-E in zowel de SD als in de REN2 ratten, maar kon dit niet tot controle levels terug brengen 
in de REN2 ratten. Expressie van verscheidene genen betrokken bij differentiatie, mobilisatie 
en ijzer metabolisme in het beenmerg is gedisreguleerd in REN2 ratten en behandeling met 
EPO kon dit niet normaliseren. Al deze resultaten samen suggereren dat beenmerg disfunctie 
een belangrijke bijdrager is aan anemie bij hartfalen in de hypertensieve REN2 rat en dat EPO 
niet een effectief middel is om anemie bij hartfalen te behandelen, in ieder geval niet in dit 
model.
TRAnslATIonEEl ondERzoEK
Voordat ik verder ga met de discussie over toekomstige experimenten die de signaal transductie 
paden van EPO kunnen helpen uitpluizen en de potentiële klinische toepasbaarheid van EPO of 
zijn derivaten, wil ik graag enkele gedachten over translationeel onderzoek delen.
Om  de  gezondheidszorg  te  verbeteren,  moeten  wetenschappelijke  ontdekkingen  vertaald 
worden in praktisch toepasbare toepassingen. Zulke ontdekkingen beginnen meestal in het 
experimentele lab met basaal onderzoek - waarin wetenschappers ziektes bestuderen op een 
moleculair of cellulair niveau - en vervolgens wordt het onderzoek vervolgt op een klinisch 
niveau, oftewel aan het bed van de patiënt. Vaak is het zo dat de preklinische onderzoekers het 
hoe en waarom onderzoeken, waar klinische onderzoekers zoeken naar de beste manier om 
hun patiënten te behandelen. Knock-out en overexpressie modellen worden gebruikt om de 
mechanismes achter ziektes bloot te leggen. Echter, in de humane setting is dit duidelijk niet 
haalbaar. Onderzoekers zijn er zich gelukkig steeds meer van bewust dat deze experimentele 
lab tot patiënt aanpak van translationeel onderzoek eigenlijk tweerichtingsverkeer is. Basale                 170
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onderzoekers verschaffen clinici nieuwe instrumenten om te gebruiken bij hun patiënten en 
om de impact van deze nieuwe instrumenten te beoordelen. En klinische onderzoekers maken 
nieuwe observaties over het karakter en de progressie van ziektes, die vaak nieuwe basale 
experimenten tot gevolg hebben.
Translationeel onderzoek heeft zich bewezen als een belangrijk proces dat klinisch onderzoek 
voortdrijft.  Helaas,  zoals  maar  al  te  vaak  voorkomt  in  translationeel  onderzoek,  worden 
resultaten gevonden in experimentele modellen, niet altijd vertaald naar de humane situatie, 
of zijn niet altijd te vertalen naar de humane situatie. Preklinisch en klinisch onderzoek zijn 
twee aparte werelden en er is vaak een teleurstellende overeenkomst tussen deze twee 
werelden. Groeiende barrières tussen klinisch en basaal onderzoek, samen met de groeiende 
complexiteit van het uitvoeren van klinisch onderzoek, maken het moeizamer en moeizamer 
om nieuwe kennis te vertalen naar de kliniek en weer terug naar het experimentele lab.
Een  sterke  infrastructuur  in  het  onderzoek  kan  dit  belangrijke  deel  van  de  dagelijkse 
onderzoekspraktijk versterken. Van belang is de arts-onderzoeker (MD, PhD), die in staat is 
om het gat tussen basaal en klinisch onderzoek te overbruggen. Hun groeiende besef dat 
niet alleen het hoe en waarom van belang is, maar ook de toepasbaarheid van deze nieuwe 
bevindingen voor hun patiënten moet de gezondheidzorg voorwaarts brengen.
ToEKomsTPERsPECTIEVEn
Nu de resultaten van de HEBE III studie gepubliceerd zijn, is het wachten op nog twee andere 
grote gerandomiseerde EPO studies. In het vierde kwartaal van 2010 komen waarschijnlijk 
de resultaten van de tweede grote studie naar de effecten van EPO bij STEMI naar buiten. 
De resultaten van de RED-HF studie, die de effecten van EPO in hartfalen onderzoekt, zullen 
naar alle waarschijnlijkheid pas in 2011 bekend worden. Beide studies moeten, samen met de 
resultaten van de HEBE III studie, het definitieve antwoord geven op het gebruik van EPO in 
cardiovasculaire aandoeningen. Echter, ongeacht de uitkomst zal het onderzoek naar cellulaire 
bescherming tegen ischemie en ischemie-reperfusie schade doorgaan.
De doses EPO gebruikt in voorgaande hartfalen studies veroorzaakten allemaal een significante 
stijging van de hematocriet waarden. Als dit in de klinische situatie zou worden toegepast, 
zou dit kunnen leiden tot ongewenste neveneffecten zoals hypertensie, toevallen, vasculaire 
trombose en overlijden, mogelijk gerelateerd aan de plotselinge verhoging van het hematocriet. 
Onze onderzoekgroep heeft recent het effect onderzocht van een lage dosis EPO, die geen 
effect had op de hematocriet. Net als een hoge dosis EPO, zorgt een lage dosis EPO voor een 
significante verbetering van de hartfunctie en een verbeterde myocardiale microvascularisatie, 
alhoewel het effect iets minder uitgesproken was. Deze resultaten suggereren niet alleen dat 
de positieve effecten van EPO op het hart onafhankelijk zijn van het verhoogde hematocriet, 
maar suggereren ook dat een lage dosis EPO een veilige en effectieve behandeloptie is voor 
patiënten met hartfalen.
Een andere optie om de potentieel negatieve effecten van chronische EPO gebruik op de 
hematocriet waarden te vermijden, is het gebruik van het recent ontdekte gecarbamyleerde EPO 
en andere erythropoietische derivaten van EPO, die wel hun cel beschermende werking hebben 
behouden, maar zonder de onwenselijke effecten op erythropoiese. Twee onafhankelijke studies      171
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Con-PL
(n=5)
Con-EPO
(n=4)
MI-PL
(n=5)
MI-EPO
(n=5)
LG (gr) 359±7 433±22 397±9 403±9
HW (mg) 1181±37 1650±172* 1959±297* 1598±89*
HW/LG (mg/gr) 3.28±0.11 3.82±0.23 4.91±0.70* 3.97±0.20*‡
MAP (mmHg) 90.8±3.8 97.0±3.1 91.0±4.5 89.6±2.9
Hf (spm) 384±36 321±13 325±13 333±9
dPdtmax (mmHg/s) 9900±764 10556±976 6225±1126* 9518±247
dPdtmin (mmHg/s) -10775±462 -9753±743 -5737±830* -8456±274
LVEDP (mmHg) 2.8±0.5 2.7±1.8 19.8±7.1* 12.8±2.5*‡
Ht (%) 51±1.9 63±5.2* 47±1.9 59±3.5*‡
ANP (x verhoging) 1.00±0.12 1.78±0.40 7.65±1.23* 5.17±1.06*‡
in modellen van een acuut hartinfarct hebben aangetoond dat deze niet-erythropoietische 
EPO’s hun beschermende potentieel behouden. Het is echter onzeker of deze nieuwe EPO’s 
in chronisch hartfalen ook de hartfunctie kunnen verbeteren. Grote gerandomiseerde studies 
moeten gehouden worden om deze vraag te kunnen beantwoorden.
Een volgende mogelijkheid is het verhogen van de kennis over de downstream signalering 
van EPO (figuur 1). Wij hebben een micro-array verricht om de te kunnen achterhalen wat de 
veranderingen zijn die plaatsvinden in transcriptie van genen na EPO behandeling in hartfalen 
dat  zich  ontwikkeld  heeft  na  het  doormaken  van  een  hartinfarct.  Voor  deze  micro-array 
hebben we mRNA gebruikt afkomstig uit het hypertrofische hartweefsel uit een diermodel 
voor hartfalen. Een micro-array is een multiplexe technologie, welke gebruikt wordt in de 
moleculaire  biologie.  Het  bestaat  uit  een  array  van  duizenden  microscopische  spots  van 
DNA oligonucleotiden, ook wel bekend als probes. Probe-target hybridisatie wordt meestal 
gedetecteerd en gekwantificeerd door detectie van fluorophoro, zilver of chemiluminicent 
gelabelde targets om de relatieve hoeveelheid van nucleïnezuur sequenties te bepalen in 
het target. Omdat een array tienduizenden probes kan bevatten, is het mogelijk om met een 
micro-array tegelijkertijd vele genetische tests uit te voeren, en in onze studie, het gehele 
genoom van een rat. We hebben geprobeerd om een set fundamentele genen te identificeren 
die gereguleerd worden door EPO en ons nieuwe mogelijke targets voor onderzoek kunnen 
verschaffen.
Tabel 1. Basis karakteristieken
Tabel heeft een overzicht van de basis karakteristieken van de verschillende groepen geanalyseerd met de micro-array. 
Sprague Dawley ratten werden gebruikt als controle. Hartfalen werd geïnduceerd door permanente ligatie van de 
LAD. Op deze manier werd er een hartinfarct geïnduceerd. Controle ratten kregen een sham procedure. Drie weken 
na het hartinfarct werden de ratten gerandomiseerd naar behandeling met het langwerkende EPO darbepoetine 
alfa (EPO, 40 μg/kg) of placebo (PL), wat elke drie weken subcutaan toegediend werd. Con = controle raten, LG = 
lichaamsgewicht, HW = hart gewicht, MAP = gemiddelde bloeddruk, Hf = hartfrequentie, dPdtmax en dPdtmin zijn 
afgeleiden van de maximale contractie en relaxatie van de linker ventrikel, LVEDP = linker ventrikel eind diastolische 
druk, Ht = hematocriet. Om te bepalen of er echt sprake was van hartfalen, hebben we atriaal natriuretisch peptide 
gemeten in het hart (ANP, weergegeven als x verhoging ten opzichte van de SD groep). Data is gepresenteerd als 
gemiddelde±SEM. * p<0.05 vs. Con-PL, ‡ p<0.05 vs. MI-PL                172
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Tabel 1 laat de basis karakteristieken zien van de groepen die met de micro-array techniek zijn 
geanalyseerd. Onder ander hebben we het transcriptoom van ratten met ischemisch hartfalen 
vergeleken met het transcriptoom van ratten met ischemisch hartfalen behandeld met EPO. 
Zeven genen zijn geïdentificeerd die verhoogd of verlaagd tot expressie worden gebracht na 
EPO behandeling.
Verhoogd tot expressie gebrachte genen
Upregulated during skeletal muscle growth 5 (Usmg5), ook wel bekend als diabetes-associated 
protein in insulin-sensitive tissues (Dapit), is een eiwit dat tot expressie wordt gebracht in 
skelet spieren. Een studie heeft aangetoond dat het verlaagd tot expressie komt in insuline 
sensitief weefsel in streptozotocin-geïnduceerde diabetes. Verder is het geassocieerd met ATP 
synthase in de mitochondria in het hart. Er is weinig bekend over de exacte functie van Usmg5. 
Het verhoogd tot expressie komen in response op actief uitrekken van skelet spieren en het 
verlaagd tot expressie komen van Usmg5 mRNA in insuline sensitief weefsel wanneer diabetes 
wordt geïnduceerd door streptozotocin verwijst mogelijk naar een rol in de energie huishouding 
van cellen in het glucose metabolisme, en/of naar een rol in oxidatieve fosforylatie.
Het tweede gen dat verhoogd tot expressie wordt gebracht, is myosin regulatory light chain 
2, ventricular/cardiac muscle isoform, oftewel Myl2. Dit gen codeert voor de regulerende 
lichte keten welke geassocieerd is met de cardiale myosine beta zware keten. Calcium zet 
de fosforylatie aan van de lichte keten, dat vervolgens leidt tot contractie van de spiercellen. 
Mutaties in Myl2 zijn geassocieerd met linker ventriculaire hypertrofie cardiomyopathy. Het 
verhoogd tot expressie brengen door EPO zou kunnen betekenen dat Myl2 een rol speelt bij 
de preventie van linker ventrikel hypertrofie, alhoewel niet veel bekend is over de rol van Myl2 
in hartfalen.
Verlaagd tot expressie gebrachte genen
Cabonic anhydrase 3 (Ca3) maakt deel uit van een familie van enzymen die de snelle conversie 
van CO2 en H2O naar bicarbonaat en protonen mogelijk maken, een reactie die zonder katalysator 
zeer langzaam zou verlopen. De primaire functie van Ca3 in zoogdieren is het behouden van 
de zuur-base balans in het bloed en weefsels en om te assisteren in het transport van CO2 uit 
de weefsels. Maar één studie beschrijft een rol voor Ca3 in het ontstaan van hypertrofie van 
het hart. Blijkbaar is activatie van de plasma membrane NA+-H+ exchanger (NHE1) en de CL-
-HCO3
- exchanger (AE3) het centrale punt in de hypertrofische cascade. Zowel NHE1 als AE3 
worden gebonden door Ca3, wat deze enzymen activeert. Behandeling van cardiomyocyten 
met phenylephirine in vitro om hypertrofie te induceren, verhoogde de expressie van Ca3, 
waar een specifieke inhibitor van Ca3 er voor zorgde dat de hypertrofie geïnduceerd door 
phenylephrine niet optrad. Mogelijk is de expressie van Ca3 verminderd in ons in vivo model 
als onderdeel van een beschermend mechanisme.
Het tweede gen dat verlaagd tot expressie komt, is het Eukaryotic translation elongation factor 
1 alpha 1, Eef1α1, dat codeert voor een ribosomaal eiwit en een rol speelt in inflammatie. Het is 
bijvoorbeeld geïdentificeerd als  een auto antigen in 66% van patiënten die lijden aan het Felty 
syndroom, een syndroom dat gekarakteriseerd wordt door een combinatie van reumatoïde 
artritis, splenomegalie en neutropenie. De rol van Eef1α1 in hartfalen is onbekend en vraagt 
om speculatie. Hartfalen wordt vaak gekarakteriseerd door een verhoging van circulerende      173
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Verhoogd tot expressie gebrachte genen
Omschrijving x verhoging p-waarde Symbool
Upregulated during skeletal muscle growth 5 2,4 0,03 Usmg5
Myosin regulatory light chain 2, ventricular/cardiac muscle isoform 1,7 0,03 Myl2
Ribosomal protein L22 like 1 1,5 0,04 RPL22L1
Thioesterase superfamily member 2 1,5 0,04 Them2
Verminderd tot expressie gebrachte genen
Omschrijving x verhoging p-waarde Symbool
Carbonic anhydrase 3 8,1 0,02 Ca3
Eukaryotic translation elongation factor 1 alpha 1 1,6 0,01 Eef1a1
WW domain binding protein 5 1,5 0,003 Wbp5
pro-inflammatoire  cytokines  (TNFα,  interleukine  (IL)-6,  IL-1,  en  IL-2)  en  hun  oplosbare 
receptoren of receptor antagonisten die verhoogd tot expressie komen als de hartfunctie 
achteruit gaat. Daarbij is het zo dat verhoogde productie van pro-inflammatoire cytokines en 
andere inflammatie markers patiënten kunnen identificeren die een verhoogd risico lopen tot 
het ontwikkelen van hartfalen in de toekomst. Verder is het mogelijk dat een oorzaakgevolg 
relatie bij kan dragen aan de ontwikkeling van hartfalen, omdat verhoogde bloedspiegels van 
TNFα en IL-6 schadelijke effecten hebben op de hartfunctie. Eef1α1 speelt mogelijk een rol in 
de downstream effecten van inflammatoire cytokines.
Deze benaderingswijze heeft wel een aantal limitaties. Als eerste zien we geen verhoging van 
bekende genen die geassocieerd zijn met de anti-apoptotische en neovasculaire eigenschappen 
van EPO, zoals STAT3 en VEGF. Helaas is een van de tekortkomingen van een micro-array dat 
de associatie met het hoeveelheid aanwezige eiwit onbekend is. Als tweede, het weefsel 
gebruikt voor deze micro-array is uitgenomen één week na de laatste gift EPO. We kunnen niet 
uitsluiten dat de effecten van deze laatste toediening van EPO niet opgepikt worden door op 
een transcriptioneel niveau.
Desalniettemin kunnen deze factoren nieuwe inzichten verschaffen in de signalering en het 
werkingsmechanisme van EPO en zou kunnen bijdragen aan nieuwe therapeutische opties 
voor hartfalen.
Tabel 2. Verhoogd en verminderd tot expressie gebrachte genen in MI vergeleken met MI-EPO
Tabel heeft een overzicht van de genen die zijn gevonden met de micro-array.  Hierin is de MI groep vergeleken met 
de MI-EPO groep, >1.5 x verhoging, p<0.05.                174
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Figuur 1.
Overzicht van de potentiële beschermende mechanismes van erythropoietine (EPO) op cellen. Activatie van de EPO 
receptor door EPO leid tot activatie van intracellulaire signaal transductie paden, zoals PI3K/Akt, ERK1/2 en STAT. De 
activatie van deze signaal transductie paden starten allemaal met de binding van EPO aan de EPO receptor, waardoor 
JAK2 geactiveerd wordt. Vervolgens worden PI3K en Akt geactiveerd door fosforylatie. Activatie van STAT kan de 
cellulaire bescherming en bescherming tegen apoptose door EPO reguleren. EPO handhaaft daardoor de cellulaire 
integriteit en verhinderd apoptose via een aantal mechanismen, zoals de modulatie van apoptosis protease activating 
factor-1, de vrijzetting van cytochroom c en de verhindering van activatie van caspase 9 en 3. Gestippelde lijnen, 
onderdrukte signaal transductie paden; doorgetrokken lijnen, geactiveerde signaal transductie paden. Voor kleuren 
figuur, zie supplement 1.Nederlandse SamenvattingsuPPlEmEnT 1. ColouREd fIguREs
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Dankwoord
Promoveren doe je niet zonder de begeleiding en de hulp van een heleboel mensen. Toen ik 
vier jaar geleden begon aan mijn promotie traject, had ik niet kunnen vermoeden dat zoveel 
mensen betrokken zouden zijn bij de totstandkoming van dit proefschrift. Dit dankwoord is 
voor hen bedoeld.
Als eerste mijn promotoren, Wiek van Gilst en Dirk Jan van Veldhuisen.
Beste Wiek, zonder jou was dit proefschrift er niet geweest. Je had nog een onderzoekers 
plek ‘tegoed’ van de RUG en zo kon ik beginnen als onderzoeker bij de afdeling cardiologie. Je 
support en vertrouwen zijn van grote invloed geweest op mijn ontwikkeling als onderzoeker. 
Als ik advies nodig had, op welk vlak dan ook, kon ik bij je binnen lopen en dat heb ik enorm 
gewaardeerd.
Beste Dirk Jan, de heldere kijk die jij hebt op onderzoek en de gave om out-of-the-box te 
denken hebben mede dit proefschrift gemaakt tot wat het nu is. Je brengt artikelen tot de kern 
terug en weet dit altijd op een begrijpelijke manier over te brengen. Dank ook voor je begrip 
voor mijn keuze om een andere weg in te slaan dan die van de cardiologie.
Als tweede mijn copromotor Rudolf de Boer.
Beste Rudolf, als copromotor ben jij het meest intensief bij mijn promotie betrokken geweest. 
In de eerste jaren wat minder toen je nog je opleiding tot cardioloog volgde, maar in de tweede 
helft van mijn promotie des te meer. Ik kon altijd binnen lopen voor advies, of zomaar een praatje. 
Je hebt me veel vrijheid gegeven in de uitvoer van de verschillende onderzoeksprojecten, waar 
ik zeer veel van geleerd heb. Je werktempo en enthousiasme voor onderzoek zorgden ervoor 
dat artikelen altijd snel retour kwamen, samen met constructief commentaar, waardoor de 
inhoud een stuk duidelijker werd. Grote dank voor je begeleiding. Ik wens je heel veel succes 
voor de toekomst en met het definitief vormgeven van de afdeling experimentele cardiologie.
De leden van de beoordelingscommissie, Prof. dr. P.A.B.M. Smits, Prof. dr. H.J. Verkade en Prof. 
dr. A.A. Voors wil ik bedanken voor het kritisch doorlezen van mijn proefschrift.
En dan kom ik toe aan mijn paranimfen. Anne, ik vind het geweldig dat je vandaag mijn paranimf 
bent. Jou promotie was mijn generale repetitie en ik kan alleen maar hopen dat ik het net zo 
goed doe. Daarnaast ben je in de afgelopen vier jaar een hele goede vriendin geworden en 
hoop dat dit blijft, waar je toekomstplannen je ook met Gijs en Tobias heen brengen. Jeroen, 
als mijn oudste broertje ben ik vereerd dat je naast me wilt staan op deze dag. Je bent altijd 
geïnteresseerd geweest in mijn promotie, al begreep je misschien niet altijd heel veel van alle 
technische termen die ik er dan doorheen gooide. 
Twee mensen wil ik speciaal bedanken. Beide zijn belangrijk geweest in deze periode. Als eerste 
Rene Tio. Rene, mijn allereerste wetenschappelijke onderzoek deed ik bij jou en Gillian. Jij bent 
de reden dat ik verder gegaan ben met onderzoek in de cardiologie en ik kon via jou als student 
voor een onderzoek naar Boston. Daarvan heb ik veel geleerd en daarvoor ben ik je dan ook 
veel dank verschuldigd. Als tweede Peter Paul van Geel. Peter Paul, onder jou begeleiding als      193
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keuze co-assistent op de afdeling cardiologie heb ik veel geleerd, ook al leek dat misschien niet 
altijd zo. Daarnaast was je de ‘aanstichter’ van het HO-1 verhaal. Dank voor je inspiratie.
Special  thanks  for  all  the  people  with  whom  I  collaborated  for  the  estradiol  and  HO-1 
manuscripts. Douglas Losordo, Marcy Silver, Atsushi Iwakura, Kengo Kusano, Douwe Dekker, 
Frank Wagener, Alwin Scharstuhl and dr. Mancuso.
Uiteraard mogen de collega’s uit het “Greenhouse” niet ontbreken. Vier jaar lang vrijdagmiddag 
borrels  in  het  Feithhuis  met  (soms)  memorabele  afloop,  cola  rondjes,  congressen  met 
Groninger avonden en jaarlijkse uitjes, waar ik met veel plezier aan meegedaan heb. Al ga ik 
een andere richting in dan de cardiologie, ik hoop jullie nog vaak te treffen. Ik mis jullie nu al. 
In willekeurige volgorde: Jardi, Liza, Kevin, Daan, Jasper, Suzan, Ali, Lennaert, Marthe, Pieter, 
Pieter Jan, Jan Pieter, Youlan, Wim, Sheba, Sandra, Marcelle, Ismaël, Wouter, Rik, Lieuwe, Tøne, 
Michiel, Jessica, Hessel, Bart, Rob, Frank, Caroline, Nicolas, Marieke, Mirjam, Mathijs, Karim, 
Renée, Vincent en Chris.
Daarnaast denk ik met veel genoegen terug aan de andere afdeling waar ik een groot deel 
van  mijn  tijd  heb  doorgebracht,  het  experimentele  cardiologie  lab.  Zonder  alle  steun  en 
medewerking van alle medewerkers en collega promovendi op het experimentele cardiologie 
lab was dit proefschrift nooit tot stand gekomen: Irma, Hisko, Laura Meems, Anne Margreet, 
Mariusz,  Leonie,  Laura  van  Loon,  Bo,  Meimei,  Hongjuan,  Lili,  Cheng,  Reinout,  Michael, 
Herman, Beatrijs, Irene, Hasan, Carla, Pim, Bibiche, Inge, Bianca, Silke, Alexander, Linda, Janny, 
Germaine, Annet, Maaike, Martin en Marjan. Ik bewaar zeer goede herinneringen aan jullie, 
aan de labuitjes en heb met heel veel plezier vier jaar lang op dit lab gewerkt.
De Cardio Research wil ik bedanken voor hun ondersteuning bij de vele hartfalen studies: 
Peter, Geert, Trienke, Anja en Karin. Greetje, Margriet en Carolien, ik heb veel plezier met jullie 
gehad, veel gelachen en gezellig momenten meegemaakt. Tot snel.
Daarnaast wil ik Alma en Audrey bedanken voor hun altijd luisterend oor en hulp en bereidheid 
om zaken te regelen. Alma, bedankt dat ik je zelfs vanuit Enschede kon storen als er iets 
geregeld moest worden voor mijn proefschrift.
Naast  promoveren,  waren  de  functietesten  een  welkome  afwisseling  in  het  bestaan  als 
promovendus. De VO2max kamer was altijd een bron van gezelligheid. Linda, Monique, Astrid, 
Ina, Gean en Jolanda, ik heb altijd met veel plezier met jullie samengewerkt en denk daar met 
genoegen aan terug. Heel veel dank voor gouden herinneringen.                194
Dankwoord
Je hebt maar een paar echt goede vrienden nodig in het leven. Gelukkig ben ik gezegend met 
een aantal waarvan ik veel steun en gezelligheid heb gehad deze afgelopen jaren: Martien, Bob, 
Gijs, Ronald, Renze, Rubertine, Timon, Arnold, Floor, Nienke en ‘groepje 4’: Eva, Frederieke, 
Lieke, Renske, Jasper, Lucas en Wilco. Ondanks dat de meeste van jullie richting het Westen 
zijn getrokken waardeer ik het contact met jullie enorm en gelukkig heb ik nu weer meer tijd 
om jullie te komen irriteren...
Uiteraard mag mijn familie niet ontbreken in dit dankwoord. Lieve oma, ik vind het bijzonder te 
promoveren op je 89ste verjaardag en dat je hierbij nog aanwezig kan zijn. Zo langzamerhand 
is het wel een enorme familie geworden. Lieve broertjes en zusjes: Anneloes, Robert-Jan, 
Elsemieke, en ‘nieuwe’ familie: Kim, Pelle, Yfke, Egbert, Jessica en Sander, dank voor jullie 
steun de afgelopen jaren. Ik hoop nu meer tijd te hebben om jullie te bezoeken, maar jullie zijn 
ook met zoveel...! Robert-Jan, super dat je de opmaak van dit proefschrift hebt willen doen, 
het ziet er fantastisch uit.
Lieve pap en mam, dank voor het kunnen volgen van een studie, ik ben niet de snelste geweest, 
maar door jullie steun kon ik het negen jaar volhouden. Daarnaast dank voor alle vertrouwen 
en steun in de afgelopen jaren. Dankzij jullie ben ik nu arts en gepromoveerd. Soms waren er 
turbulente tijden, maar nu allemaal weer in rustig vaarwater. Dank!DankwoordBIBlIogRAPHy
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